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1. INTRODUCTION 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder of still largely unknown etiology (Poewe et al., 2017), and it is 
estimated that the number of patients will reach minimally 8.7 million by 2030, 
leading to the increasing disease-related burden on the society (Dorsey et al., 
2007). Aging is known to be the greatest risk factor for the development of 
idiopathic PD, illustrated by the worldwide prevalence and incidence rates 
increasing steadily with age (Hirsch, Jette, Frolkis, Steeves, & Pringsheim, 
2016; Pringsheim, Jette, Frolkis, & Steeves, 2014). It is estimated that 0.3% of 
all the population and up to 4% of the people in the highest age groups are 
suffering from this chronic and progressive neurodegenerative disease (de Lau 
& Breteler, 2006). 
Men and women are affected both, however, males have frequently reported 
to be at higher risk for the disease development than women (Moisan et al., 
2016). Incidence and prevalence rates of PD vary across different studies to a 
large extent and this has been proposed to result from environmental and 
genetic factors as well as due to methodological discrepancies across the studies 
(Abbas, Xu, & Tan, 2018). There are only few studies that have investigated PD 
epidemiology in the same geographical area using the same study design and 
diagnostic criteria, showing an increasing prevalence of PD, however, the 
results on the dynamics of incidence have been more inconclusive (Evans et al., 
2016; Kuopio, Marttila, Helenius, & Rinne, 1999a; Yamawaki, Kusumi, Kowa, 
& Nakashima, 2009). It has been shown that PD patients have an average of 1.5 
times higher risk of dying compared to the general population (Macleod, 
Taylor, & Counsell, 2014). The risk of mortality has been found to be related to 
the duration of disease (de Lau, Verbaan, Marinus, & van Hilten, 2014; Hobson 
& Meara, 2018; Pinter et al., 2015). It has been shown that PD diagnosis is 
frequently underreported on death certificates (Benito-León, Louis, Villarejo-
Galende, Romero, & Bermejo-Pareja, 2014; Hobson & Meara, 2018).  
Neuropathologically, PD is characterized by nerve cell loss in the Substantia 
nigra in the midbrain and the presence of Lewy bodies and Lewy neurites (Gibb 
& Lees, 1988), i.e α-synuclein-containing inclusion bodies, that are indicative 
pathological hallmarks of sporadic PD, and not only found in the basal ganglia, 
but also in other brain regions (Spillantini 1997; Braak et al. 2003). The general 
idea of the Braak staging is that α-synuclein pathology has a caudal-to-rostral 
progression, spreading from medulla oblongata or the olfactory bulb (stages 1 
and 2) up to the the neocortex (stages 5 and 6) (Braak et al., 2003). Lewy-type 
pathology in PD patients can also be found in tissues outside the central nervous 
system, in particular in the sympathetic ganglia, gastrointestinal tract, heart, 
adrenal and salivary glands and skin (Adler et al., 2016; Gelpi et al., 2014; 
Gibbons, Garcia, Wang, Shih, & Freeman, 2016). 
Clinical cardinal manifestations of PD include tremor, bradykinesia, rigidity 
and postural instability (Lees, Hardy, & Revesz, 2009; Poewe et al., 2017). In 
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addition to the alterations in dopaminergic nigrostrial pathways in the brainstem 
that are related to the emergence of motor features, degeneration also occurs in 
other brain structures and neurotransmitter systems. Involvement of non-
dopaminergic patterns of neurodegenerations is associated with most of the non-
motor symptoms of PD that are classified into sensory features, neuro-
psychiatric symptoms, sleep and autonomic disorders (Jellinger, 2015; Schapira, 
Chaudhuri, & Jenner, 2017). Among other factors, higher burden of non-motor 
symptoms has been linked with longer duration and greater severity of the 
disease, as well as with postural instability and gait disorder (PIGD)- dominant 
subtype (Barone et al., 2009; Hely, Morris, Reid, & Trafficante, 2005; Müller, 
Larsen, Wentzel-Larsen, Skeie, & Tysnes, 2011). 
PD is an uncurable neurological condition and currently available pharmaco-
therapy is only symptomatic (Charvin et al. 2018). Levodopa is the most fre-
quently used antiparkinsonian medication, however, as the disease progresses, 
levodopa becomes less effective, higher doses are needed to manage the motor 
symptoms, and eventually, levodopa treatment-related motor and non-motor 
complications occur in majority of patients (Chaudhuri, Poewe, & Brooks, 2018). 
Most commonly, cumulative dose and longer treatment duration of levodopa 
and longer disease duration are reported as risk factors associated with the 
occurrence of motor complications (Hashim et al., 2014; Hauser, McDermott, & 
Messing, 2006; Kum et al., 2009; Olanow et al., 2013; Schrag & Quinn, 2000a). 
Non-motor symptoms dominate in the clinical profile of moderate and 
advanced PD patients and predict an impaired quality of life, disability and 
mortality (Chaudhuri, Healy, & Schapira, 2006). Numerous studies have 
demonstrated that non-motor symptoms may be more detrimental for reduced 
health-related quality of life (HRQoL) than motor symptoms (Erro et al., 2016; 
Müller, Assmus, Herlofson, Larsen, & Tysnes, 2013; Ophey, Eggers, Dano, 
Timmermann, & Kalbe, 2018; Prakash, Nadkarni, Lye, Yong, & Tan, 2016). 
Besides the non-motor and motor symptoms of PD, literature on the determinants 
of HRQoL has highlighted several other predictors including disease duration 
and severity, presence of motor complications and several socio-demographic 
factors (Soh, Morris, & McGinley, 2011). 
The primary aim of this study was to investigate the prevalence, incidence 
and mortality rates of PD in a defined population in Estonia. As it was the 
second population-based study using the identical diagnostic criteria and sub-
stantially overlapping case-ascertainment methods in the same geographical 
region, we also aimed at investigating dynamic changes in prevalence and 
incidence rates over 20 years. Mortality of PD in Estonia has not been studied 
before. The second main objective of this study was to assess the clinical 
characteristics of the disease, particularly the frequency of non-motor symptoms 
and their association with various clinical and socio-demographic factors. The 
third aim was to investigate the frequency of levodopa-induced motor compli-
cations and factors associated with them. Finally, the fourth aim was to 
investigate the HRQoL and its determinants in people with PD. 
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2. REVIEW OF THE LITERATURE 
2.1. Epidemiology of PD 
2.1.1. General aspects 
Point prevalence is defined as the number of affected persons present in the 
population at a specific date divided by the number of persons in the population 
at that point in time (Gordis, 2014). The prevalence of PD is generally estimated 
to be 0.3% of the entire population, about 1% in people over 60 years of age, 
and up to up to 4% in the highest age groups (de Lau & Breteler, 2006). The 
incidence rate of a disease is defined as the number of new cases of a disease 
that occurs during a specified period of time in a population at risk for 
developing the disease (Gordis, 2014). The incidence of PD disease ranges from 
8–18 per 100,000 person-years (de Lau & Breteler, 2006). Both prevalence and 
incidence vary widely across different studies, that could most likely be 
attributed to methodological differences such as distinct study designs, case-
finding strategies and diagnostic criteria. Differences in the exposure of 
environmental and genetic risk factors could also affect the variability of PD 
epidemiological estimates across populations worldwide (Abbas et al., 2018). 
Mortality of PD is less studied compared to the prevalence and incidence. A 
frequently used estimate to evaluate the mortality is a standardized mortality 
ratio, i.e the ratio of the total number of deaths actually observed to the total 
number of deaths expected in the general study population without the disease 
(Gordis, 2014). Majority of prospective cohort studies have found that PD 
patients have a nearly 2-folded higher mortality risk than persons without PD, 
and the risk is related to the duration of disease (de Lau et al., 2014; Hobson & 
Meara, 2018; Pinter et al., 2015). 
 
 
2.1.2. Diagnostic accuracy and diagnostic criteria 
No single disease-specific ante mortem diagnosing method is yet available and 
the diagnosis of PD is clinical, therefore the diagnostic accuracy presents a 
challenging issue in PD related research studies. In a recent metaanalysis of 11 
autopsy-verified studies, a pooled diagnostic accuracy of 81% was reported 
(Rizzo et al., 2016). Schrag et al. (2002) showed that a diagnosis of probable 
PD was confirmed in 83% of patients with a prior diagnosis. Diagnostic 
accuracy improves over time, because new aspects in the clinical picture of the 
condition may give suspicion to alternative neurological disorders. A prospective 
cohort study on PD incidence by Duncan et al. (2014a) showed that 86% of 
those who were initially suspected to have PD retained the clinical diagnosis of 
probable PD 18 months later. In the metaanalysis by Rizzo et al. (2016), the 
most frequent misdiagnoses among hospital-based studies were multiple system 
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atrophy, Lewy body dementia, vascular encephalopathy, and progresssive 
supranuclear palsy. 
 The most widely used criteria for PD in clinical practice and research have 
been the UK Parkinson’s Disease Society Queen Square Brain Bank (QSBB) 
criteria that use a three-step process for establishing PD diagnosis (Gibb & Lees, 
1988; Lees et al., 2009). First, for the diagnosis of parkinsonian syndrome, 
bradykinesia in combination with either muscular rigidity, rest tremor or postural 
instability must be present. Second step is to define whether parkinsonism is 
actually caused by PD, i.e no exclusion criteria should be present. Finally, for 
establishing the definite diagnosis of PD, at least three supportive criteria 
should be met (Table 1). 
 
Table 1. QSBB clinical diagnostic criteria for the diagnosis of PD (Gibb & Lees, 1988; 
Lees et al., 2009). 
Step 1 Diagnosis of parkinsonian syndrome 
Bradykinesia (slowness of initiation of voluntary movement with progressive 
reduction in speed and amplitude or repetitive actions) 
And at least one of the following: 
• Muscular rigidity 
• 4–6 Hz rest tremor 
• Postural instability not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction 
Step 2 Exclusion criteria for PD 
• History of repeated strokes with stepwise progression of parkinsonian features 
• History of repeated head injury 
• History of definite encephalitis 
• Oculogyric crises 
• Neuroleptic treatment at onset of symptoms 
• More than one affected relative 
• Sustained remission 
• Strictly unilateral features after 3 years 
• Supranuclear gaze palsy 
• Cerebellar signs 
• Early severe autonomic involvement 
• Early severe dementia with disturbances of memory, language, and praxis 
• Babinski signs 
• Presence of a cerebral tumour or communicating hydrocephalus on CT scan 
• Negative response to large doses of levodopa 
• MPTP exposure 
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Step 3 Supportive prospective positive criteria of PD 
Three or more required for diagnosis of definite PD: 
• Unilateral onset 
• Rest tremor present 
• Progressive disorder 
• Persistent asymmetry affecting the side onset most 
• Excellent response (70–100%) to levodopa 
• Severe levodopa-induced chorea 
• Levodopa response for 5 years or more 
• Clinical course of 10 years or more 
• Hyposmia 
• Visual hallucination 
Abbrevations: PD, Parkinson’s disease; QSBB, Queen Square Brain Bank; MPTP, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine.  
 
In the light of numerous advances in genetics and pathology, the new clinical 
diagnostic criteria for PD created by the International Parkinson and Movement 
Disorder Society (MDS) were published in 2015 (Postuma et al., 2015). In these 
criteria, core parkinsonian features are bradykinesia, rigidity and rest tremor. 
Postural instability is not a part of MDS-PD criteria (because when present 
early, it is suggestable to an alternative diagnosis) (Postuma et al., 2015). 
Similarly to the QSBB criteria, the second step of the MDS-PD criteria is to 
define whether parkinsonism is attributable to PD. Finally, for the clinically 
established diagnosis of PD, absolute exclusion criteria must be absent, at least 
two supportive criteria met and no red flags present. The non-motor symptoms 
have been incorporated into these criteria and particularly into the separate 
criteria for prodromal PD (Berg et al., 2015; Postuma et al., 2015). 
 
 
2.1.3. Prevalence and incidence 
2.1.3.1. Age-adjusted rates 
Most population-based studies that combined multiple available sources to 
identify cases in all ages and examined participants in-person, found the age-
adjusted prevalence rates of PD to range from 105 to 218 per 100,000 persons 
(Hobson, Gallacher, & Meara, 2005; Osaki, Morita, Kuwahara, Miyano, & Doi, 
2011; Walker, Hand, Jones, Wood, & Gray, 2010; Wermuth et al., 2008). Age-
adjusted prevalence rates obtained from door-to-door type of surveys that 
screened patients at all ages range from 53 to 202 per 100,000 (Das et al., 2010; 
Durmus, Gokalp, & Hanagasi, 2015). Studies with an approach to case-
ascertainment based on the drug prescription archive or healthcare insurance 
Table 1. Continuation
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databases without in-person examination of participants have yielded to age-
adjusted prevalence rates varying from 130 to 511 per 100,000 in surveys where 
all ages were screened (Blin et al., 2015; Heinzel et al., 2018; Newman, 
Grosset, & Grosset, 2009). Table 2 and 3 show the reported prevalence rates of 
PD from worldwide epidemiological studies with different study designs. 
Reported age-adjusted incidence rates of PD range mostly from 6 to 36 new 
cases per 100,000 person-years in various study designs used and all ages 
accounted (Blin et al., 2015; Caslake et al., 2013; Das et al., 2010; Savica, 
Grossardt, Bower, Ahlskog, & Rocca, 2016; Van Den Eeden et al., 2003). 
Studies with case-ascertainment based on healthcare insurance databases or 
drug prescription archives have yielded to more variable age-adjusted incidence 
rates when all ages accounted compared to prospective studies with multiple 
case-finding sources and in-person examination of cases, ranging from 10.5 to 
84 (Blin et al., 2015; Heinzel et al., 2018; Morioka et al., 2002; Van Den Eeden 
et al., 2003) and, 9 to 22.5, respectively (Alves et al., 2009; Duncan et al., 
2014a; Linder, Stenlund, & Forsgren, 2010; Winter et al., 2010a). Table 4 and 5 
show the reported incidence rates of PD from worldwide epidemiological 
studies with different study designs. 
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2.1.3.2. Age-specific rates 
A recent meta-analysis of the worldwide data revealed a sharply rising preva-
lence of PD with the increasing age: 41 per 100,000 in individuals 40 to 49 years 
old, reaching as high as 1903 per 100,000 in individuals over age 80 
(Pringsheim et al., 2014). There are inconclusive findings whether the fre-
quency of PD increases along with the advancing age till the very end of life or 
not. Some population-based prevalence studies have found that the highest age-
specific prevalence rates are among the oldest groups studied, i.e over 85 or 95 
years old (Newman et al. 2009; Blin et al. 2014), others suggest that the disease 
frequency peaks in the age-group of 80–84 years old and declines thereafter 
(Walker et al., 2010; Wermuth et al., 2008). It has been suggested that the 
decline in the age-specific prevalence rates in the oldest old is likely an artifact 
caused by decreased diagnostic uncertainty due to comorbid disorders, 
diagnostic denial, and selective loss to follow-up (de Rijk et al., 2000). 
Similarly to the meta-analysis of the prevalence, the worldwide data on the 
PD incidence revealed a sharply rising occurence of PD with the increasing age 
with the peak in those older than 80 years for both men and women (Hirsch et 
al. 2016). Recent meta-analysis on the age-specific incidence rates found that 
these peaked in age-group of 70–79 (Macleod et al., 2018). Several population-
based studies have reported that incidence of PD declines sharply after the age 
of 80 years or over (Duncan et al., 2014a; Hristova et al., 2010; Linder et al., 
2010)..On the contrary, many other studies have demonstrated that incidence 
rates continued to rise in the oldest old people (Bauso et al., 2012; Caslake et 
al., 2013; Savica et al., 2016; Van Den Eeden et al., 2003). It has been proposed 
that mostly diagnostic uncertainty and difficulties with case-finding in the 
elderly people may be responsible for the underestimation of rates of the oldest 
old people in epidemiological and research studies of PD (Macleod et al., 2018). 
 
2.1.3.3. Repeat incidence studies and timetrends 
There have only been a few repeated epidemiological studies of PD prevalence 
in the same geographical area over different time periods showing a modestly 
increasing frequency of the disease (Kuopio et al. 1999a; Wermuth et al. 2008; 
Yamawaki et al. 2009). Prevalence estimates based on studies that report the 
dynamics for several consecutive years have mostly shown an upward trend of 
the disease frequency (Chillag-Talmor et al., 2011; Liu et al., 2016; Myall et al., 
2017). This observation of an increasing frequency of PD is most likely related to 
the shifts in the demographical situation, i.e aging of populations and lengthened 
survival.  
Few studies on the time trends in incidence of PD have found no change or 
reduced incidence rate of overall PD (Chillag-Talmor et al., 2011; Darweesh et 
al., 2016; Horsfall et al., 2013; Liu et al., 2016; Myall et al., 2017). Some 
researchers have shown the trend of increasing incidence of PD particularly 
among men but not in women (Savica et al. 2016; Kuopio et al. 1999a). Three 
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record-based epidemiological studies using the same case-finding methodology 
and diagnostic criteria in Yonago, Japan in 1980, in 1992, an in 2004, have 
shown quite a large increase in overall crude incidence rates (rising from 10.2 to 
18.2 per 100,000), but no changes in adjusted incidence rates (10.3 per 100,000 
in 2004 and similar rates for two earlier studies) (Harada et al. 1983; Kusumi et 
al. 1996; Yamawaki et al. 2009). Another repeat incidence study in Cambridge-
hire, UK, conducted in years 2000–2002 and 2008–2010, found no significant 
differences in age-adjusted incidence rates, being around 13 per 100,000 
person-years (Evans et al., 2016; Foltynie et al., 2004).  
 
2.1.3.4. Influence of gender 
In a meta-analysis on PD prevalence conducted by Pringsheim et al. (2014) that 
included 47 door-to-door or population-based studies, a significant difference in 
age-specific prevalence rates dominating in men was found only for individuals 
50 to 59 years old. Males have been related to higher age-adjusted prevalence 
rates in majority of studies (Kuopio et al. 1999a; Ferreira et al. 2017; Blin et al. 
2014; Newman et al. 2009; Nerius et al. 2017; Riedel et al. 2016). Other studies 
have not observed a statistically significant difference between gender and 
adjusted PD prevalence rates or have reported higher rates for women (Das et 
al. 2010; Osaki et al. 2011; Taba & Asser 2002; Walker et al. 2010; de Rijk et 
al. 1997; Yamawaki et al. 2009). 
Higher age-adjusted incidence of PD in men than in women has been found 
in numerous surveys (Hristova et al. 2010; Alves et al. 2009; Caslake et al. 
2013; Moisan et al. 2016; Savica et al. 2016). Meta-analysis of PD incidence 
studies conducted worldwide from 2001 to 2014 reported an annual crude 
incidence rate of PD in females 40 years and older, 38 per 100,000 person-
years, and 61 in males 40 years and older (Hirsch et al., 2016). One recent meta-
analysis of 22 incident studies found the overall pooled male-to-female 
incidence ratio to be 1.57 (Moisan et al., 2016). However, no significant gender 
differences in PD incidence have been observed in several other studies (Chen 
et al., 2001; Das et al., 2010; Linder et al., 2010; Morioka et al., 2000; Taba & 
Asser, 2003; Tan et al., 2007). Taken together, the effect of gender on PD 
remains an unresolved issue, however, many possible gender-related risk factors 
that shift males to be more predisposed to PD have been proposed (Gillies, 
Pienaar, Vohra, & Qamhawi, 2014). 
 
2.1.3.5. Influence of geographical region and race/ethnicity 
With regard to the geographical distribution, notable continental differences in 
the frequency and occurrence of PD arise. Door-to-door studies from 1985 to 
2010 in the Republic of China that enrolled subjects aged 55 years or more, 
found the age-adjusted prevalence rate to range from 17−177 per 100,000 (Zou, 
Liu, Tian, Lu, & Zhou, 2015). African studies conducted in the mid-1980s and 
mid-1990s that used different study designs and screened subjects in variable 
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ages, found the crude prevalence in range of 10 to 43 per 100,000 (Okubadejo, 
Bower, Rocca, & Maraganore, 2006). Crude prevalence rate estimates in 
Europe based on studies of various designs and age-groups enrolled ranged 
from 65.6 per 100,000 to 12,500 per 100,000 (von Campenhausen et al. 2005). 
More recent systemic review on the prevalence of PD reported that the crude 
prevalence rate of PD in Europe, North-America and Australia range from 
113/100,000 in persons aged 50 to 59 up to 2953 per 100,000 in persons aged 
80 years and more. For comparison, the same rates for South America and Asia 
were 228 up to 6096 and 88 up to 1418, respectively (Pringsheim et al., 2014).  
Age-adjusted incidence estimates in Europe varied from 9 to 84 new cases 
per 100 000 person-years when all ages accounted and different study types 
used (Alves et al., 2009; Blin et al., 2015; Caslake et al., 2013; Heinzel et al., 
2018; Hristova et al., 2010; Linder et al., 2010; Moisan et al., 2016; Myall et al., 
2017; Winter et al., 2010a). In North-America, age-adjusted incidence rates 
ranged from 238 to 446 per 100,000 person-years among people aged 65 or 
more (Gordon et al., 2015; Jones et al., 2012; Willis, Evanoff, Lian, Criswell, & 
Racette, 2010). In Asian countries, the age-adjusted incidence rate for people at 
all ages ranged from 5.7 to 17 per 100,000 person-years (Das et al. 2010; 
Morioka et al. 2000). Taken together, prevalence and incidence of PD appear to 
be higher in western than in eastern countries referring to possible role of 
environmental exposures and genetic predisposition, however, different 
methodological approaches may hamper the comparison of studies (Abbas et 
al., 2018; Wirdefeldt, Adami, Cole, Trichopoulos, & Mandel, 2011). 
In terms of race and ethnicity, a significant ethnic diversity in the prevalence 
and incidence of PD was found in an epidemiologic study of PD among people 
aged 65 years and more living in USA. When compared to the Whites, the ratios 
of crude prevalence and incidence rates were 0.58 and 0.69 for Asians and 0.62 
and 0.74 for Blacks, respectively (Willis et al., 2010). Another population-based 
study screening PD incident cases at all ages in USA found that the age- and 
gender-adjusted incidence rates were highest among Hispanics, followed by 
non-Hispanic Whites, Asians, and Blacks (Van Den Eeden et al., 2003). Across 
the major ethnic groups within the New Zealand, Europeans were found to have 
the highest age-adjusted incidence rate of 33 per 100,000 person-years, 
followed by Asian, 28, Pasifika, 27, and Māori groups, 20, respectively (Pitcher 
et al., 2018). High frequency of PD has been found to be in Israel with the 
adjusted prevalence and incidence rates of 334 per 100,000 and 45 per 100,000, 
respectively, a phenomenon that is likely to be related to the specific genetic 
backround (Chillag-Talmor et al., 2011). One of the highest frequences of PD 
has been found in an Amish community in USA where the crude prevalence 
rate was reported to be 5,703 per 100,000 in persons aged 60 years or more 
(Racette et al., 2009).  
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2.1.4. Mortality and comorbidity 
Majority of studies with varying methodological approaches and disease 
duration have found that PD patients have a significantly higher overall 
mortality risk than persons without PD, with standardized mortality ratio 
ranging from 0.5 to 3.8 (Hely, Reid, Adena, Halliday, & Morris, 2008; Pinter et 
al. 2015; Hobson & Meara 2018; de Lau et al. 2014; Morgan et al. 2014; Das et 
al., 2010). One recent meta-analysis reported the overall pooled standardized 
mortality ratio to be 1.52 (Macleod et al., 2014). Several reports have shown 
that there is no excess of mortality in the first ten years of the disease 
(Williams-Gray et al. 2013; Zhang et al. 2018). PD patients with dementia have 
shown to have a particularly higher risk of mortality (Herlofson et al. 2004; Lau 
et al. 2014; Posada et al. 2011; Pinter et al. 2015). Other risk factors of mortality 
have been found to be higher age, male sex, PIGD, and the presence of 
psychotic symptoms (de Lau et al., 2014; Williams-Gray et al., 2013; Zhang et 
al., 2018). No significant gender differences in standardized mortality ratios of 
PD males and PD females have been found by two of the longest follow-up 
cohort studies (Hely et al., 2008; Pinter et al., 2015). Some studies have 
reported that female PD patients had a greater reduction in lifespan compared to 
male PD patients (Morgan et al., 2014) and that survival rates of men were 
closer to that of women in patients with PD than in persons without PD (Chen et 
al., 2001).  
Most of the information on causes of death comes from death certificates. It 
has been identified by many studies that PD is often underrepresented on death 
certificates, mentioned as a primary or underlying cause of death in 15 to 60% 
among those who had the clinical diagnosis while alive (Benito-León et al., 
2014; Goldacre, Duncan, Griffith, & Turner, 2010; Hobson & Meara, 2018; 
Moscovich et al., 2017; Williams-Gray et al., 2013). The leading underlying 
causes of death among PD patients are pneumonia, cerebrovascular and 
cardiovascular diseases (Williams-Gray et al. 2013; Allyson Jones et al. 2012; 
Moscovich et al. 2017; Pinter et al. 2015; Hely et al. 2005; Das et al. 2010). 
There is evidence from cohort studies that cancer in PD patients is less 
commonly represented on death certificates than in persons without PD (Benito-
León et al. 2014; Hobson & Meara 2018; Allyson-Jones et al. 2012), although 
not shown by some other studies (Pinter et al. 2015). Some tumours, parti-
cularly melanoma, are found to be more common in patients with PD compared 
to the general population (Ferreira et al., 2010). 
Studies investigating the burden of comorbidities among PD patients 
compared to the general population have yielded to inconsistent results. Several 
longitudinal cohort studies have found that PD patients have a higher frequency 
of comorbidities and total load of polypharmacy compared to healthy controls 
(García et al., 2017; McLean, Hindle, Guthrie, & Mercer, 2017). On the 
contrary, no differences between the overall load of comorbidities was evidenced 
in a cohort study of incident PD patients (Macleod, Goddard, & Counsell, 
2016). Recent record-based cohort study in Germany found that PD patients 
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have a significantly higher prevalence of diabetes and hypertension compared to 
controls (Heinzel et al., 2018). 
 
 
2.1.5. Risk factors 
No exact molecular mechanism of the neurodegeneration has yet been identified 
but oxidation of dopamine, mitochondrial dysfunction, endoplasmic reticulum 
stress, impaired autophagy, and dysregulation of immunity are widely accepted 
as the main contributive factors involved in the death of dopaminergic neurons 
in the Substantia nigra (Blennow, Biscetti, Eusebi, & Parnetti, 2016; Zeng, 
Geng, Jia, Chen, & Zhang, 2018). Although majority of PD cases are sporadic, 
monogenetic forms with a high penetrance account for approximately 5–10% of 
all cases and these have contributed to our understanding of the pathogenesis of 
the disease (Poewe et al. 2017; Mullin & Schapira 2015). Several single genes 
have been identified that are confirmed to cause PD of classic Mendelian 
inheritance. Genes encoding α-synuclein (SNCA), leucine-rich repeat kinase 2 
(LRRK2) and vacuolar protein sorting 35 (VPS35) are linked with the 
autosomal dominant hereditary PD (Mullin & Schapira, 2015). LRRK2 is the 
most commonly mutated gene in PD that is associated with less severe disease, 
slower rate of progression and less frequent presence of cognitive decline and 
anosmia than idiopathic PD (Healy et al. 2008). The highest frequency of 
LRRK2 mutations (both hereditary and sporadic cases) has been found in north 
African Arabs and Ashkenazi Jews (Healy et al., 2008). Other genes, parti-
cularly Parkin-gene, PINK-1-gene, DJ-1 and ATP13A2-gene are associated 
with the autosomal recessive hereditary pattern of the disease (Mullin & 
Schapira, 2015). 
Beyond the monogenic PD cases, whole-genome association studies have 
identified a growing number of disease-predisposing genes (Lill et al., 2012). 
So far, at least 24 loci with polymorphisms within certain genes that may 
influence the risk for the disease occurrence have been identified (Redenšek, 
Trošt, & Dolžan, 2017). These are relatively common mutations with lower or 
variable penetrance compared to monogenic PD forms accounting for up to 
30% of PD cases (Mullin & Schapira, 2015). There is some overlap between 
genes associated with familial and sporadic disease; in particular, SNCA and 
LRRK2 are involved in both forms (Borrageiro et al. 2018; Redenšek et al. 
2017). One of the greatest genetic risk factors for the development of PD are 
heterozygous mutations in gene encoding the lysosomal enzyme glucocerebro-
sidase (GBA). Single GBA mutation increases the risk for the development of 
PD by approximately 5-fold (Sidransky et al. 2009). GBA-associated PD is 
linked to the higher likelihood of earlier disease onset, higher incidence of 
cognitive decline, more rapid progression and reduced survival (Brockmann et 
al., 2015; Sidransky et al., 2009). GBA mutations are particularly high among 
the Ashkenazi Jewish, being present in 15% of PD patients of this ethno-
religious nation (Sidransky et al., 2009). Mendelian and identified high-risk loci 
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explain altogether between approximately 10% and 40% of PD risk in most 
populations assessed (Hardy, 2010). 
Beyond the inherited forms of PD, risk of developing sporadic PD is with 
great probability multifactorial, resulting from complicated interaction between 
environmental, genetic and epigenetic factors affecting numerous fundamental 
cellular processes (Kalia & Lang, 2015; Lees et al., 2009). One of the strongest 
risk factors for the development of PD is increasing age (Poewe et al., 2017). 
Disease onset is relatively infrequent under the age of 55, only approximately in 
4–10% of all cases in the population-based studies conducted in the Eastern 
Europe (Hristova et al., 2010; Taba & Asser, 2003; Winter et al., 2010a). 
No environmental risk factor with a convincing pathogenic role in the 
disease has yet been described (Hardy, 2010). However, epidemiological studies 
have provided evidence that the incidence of PD is significantly greater in 
individuals exposed to certain environmental factors. Living in rural area has 
been found to be a risk factor for PD in some studies (Kuopio et al. 1999a; Kab 
et al. 2017), but not supported by other surveys (Hristova et al., 2010; Taba & 
Asser, 2003). A nested case-control study by Tanner et al. (2011) supported the 
role of pesticides in PD pathophysiology; these environmental factors have long 
been linked with the disease’s etiology. Exposure to pesticides, consumption of 
dairy products, history of melanoma, and traumatic brain injury were found to 
be associated with the increased PD risk in a recent review (Ascherio & 
Schwarzschild, 2016). Numerous potential protective factors of PD have been 
proposed, among them, cigarette smoking and coffee drinking most frequently 
shown to be inversely related to PD (Ascherio & Schwarzschild, 2016; Martino 
et al., 2017; Noyce et al., 2012). Rossi et al. (2018) have suggested that there 
will be an increase of additional 10% of PD cases by the year 2040, when the 
prevalence of non-smoking is accounted. Also higher serum urate concent-
rations, physical activity, and use of ibuprofen have been linked with the 
reduced risk of PD (Ascherio & Schwarzschild, 2016). 
 
 
2.2. Clinical presentation of the disease 
PD is a progressive neurodegenerative disorder characterized by the presence of 
motor and non-motor features. There are four cardinal parkinsonian features 
including bradykinesia, rest tremor and rigidity, as well as postural instability 
that is more characteristic to the later course of the disease (Jankovic, 2008; 
Lees et al., 2009). The wide range of non-motor problems encompass sensory 
features (i.e olfactory deficits, visual disturbances, pain and somatosensory 
disturbances), neuropsychiatric symptoms (i.e anxiety, depression, apathy and 
fatigue, cognitive deficits, dementia and psychoses), sleep disorders and 
autonomic dysfunction (i.e bladder and gastrointestinal dysfunction and 
cardiovascular features) (Schapira et al., 2017). 
 
 
25 
Population-based incidence studies indicate that the mean age of onset of 
motor symptoms is most commonly in the range of 65 to 77 years (Kuopio et al. 
1999a; Hristova et al. 2010; Caslake et al. 2013; Nerius et al. 2017). Early 
motor features can be subtle, worsen gradually and patients may first come to 
medical attention some time after the occurrence of first symptoms (Lees et al., 
2009). Mean time from onset of motor symptoms to the diagnosis of PD has 
been reported to vary from 1.4 to 2.2 years (Hristova et al., 2010; Linder et al., 
2010; Taba & Asser, 2003). The most frequent initial classical symptom of PD 
appears to be tremor, reported in 55 to 72% of all incident cases (Caslake et al., 
2013; Linder et al., 2010; Taba & Asser, 2003; Winter et al., 2010a). 
It is currently well accepted that pathological changes of PD begin earlier 
than classical motor signs appear, giving rise to a number of non-motor 
symptoms (Gaig & Tolosa, 2009). The so-called prodromal phase of PD, is 
characterized by the presence of specific non-motor symptoms, particularly 
olfactory deficit, REM sleep behaviour disorder, constipation, depression and 
excessive daytime sleepiness, that may manifest years or even decades before 
the onset of classical motor symptoms (Claassen et al., 2010; Gaenslen et al., 
2014; Ross, Abbott, Petrovitch, Tanner, & White, 2012).  
Cross-sectional data on PD patients using different instruments to measure 
individual non-motor symptoms suggest that at least one non-motor symptom is 
present in almost all PD patients, with the mean number of 8–11 features in 
each patient (Kovács et al. 2016; Gallagher et al. 2010; Martinez-Martin, 
Rodriguez-Blazquez, Kurtis & Chaudhuri 2011a). The most common non-
motor symptoms assessed with the Non-Motor Symptoms Questionnaire 
(NMSQuest) among patients with the mean duration of disese about 8 years 
have been reported to be nocturia (65%), urgency (60%), memory difficulties 
(51%), low mood (49%), constipation (48%), taste/olfactory deficit (43%) and 
dribbling saliva (42%) (Chaudhuri et al. 2010). Female PD patients may 
experience more severe depressive and anxiety symptoms, pain, and orthostatic 
problems compared to men (Kovács et al., 2016). On the contrary, men have 
been found to experience more frequently sexual problems, sialorrhoea and 
excessive daytime sleepiness (Martinez-Martin et al. 2012). 
 
 
2.2.1. Clinical subtypes 
Clinical picture and rate of progression of PD are highly heterogenous indicating 
to the underlying biological or pathophysiological differences between 
individuals (Marras & Lang, 2013). Several different subtype classification 
systems have been introduced with an attempt to classify patients according to 
age-at-onset categories, major motor phenotypes, patterns of cognitive impair-
ment, and other non-motor symptoms (Marras & Chaudhuri, 2016). Among the 
PD clinical subtypes based on the most prominent motor feature, common 
categorizations divide the phenotype into tremor-dominant versus PIGD or 
tremor-dominant and akinetic-rigid/PIGD and mixed phenotypes (Alves, 
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Larsen, Emre, Wentzel-Larsen, & Aarsland, 2006; Jankovic et al., 1990; 
Stebbins et al., 2013; Thenganatt & Jankovic, 2014). In general, patients with 
the PIGD type of PD tend to have higher risk for dementia and mortality; while 
patients with tremor-dominant phenotype have a more benign course and slower 
rate of cognitive decline (Reijnders et al. 2009; Alves et al. 2006; Anang et al. 
2014). It has been proposed that different motor subtypes of PD may not 
represent different biological entities, but rather different stages of disease (Nutt 
2016). Alves et al. (2006) found that 44% of patients with tremor-dominant 
phenotype at baseline had converted to PIGD after a follow-up of 8 years. With 
regard to the classification by age of onset, patients with younger age at onset 
may have a slower disease progression, an increased rate of dystonia at onset or 
during treatment, lower rate of dementia, and an increased rate of dyskinesias in 
response to levodopa treatment (Wickremaratchi, Ben-Shlomo, & Morris, 
2009). 
 
 
2.2.2. Progression of the disease 
Progression of PD is characterized by worsening disability due to an increase in 
severity of motor symptoms and with the occurrence of levodopa-induced motor 
complications, as well as due to an increase in the burden of non-motor 
symptoms (Coelho & Ferreira, 2012). As regards motor symptoms, the 
progression of PD appears to have a faster rate of motor deterioration in the 
earlier stage and the decreasing rate of progression in more advanced stage of 
disease, whereas the disability continues to deteriorate along with the entire 
duration of disease (Schrag et al., 2007). Prognostic factors for faster motor 
impairment have been found to be male gender, and cognitive dysfunction 
present at newly diagnosed patients (Velseboer et al., 2013). The median 
increase of the Unified Parkinson Disease Rating Scale (UPDRS) part III (Fahn, 
Elton, & UPDRS Program Members, 1987) over the follow-up of 2 years has 
been reported to be 4 points in patients with the mean disease duration of 5.8 
years at baseline PD (Prakash et al., 2016). One of the largest, multi-center, 
international, cross-sectional study of the 3206 PD patients (the Quality of Life 
in Parkinson’s disease [QUALPD] study cohort) showed that all the subcores of 
Parts I–IV of the Movement Disorder Society (MDS)-revision of the UPDRS 
(MDS-UPDRS) (Goetz et al., 2008) increased significantly with 5-year 
increments of duration only in the first 15 years of disease (Skorvanek et al., 
2017). The same study also revealed that all the subscores of MDS-UPDRS 
Parts I–IV increase along with the progression of Hoehn and Yahr (HY) stages 
(Hoehn & Yahr, 1967) through I to V. 
Longitudinal data suggests that the overall burden of non-motor symptoms 
increases significantly over time (Antonini et al., 2012; Erro et al., 2016; Müller 
et al., 2013). In contrary, another prospective study enrolling newly diagnosed 
PD patients (n=227) found the total burden of non-motor symptoms to be 
slightly decreased over the follow-up of 2 years (Prakash et al., 2016). By 
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individual symptoms, sleep and autonomic problems, cognitive impairment and 
skin disturbances became more prevalent along with the duration of disease in 
another prospective study with 707 prevalent cases followed for 2 years 
(Antonini et al., 2012). Erro and co-workers (2016) found that swallowing 
difficulties, nausea/vomiting, nocturia, hallucinations, sex drive, dizziness, 
daytime sleepiness and restless leg syndrome were the non-motor symptoms 
that had the highest increase after 4 years since diagnosis. 
Surveys such as that conducted by Williams-Gray et al. (2013) and Hely et 
al. (2008) have shown that dementia is present in about 50% of patients after 
10 years, and in 83% of patients after 20 years from disease onset, respectively. 
Motor and non-motor fluctuations, mild dementia, hallucinations, repeated falls, 
and difficulty with activities of daily living are indicators to the stage of 
advanced PD (Antonini, Moro, Godeiro, & Reichmann, 2018). Late-stage PD is 
defined as a phase of the disease where patients are highly dependent on 
caregivers for activities of daily living, owing to motor symptoms or non-motor 
symptoms that are resistant to levodopa (Coelho & Ferreira, 2012). In a clinico-
pathological study, visual hallucinations preceded death by about 5 years, 
regular falls by 4.1 years, dementia by 3.3 years, and need for residential care 
by 3.3 years stage (Kempster, O’Sullivan, Holton, Revesz, & Lees, 2010).  
 
 
2.3. Treatment 
Currently available PD pharmacotherapy is only symptomatic, it does not 
prevent, delay, halt neither slow the progression of the disease (Charvin et al., 
2018; Lang & Espay, 2018). Although there is no general consensus when to 
initiate the therapy, the widespread recommended strategy is to start PD 
treatment as early as possible because this is likely to relief motor features, 
improve the quality of life and maintain the productivity of affected patients 
(Löhle, Ramberg, Reichmann, & Schapira, 2014). One earlier longitudinal 
study over 18 months showed that the HRQoL was lower in those patients who 
were left untreated (n=114) compared to those (n=74) who had started 
antiparkinsonian treatment soon after the diagnosis was established (Grosset et 
al., 2007). 
The Movement Disorder Society Evidence-Based Medicine Committe 
recommends oral levodopa, dopamine agonists, monoamine oxidase B (MAO-B) 
inhibitors, amantadine and anticholinergics as a monotherapy or as an adjunct 
therapy to levodopa for reducing motor symptoms in early or stable PD patients 
(Fox et al., 2018). Specific drug choice class for the initial treatment depends on 
characteristics of patients (age, mental status, occupation, comorbidities), 
disease severity and efficacy, safety and side-effects of each drug (Stocchi, 
Vacca, & Radicati, 2015). 
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2.3.1. Levodopa induced complications 
Levodopa, the first drug introduced specifically for PD in the 1960s (Lees, 
Tolosa, & Olanow, 2015), is the most effective and most frequently prescribed 
antiparkinsonian medication. As the disease progresses, levodopa becomes less 
effective, higher doses are needed to manage the motor symptoms, and 
eventually, levodopa treatment-related motor and non-motor complications (i.e. 
motor and non-motor fluctuations and dyskinesias) emerge in majority of 
patients (Chaudhuri et al., 2018).  
In the early phases of PD, oral dopaminergic therapies are usually effective, 
but when the disease progresses these conventional oral treatments no longer 
ameliorate the symptoms, including levodopa induced fluctuations and 
dyskinesias (Odin et al., 2015). Advanced PD is also characterized by an 
increasing burden of non-motor (e.g. cognitive impairment, orthostatic hypo-
tension) and axial symptoms (e.g. freezing, postural instability, falls, dysarthria, 
dysphagia), features that are known to respond poorly to dopaminergic drugs, 
therefore complicating even more the management of those patients (Antonini 
et al., 2018). 
To postpone the onset of motor complications, a levodopa-sparing initial 
therapy is justified for young patients (<60 years), as well as for those with mild 
symptoms or when tremor is the most prominent symptom (Connolly & Lang, 
2014). A longitudinal study by Lopez et al. (2010) reported that all PD patients 
needed levodopa within 5 years since diagnosis and the frequency of motor 
complications by the 10th year since diagnosis was similar among those whose 
initial treatment was levodopa compared to those who received another drug. 
Furthermore, no long-term benefit of a levodopa sparing initial therapy was 
evidenced in controlled trials comparing levodopa and bromocriptine (Katzen-
schlager et al., 2008) and dopamine agonists or MAO-B inhibitors and levodopa 
alone (PD MED Collaborative Group, 2014). An earlier guideline for thera-
peutic management of PD concluded that controlled-release levodopa does not 
delay motor complications compared with standard levodopa (Ferreira et al., 
2013). 
The main risk factors for the development of motor complications are higher 
cumulative dose and longer treatment duration of levodopa and longer disease 
duration (Hauser et al., 2006; Olanow et al., 2013; Scott, Macleod, & Counsell, 
2016). It is recommended to use low doses of levodopa that provides satis-
factory clinical control but postpones levodopa-induced complications (Olanow 
et al., 2013). Female gender (Bjornestad et al., 2016; García-Ruiz, del Val, 
Fernández, & Herranz, 2012; Olanow et al., 2013; Scott et al., 2016), and 
younger age at onset (Bjornestad et al., 2016; García-Ruiz et al., 2012; Hashim 
et al., 2014; Olanow et al., 2013) are among other variables that potentially 
increase the risk for earlier occurrence of motor complications. 
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2.3.1.1. Motor fluctuations 
Motor fluctuations are alterations of clinical state with a good motor response to 
medication (“on”) and clinical state with no response to medication and 
worsening of motor symptoms (“off”) (Aquino & Fox, 2015). Classification of 
motor fluctuations by clinical pattern includes wearing-off, delayed on, dose-
failures and random on-off (Chaudhuri et al., 2018). Most common subtype of 
motor fluctuation is a wearing-off phenomenon being present in about 80% of 
those with motor fluctuations (Chapuis, Ouchchane, Metz, Gerbaud, & Durif, 
2005; Hely et al., 2005). 
Cross-sectional studies involving PD patients with variable duration of 
disease have found the frequency of motor fluctuations in a range of 22% to 
75% (Chapuis et al., 2005; Hechtner et al., 2014; Kum et al., 2009; Larsen, 
Karlsen, & Tandberg, 2000; Perez-Lloret et al., 2017). Prospective studies have 
reported the prevalence of motor fluctuations to range from 21% to 50% after 5 
years (Bjornestad et al., 2016; Kumar, Van Gerpen, Bower, & Ahlskog, 2005; 
López et al., 2010; Scott et al., 2016), 95% after 10 years (López et al., 2010), 
and 100% of patients after 20 years from diagnosis (Hely et al., 2008). The 
prevalence of motor fluctuations across different studies is illustrated in Table 6. 
For advanced PD patients with motor fluctuations, the evidence-based review 
recommends to use dopamine agonists including apomorphine, levodopa, 
catechol-O-methyltransferase (COMT) inhibitors, and MAO-B inhibitors (Fox 
et al., 2018). If motor complications are not satisfactorily controlled by orally 
delivered agents, device-aided therapies (levodopa/carbidopa intestinal gel 
infusion, apomorphine infusion, and deep brain stimulation) are recommended 
(Antonini et al., 2018). 
 
2.3.1.2. Dyskinesias 
Dyskinesias are abnormal hyperkinetic movements, usually affecting head, 
neck, trunk, and limbs, most typically presenting as peak-dose or biphasic. Off-
period dystonia is another type of dyskinesia that frequently involves the foot 
and leg; it is often painful and usually starts at night or early in the morning 
(Aquino & Fox, 2015; Vijayakumar & Jankovic, 2016).  
Based on cross-sectional studies, the frequency of dyskinesias ranges from 
10% to 77% (Chen et al., 2014; Kum et al., 2009; Perez-Lloret et al., 2017; 
Schrag & Quinn, 2000a). Similar to motor fluctuations, prospective studies have 
consistently shown an association between dyskinesias and disease duration, 
occurring in 13% to 28% of patients by the 5th year (Bjornestad et al., 2016; 
Scott et al., 2016), in 71% by the 10th year (López et al., 2010), in 94% by the 
15th year (Hely et al., 2005), and in 100% by the 20th year (Hely et al., 2008). 
The prevalence of dyskinesias across different studies is illustrated in Table 6. 
When dyskinesias are severe, antidyskinetic agents such as amantadine or 
clozapine as oral forms of medications are recommended to be used. Among 
surgical interventions used to treat dyskinesias, intestinal infusion of levodopa 
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and deep brain stimulation and pallidotomy have also proven to be clinically 
useful and to have acceptable safety properties (Fox et al., 2018). 
 
2.3.1.3. Non-motor fluctuations 
Long-term dopaminergic therapy may complicate not only with the fluctuations 
of motor symptoms but also with a range of non-motor symptoms classified into 
neuropsychiatric, autonomic and sensory features (Chaudhuri et al. 2018). 
Cross-sectional studies using different assessment methods have reported the 
prevalence of non-motor fluctuations to range from 14% to 40% of patients, 
with higher rates in women (Altavista et al., 2015; Brun et al., 2014; Picillo et 
al., 2016). Anxiety, mood changes, pain and cloudy mind have been the most 
frequently reported non-motor features that fluctuate (Altavista et al., 2015; 
Picillo et al., 2016; Stocchi et al., 2014). 
Presence of motor fluctuations has been found to be the predictor for the 
development of non-motor fluctuations and they may develop on average of 10 
years after disease onset (Brun et al., 2014). Other factors reported to be 
associated with the risk of emergence of non-motor fluctuations include female 
gender, younger age at disease onset, longer duration of levodopa and severity 
of the disease (Altavista et al., 2015; Picillo et al., 2016). Management is similar 
to the treatment of motor-fluctuations including device-aided continuous 
dopaminergic treatments (Martinez-Fernandez et al., 2016). 
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2.4. Health-related quality of life 
World Health Organization (WHO) defines quality of life as an individual’s 
pereception of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectations, standards 
and concerns (Whoqol Group, 1995). HRQoL is a more narrower concept 
characterized by domains related to physical, mental, emotional, and social 
functioning, and focuses on the impact health status has on quality of life 
(Martinez-Martin, 1998). It has been well documented that PD patients have a 
significantly reduced quality of life compared to the general population based 
on using generic instruments such as Short-Form Health Survey (SF-36) and 
Euro Qol (EQ5D) (Schrag, Jahanshahi, & Quinn 2000c; Reuther et al. 2007). 
Furthermore, a multicenter cohort study on multimorbidity among elderly 
persons in Germany found that out of all chronic diseases PD has the most 
negative impact on the HRQoL, and „self-care“ and „usual activities“ of the 
EQ5D were the dimensions affected the most (Brettschneider et al., 2013).  
Among the disease-specific instruments that measure HRQol in PD patients, 
the most thoroughly tested and used is the Parkinson’s disease Questionnaire 
(PDQ-39) (Martinez-Martin et al., 2011b). PDQ-39 is composed of 39 items 
grouped in 8 domains: mobility, activities of daily living, emotional well-being, 
stigma, social support, cognition, communication, and bodily discomfort 
(Jenkinson, Fitzpatrick, Norquist, Findley, & Hughes, 2003; Peto, Jenkinson, 
Fitzpatrick, & Greenhall, 1995). The highest scores (showing worse quality of 
life) in PD patients have been reported to be in the domains of mobility, 
activities of daily living, emotional well-being and bodily discomfort, while the 
lowest scores (i.e least affected) in the domain of social support (Barone et al., 
2009; Rodríguez-Violante et al., 2013; Sławek, Derejko, & Lass, 2005). 
Assessment of HRQoL of PD patient helps to understand his or her condition, 
identify the main factors causing HRQoL impairment, and establish priorities of 
management according to them (Martinez-Martin, 2017). The PDQ-39 and its 
short form PDQ-8 are common outcome measures used in many trials to assess 
the therapeutic effect (Martinez-Martin, Rodriguez-Blazquez, Forjaz, & Kurtis, 
2015). 
Persons with PD are particularly vulnerable to deterioration of HRQoL due 
to the progressive nature of motor disability and the increasing burden of non-
motor symptoms (Chaudhuri et al., 2006). While some clinically relevant 
factors have been almost conclusively found to be negative independent strong 
predictors of HRQol (eg. depression) (Müller et al., 2013; Skorvanek et al., 
2018; van Uem et al., 2018), results on other determinants (e.g. dyskinesias) 
have been more inconclusively reported by various authors (Hechtner et al., 
2014; Rahman, Griffin, Quinn, & Jahanshahi, 2008; Winter et al., 2011). Impact 
of certain socio-demographic factors may also contribute to the reduced 
HRQoL. A summary of cross-sectional studies on HRQoL determinants using 
multiple regression analysis is demonstrated in Table 7. Determinants of HRQol 
are reported in more detail in the text below. 
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2.4.1. Impact of gender, age and age at onset 
There are inconclusive results about the influence of gender on HRQoL. Some 
studies have identified female gender to be an independent negative predictor of 
lower HRQol (Balzer-Geldsetzer et al., 2018; Behari, Srivastava, & Pandey, 
2005; Kovács et al., 2016; Morimoto et al., 2003), but others have not found 
such an association (Hinnell, Hurt, Landau, Brown, & Samuel, 2012; Klepac et 
al., 2007; Marras et al., 2008; Ophey et al., 2018; Prakash et al., 2016; Schrag, 
Jahanshahi, & Quinn, 2000d; Skorvanek et al., 2015). Women have demon-
strated significantly more negative assessment of their HRQoL than men in 
domains of mobility, emotional-well-being and bodily discomfort (Balzer-
Geldsetzer et al., 2018; Kovács et al., 2016). Several studies have found that 
women seem to have a higher total burden of non-motor symptoms, particularly 
regarding depression, anxiety, fatigue and pain (Guo et al. 2013a; Kovács et al. 
2016; Solla et al. 2012). Women have also known to be at higher risk of 
developing dyskinesias (Bjornestad et al., 2016; García-Ruiz et al., 2012; 
Olanow et al., 2013; Scott et al., 2016), and non-motor fluctuations (Picillo et 
al., 2016). Some authors have reported that female PD patients have worse 
postural stability (Kovács et al., 2016; Solla et al., 2012). In light of the 
abovementioned gender differences, there might be several reasons why quality 
of life of female PD patients could be more affected than that of men. 
A number of prospective and cross-sectional studies have postulated no 
convergence between age and the overall HRQoL (Balzer-Geldsetzer et al., 
2018; Carod-Artal, Vargas, & Martinez-Martin, 2007; Marras et al., 2008; 
Prakash et al., 2016; Skorvanek et al., 2015). However, authors of one earlier 
prospective cohort study in Norway using the generic health questionnaire 
Nottingham Health Profile (NHP) reported that higher age at baseline of 
prevalent PD cases was associated with poorer overall quality of life in a 
follow-up of 8 years. Aspects of energy, social isolation and physical mobility 
were affected the most (Forsaa, Larsen, Wentzel-Larsen, Herlofson, & Alves, 
2008). One other prospective study (DATATOP trial) that used the SF-36 as an 
outcome measure of HRQoL found that advancing age predicts impairment in 
mental domain (Marras et al., 2008). Also Winter et al. (2010b) found in their 
cross-sectional study conducted in Russia that increasing age was an inde-
pendent determinant for reduced HRQoL assessed by the EuroQol instruments. 
On the other hand, Schrag et al. (2000c) described that particularly younger PD 
patients were more prone to reduced quality of life in aspects of physical and 
social functioning, physical role limitations and general health perceptions when 
compared to the norms retrieved from the general population. Younger age 
predicted poorer HRQoL also in a few other studies (Hinnell et al. 2012; 
Rodríguez-Violante et al. 2013).  
The impact of PD on HRQoL may differ depending on age at onset. Higher 
age at onset was found to be a prognostic factor for a steeper decline of the 
HRQoL in a prospective CARPA study in the Netherlands (Velseboer et al., 
2013). One earlier cross-sectional study in Poland did not identify any 
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differences in the overall HRQoL between PD patients of young-onset or old-
onset (young-onset defined as below 47 years of age, old-onset defined as above 
66 years of age) (Zach, Friedman, Sławek, & Derejko, 2004). Nonetheless, 
differences in several aspects of quality of life stratified by onset age were 
found, i.e. young-onset patients reported to have poorer HRQoL in domains of 
activities of daily living, emotional well-being, stigma and communication, 
while social support was assessed higher compared to patients with older onset 
age (Zach et al., 2004). Younger age at onset also predicted a lower quality of 
life in aspects of mental health and vitality assessed by the SF-36 (Kuopio, 
Marttila, Helenius, Toivonen, & Rinne, 2000). In a case-control study by Knipe 
and colleagues (2011) early-onset PD patients (defined as below 45 years of 
age) were found to have poorer overall HRQoL assessed by the PDQ-39, 
however the effect was weakened after the adjustment for depression as an 
intermediary factor. In the same study, younger onset age was also a predictor 
for poor emotional well-being independent of depression status (Knipe, 
Wickremaratchi, Wyatt‐Haines, Morris, & Ben‐Shlomo, 2011). 
 
 
2.4.2. Impact of other socio-demographic variables 
Lower education has been revealed to be an independent determinant of HRQol 
by some authors (Carod-Artal et al., 2007; Cubo et al., 2002; Knipe et al., 2011) 
but not by others (Prakash et al., 2016; Rodríguez-Violante et al., 2013; Skorva-
nek et al., 2018; Sławek et al., 2005). In terms of living area, some studies have 
found no difference between the quality of life between PD patients living in 
urban or rural area (Kuopio et al., 2000), while others have reported that rural 
living is an independent negative predictor of reduced HRQoL (Klepac et al., 
2007; Soh, McGinley, Watts, Iansek, & Morris, 2012). Higher number of 
persons in household was found to be an independent positive predictor of 
better HRQoL (Winter er al. 2010b), but living together with children or 
grandchildren did not emerge as a significant determinant of quality of life in 
other studies (Behari et al., 2005; Sławek et al., 2005). Comorbidities were 
found to be independently related to the reduced quality of life in several studies 
(Carod-Artal, Ziomkowski, Mourão Mesquita, & Martínez-Martin, 2008; 
Hinnell et al., 2012; Post, Muslimovic, van Geloven, & Speelman, 2011), but no 
such association was found in other studies (Sławek et al., 2005). 
 
 
2.4.3. Impact of disease duration 
A number of cross-sectional studies have found that increasing disease duration 
is related to the reduced HRQoL (Benge et al., 2016; Morimoto et al., 2003; 
Zach et al., 2004). Change might not be uniform across all components of 
HRQol. A prospective study on de novo PD patients followed over 4 years in 
Italy showed an improvement of the domain of stigma, whereas the domain of 
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the bodily discomfort significantly got worse (Erro et al., 2016). On the contrary, 
cross-sectional studies have demonstrated that disease duration contributes most 
to the activities of daily living, stigma and communication, but it does not affect 
social support nor bodily discomfort (Benge et al., 2016; Zach et al., 2004). 
With the progression of neurodegeneration and advancing disease severity, 
several non-motor problems such as cognitive impairment, autonomic dysfunc-
tion and sleep disorders become to dominate the clinical picture and are the 
main determinants of quality of life and institutionalization (Chaudhuri et al., 
2006). 
 
 
2.4.4. Impact of motor and non-motor symptoms 
Among the motor symptoms, the most related to the impaired HRQoL are 
problems with activities of daily living (Skorvanek et al., 2018; Müller et al. 
2013; Rahman et al. 2008; Muslimović et al. 2008; Schrag et al. 2000d; Cubo et 
al. 2002; Martínez-Martín, Rodríguez-Blázquez et al. 2014; Carod-Artal et al. 
2007; Behari et al. 2005). Dependency in activities of daily living is most 
commonly assessed using the Schwab and England Activities of Daily Living 
Scale (S&E) (Schwab & England, 1969) and Part II of UPDRS in earlier studies 
or of the MDS-UPDRS in more recent studies, that evaluate the performance of 
motor daily living experiences. One of the main results of the QUALPD study 
was that activities of daily living (assessed by the MDS-UPDRS Part II), 
followed by the non-motor symptoms (MDS-UPDRS Part I) contribute most to 
the reduced HRQol (Skorvanek et al., 2018). Shuffling, difficulty turning, falls, 
and difficulty in dressing have been found to be significant predictors of poor 
HRQoL (Rahman et al., 2008). The author concluded that interventions to 
facilitate everyday life activities should be interrogated to the multidisplinary 
management approach of PD patients (Rahman et al., 2008). 
Axial impairment has also found to be a risk factor for reduced HRQoL 
(Marras et al., 2008; Müller et al., 2013; Muslimović et al., 2008; Rahman et al., 
2008; Schrag et al., 2000d). There is an interrelation between axial impairment 
and reduced functionality, i.e patients with PIGD as the dominant feature are 
also more disabled in everyday activities (Muslimović et al., 2008). A 
prospective cohort study (n=188) in Germany that investigated HRQoL in early 
PD patients with the use of SF-36, found that gait dysfunction and activities of 
daily living assessed by the UPDRS Part II, were the most important motor 
symptoms predicting risk for reduced HRQoL at the time of diagnosis and 3 
years later (Müller et al., 2013). Studies that have compared the HRQoL 
between tremor-dominant and non-tremor dominant patients have yielded to 
inconclusive results (Rodríguez-Violante et al., 2013; Schrag et al., 2000d). 
Disease severity as measured by the HY staging also has been found to be a 
predictive factor for reduced HRQoL (GPDS Steering Committee, 2002; 
Morimoto et al., 2003; Schrag et al., 2000d; Sławek et al., 2005). The scale is 
based on the concept that the severity of overall parkinsonian dysfunction 
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relates to the bilateral motor involvement and worsening balance and gait 
(Hoehn & Yahr, 1967). Rahman et al. (2008) indicated that patients with 
advanced stage of PD (HY≥3) compared to those with HY ≤2.5 have worse 
HRQoL in all aspects except in the domain of bodily discomfort. 
Another frequently used outcome for evaluating the severity of motor 
symptoms is the motor section of the MDS-UPDRS (Part III) that includes 18 
items covering the nearly full range of motor features (Goetz et al., 2008). 
Inconclusive findings have emerged from the literature in terms of the assoction 
between HRQoL and Part III of the UPDRS or the more recent MDS-UPDRS. 
Higher score of UPDRS Part III has been found to be an independent determi-
nant of HRQoL in some studies (Klepac et al., 2007; Rodríguez-Violante et al., 
2013; Winter et al., 2011), but not in many others (Cubo et al., 2002; Martínez-
Martín et al., 2014; Müller et al., 2013; Schrag et al., 2000d; Skorvanek et al., 
2018). Gait was the only motor symptom from the MDS-UPDRS Part III that 
correlated with the PDQ-8 in the QUALPD study cohort (Skorvanek et al., 
2018). It has been proposed that HY scale might be more sensitive tool than the 
motor section of UPDRS to assess the impact of illness’s severity on patients’ 
lives (Schrag et al., 2000d). However, limitations of HY scale include the fact 
that it is weighted toward postural instability assessments, progressive disability 
and impairments due to other features of PD, are not captured by the HY scale 
(Goetz et al., 2004). 
There is an evidence from both cross-sectional and longitudinal studies that 
non-motor symptoms may be more detrimental for reduced HRQoL than motor 
symptoms (Erro et al., 2016; Müller et al., 2013; Ophey et al., 2018; Prakash et 
al., 2016; Rodríguez-Violante et al., 2013). Non-motor symptoms dominate in 
the clinical profile of moderate and advanced PD patients and predict an impaired 
quality of life, disability and mortality (Chaudhuri et al., 2006). The main non-
motor symptoms negatively associated with the HRQol are depression, anxiety, 
apathy, memory impairment, fatigue, autonomic disturbances and sleep problems 
(D’Iorio et al., 2017; Gallagher et al., 2010; Martinez-Martin et al., 2011a; 
Rodríguez-Violante et al., 2013; Skorvanek et al., 2018), a more detailed insight 
into each of these non-motor symptoms is described below. 
 
2.4.4.1. Depression 
There is a number of surveys in different cultural regions of the world with the 
use of heterogenous study methods and study participants which suggest that 
depression has the strongest association with reduced HRQol (Carod-Artal et 
al., 2007; Gallagher et al., 2010; Ophey et al., 2018). The prevalence of clini-
cally significant depression is as high as about 35% (Reijnders, Ehrt, Weber, 
Aarsland, & Leentjens, 2008) and some studies suggest that it is more common 
and more severe in female than in male PD patients (Kovács et al., 2016; Solla 
et al., 2012). In the longitudinal analysis on PROPARK cohort (n=411) over 
5 years of follow-up, female gender, more severe disability, more cognitive 
impairment, motor fluctuations, nighttime sleep problems, increased daytime 
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sleepiness, more autonomic dysfunction (urinary and cardiovascular domains) 
and the use of antidepressants were independently associated with higher BDI 
scores over the time (Zhu, van Hilten, & Marinus, 2016). Interestingly, 
depression was found to be a less strong contributor to HRQoL in one longi-
tudinal study of early PD patients after a follow-up of 3 years compared to the 
baseline (Müller et al., 2013).  
 
2.4.4.2. Anxiety 
Among several neuropsychiatric symptoms, anxiety with its wide spectrum has 
a prevalence of 31% (Broen, Narayen, Kuijf, Dissanayaka, & Leentjens, 2016) 
and has an important negative impact on HRQoL (Carod-Artal et al., 2008; 
D’Iorio et al., 2017; Skorvanek et al., 2015). In a study by Duncan et al (2014b) 
on the quality of life of 158 PD patients in early stage of disease (mean disease 
duration of 6.3 years), anxiety was found to be among the most common non-
motor symptoms (42%) and also among the significant determinants that 
reduced the HRQoL. Anxiety has been identified to affect negatively certain 
aspects of the HRQoL, such as emotional well-being and cognition (assessed by 
PDQ-39) (Skorvanek et al., 2015). Anxiety has been demonstrated to be more 
frequent in female PD patients compared to men (Kovács et al., 2016; Solla et 
al., 2012). One recent prospective study on the course and predictors of 
depression and anxiety in Singapore in mild PD patients (n=89) revealed that 
unlike depression that remained relatively stable over 18 months, anxiety 
symptoms reduced over the study period. In the same study, the strongest 
predictors for anxiety were mainly demographic variables such as younger age 
at diagnosis, older age, higher education, and with smaller contribution, also 
concomitant depression and excessive daytime sleepiness (Wee et al., 2016). 
 
2.4.4.3. Apathy 
Apathy which has a prevalence of about 40% (den Brok et al., 2015), has found 
to be among the main determinants of reduced HRQoL in some studies (D’Iorio 
et al., 2017; Skorvanek et al., 2018). Risk factors that are associated with apathy 
include higher age, lower cognitive ability, co-morbidity of depression, higher 
severity of motor symptoms and disability of PD (den Brok et al., 2015). Out of 
all the valuated 12 types of non-motor symtoms, presence of apathy was 
associated with the worst quality of life in the PRIAMO study (Barone et al., 
2009). Apathy has been reported to be more common in male than in female PD 
patients (Kovács et al., 2016). Certain non-motor symptoms, including apathy, 
depressive mood, features of dopamine dysregulation syndrome and urinary 
problems were found to be independent negative determinants of the PDQ39 
domain stigma (Skorvanek et al., 2015).  
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2.4.4.4. Memory impairment 
A recent case-control study (ONSET PD) revealed that memory complaints 
were significantly more common in early PD patients compared to the general 
population in the same age, reported by 32% of patients with a mean disease 
duration of 11 months and by 20% of the age-matched healthy controls (Pont-
Sunyer et al., 2014). Cognitive decline is a typical feature of the advanced or 
late-stage PD with a prevalence of 84% in patients of 15 years of disease 
duration (Hely et al., 2005). One cross-sectional study (n=302) identified that 
the mean scores of the PDQ-39 domain cognition were similar across PD 
patients with 0–5 and 6–10 years of disease, but the outcome was significantly 
worse in those with longer (11+ years) than in those with shorter disease 
duration (Benge et al., 2016).  
Overall HRQoL, and domains of mobility and activities of daily living have 
been found to be significantly lower in PD patients with dementia compared to 
non-demented PD patients (van Uem et al., 2018). Lower Mini-Mental State 
Examination (MMSE) (Folstein, Folstein, & McHugh, 1975) score was 
identified as one of the significant predictors of the PDQ-39 domain of 
activities of daily living but not in case when demented patients were excluded 
from the analysis (van Uem et al., 2018). Cognitive impairment has been 
identified to be among the main contributors of the reduced HRQoL in few 
studies that have included this clinical characteristic as a potential determinant 
into the multiple regression models (Rodríguez-Violante et al., 2013; Schrag et 
al., 2000d; Winter et al., 2011). On the contrary, the CARPA study on newly 
diagnosed PD patient followed up for 5 years showed that cognitive impairment 
at baseline was the most important predictor for increased progression of 
disability and motor impairment, but it did not predict the deterioration of 
HRQoL (Velseboer et al., 2013). Supportive to the previous finding, no 
contribution of cognitive impairment to the HRQoL was found in another large, 
multi-center, cross-sectional study (Skorvanek et al., 2018).  
 
2.4.4.5. Impulse control disorders 
Impulse control disorders (ICDs), mainly caused by dopaminergic treatment, 
have a prevalence of 18% to 30% across all PD patients (Antonini et al., 2017; 
Hurt et al., 2014) and up to 55% among patients with dyskinesias (Biundo et al., 
2017). No significant relationship between HRQoL and impulse control dis-
orders were found in some cross-sectional studies (D’Iorio et al., 2017), 
however other studies have reported the negative impact of those on disability 
and HRQoL (Leroi et al., 2011; Skorvanek et al., 2015). 
 
2.4.4.6. Fatigue 
Among other non-motor symptoms besides the neuropsychiatric disturbances, 
fatigue with a prevalence of about 50% of cases (Del Sorbo & Albanese, 2012) 
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has been found to be one of the main predictors of HRQol in several studies 
(Dogan et al., 2015; Gallagher et al., 2010; Skorvanek et al., 2018). It has been 
revealed that fatigue impacts negatively most of the aspects of HRQoL, 
particularly mobility, activities of daily living and cognition (Skorvanek et al., 
2015). Female PD patients have been found to have more frequent and more 
severe complaints of fatigue compared to men (Martinez-Martin et al., 2012; 
Solla et al., 2012). Some cross-sectional studies have established an association 
between fatigue and longer disease duration (Barone et al. 2009; Guo et al. 
2013b) while others have not found such an association (Solla et al., 2014). 
However, the contribution of fatigue to the HRQoL increased markedly over a 
follow-up of 3 years in a longitudinal study enrolling incidence PD patients 
(n=188) by Müller et al. (2013). The higher overall burden of non-motor 
symptoms has been reported to predict the higher occurrence and severity of 
fatigue (Solla et al., 2014).  
 
2.4.4.7. Autonomic disturbances 
In the study by Martinez-Martin et al. (2013) with 434 PD patients enrolled, the 
common autonomic non-motor symptoms assessed by the MDS-UPDRS Part I 
were constipation (70%), urinary problems (64%), and lightheadedness (36%). 
Reduced olfaction, urinary problems, hypersalivation and constipation have 
been found to be the most frequent autonomic symptoms already in the early 
stage of PD (Müller et al., 2011). With the duration of the disease, most of the 
autonomic symptoms have shown to become more common and severe (Guo et 
al. 2013b; Erro et al. 2016). Several studies have demonstrated the evidence that 
autonomic disturbances, particularly urinary incontinence, constipation and 
orthostatic hypotension, have a significant negative impact on the quality of life 
of PD patients (Gallagher et al., 2010; Rahman et al., 2008). 
 
2.4.4.8. Sleep problems 
In PD, sleep disorders have been found in over 60% of patients and their 
frequency correlates with the duration of disease (Barone et al. 2009; Guo et al. 
2013b). In some surveys, sleep disturbances were found to be independent 
strong determinants of HRQoL (Qin et al. 2009; Visser et al. 2009; Kovács et 
al. 2016; Duncan et al. 2014b; Gallagher et al. 2010), other studies have shown 
only low or no association between HRQoL and sleep problems (Müller et al., 
2013; Skorvanek et al., 2015, 2018). It has been reported that sleep problems 
affect particularly some HRQoL aspects such as emotional well-being and 
cognition (Rodríguez-Violante et al., 2013; Skorvanek et al., 2015). Daytime 
sleepiness has been found to be more frequent and severe in men than in women 
(Kovács et al., 2016; Martinez-Martin et al., 2012). 
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2.4.5. Impact of levodopa dose and levodopa induced complications 
It has inconclusively been shown that a higher intake of levodopa is associated 
with lower HRQoL (Behari et al., 2005; Hinnell et al., 2012; Ophey et al., 2018; 
Prakash et al., 2016; Skorvanek et al., 2018), but no such a finding has been 
reported by few other studies (Qin et al., 2009). One recent prospective cohort 
study with the follow-up of 6 months in Finland evaluated the changes of 
HRQoL in patients whose medication dose was increased for clinical reasons 
(n=82) and in patients whose medication remained unchanged (n=137). No 
differences in the baseline or in the change of HRQoL (assessed by the generic 
instruments EQ-5D and 15D) between the treatment groups were seen (Järvelä 
& Kaasinen, 2016). 
Several studies have reported that motor fluctuations significantly worsen 
the HRQoL (Chapuis et al. 2005; Hechtner et al. 2014; Rahman et al. 2008; 
Kerr et al. 2016; Sławek et al. 2005). Usual daily activities frequently identified 
by PD patients as the most bothersome during “off”- time’ compared to “on”-
time include dressing, washing and keeping clean, communicating effectively, 
getting around the house and walking short distances (Kerr et al., 2016). On the 
contary, mixed findings concerning the impact of dyskinesias on the quality of 
life have been demonstrated (Chapuis et al., 2005; Hechtner et al., 2014; 
Rahman et al., 2008; Rodríguez-Violante et al., 2013; Winter et al., 2011). For 
example, one study in Germany involving 817 PD patients did not identify the 
presence of dyskinesias to be a predictor for the reduced overall quality of life, 
although abnormal movements did affect the activities of daily living, 
cognition, stigma, and bodily discomfort (Hechtner et al., 2014). It has been 
proposed that dyskinesias may not always be a major concern for PD patients 
because nowadays they are frequently mild and not disabling (Kerr et al., 2016). 
Recent cross-sectional study in France reported that the severity but not the 
duration of dyskinesias is an independent determinant of HRQoL (Perez-Lloret 
et al., 2017). 
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3. AIMS OF THE STUDY 
The primary objective of the current study was to describe the epidemiologic 
characteristics of PD in a defined population in Tartu, Estonia. Additional goals 
of this study were to evaluate the clinical characteristics, the treatment-related 
complications and the HRQoL of patients with PD. 
 
1. To evaluate the prevalence of PD in the city and county of Tartu and detect 
the dynamic changes in the disease frequency compared to the similar 
epidemiologic study conducted in the same geographical area 20 years ago 
(Study I). 
 
2. To evaluate the incidence of PD in the city and county of Tartu and detect 
the dynamic changes in the disease occurrence compared to the similar 
epidemiologic study conducted in the same geographical area 20 years ago 
(Study II). 
 
3. To describe the characteristics of mortality and causes of death of PD 
patients (Study II). 
 
4. To describe the frequency of motor complications among patients with PD 
who receive levodopa treatment and to assess the effect of various 
demographic and clinical factors on the occurrence of motor complications 
(Study III). 
 
5. To investigate the frequency and severity of non-motor PD symptoms and to 
identify differences in the prevalence of non-motor symptoms among 
subgroups of PD patients (Study IV). 
 
6. To evaluate the impact of a wide range of socio-demographic and clinical 
factors upon the HRQoL of PD patients (Study V). 
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4. PATIENTS AND METHODS 
4.1. Study design  
All the studies included in this thesis were observational studies for which a 
large PD sample derived from the whole source population of city and county of 
Tartu was used. 
Study I was a descriptive, cross-sectional, epidemiologic study that included 
prevalent and incident PD patients with a goal to determine the prevalence of 
PD on the prevalence day of 1st of October, 2013, in the city and county of 
Tartu. 
Study II was a descriptive epidemiologic study investigating incidence and 
mortality of PD in the city and county of Tartu. For the incidence study, both a 
retrospective and prospective approach for finding new PD cases over a defined 
period (2002–2012) was used. For the mortality study, a prospective obser-
vation of a cohort of PD patients (stratified into inception and non-inception 
subcohorts) over a defined follow-up period (2010–2016) was used. The 
mortality rates of the PD patient cohort with those expected from the general 
population data were compared. 
Study III was a cross-sectional multi-centre analytical study on motor 
complications of levodopa treatment based on a PD cohort derived from the 
earlier years (2010–2013) of the epidemiological study of the city and county of 
Tartu, but also included hospital-based samples of PD patients from two other 
regions of Estonia (i.e Pärnu and Tallinn).  
Study IV on non-motor features, and Study V on HRQoL were cross-
sectional analytical studies based on a PD cohort derived from the earlier years 
(2010–2013) of the epidemiological study of city and county of Tartu. 
 
 
4.2. Ethical issues 
All the studies have been approved by the Research Ethics Committee of the 
University of Tartu (Certificate No 216/M-29). Permission from the Estonian 
Data Protection Inspectorate was obtained to process personal data without the 
subject’s consent (Certificate No 2.2-7/13/643r). Subjects gave their written 
informed consent. 
 
 
4.3. Diagnostic criteria 
Diagnosis was based on the QSBB clinical diagnostic criteria, i.e the diagnosis 
of PD was confirmed by the presence of bradykinesia and at least one of the 
following symptoms: resting tremor, rigidity, or impaired postural reflexes 
(Table 1; Gibb & Lees, 1988; Lees et al., 2009). Since this was primarily an 
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epidemiological study, all patients with a confirmed PD diagnosis were enrolled, 
and no other specific exclusion criteria (except those from the QSBB) were set. 
Two criteria of the QSBB were not taken into account, firstly, patients with 
Babinski sign were not excluded if they presented with typical PD and no other 
exclusion criteria were evidenced. Also patients were not excluded from the 
study if they had more than one relative with PD. Patients with drug-induced, 
vascular, atypical or unspecified parkinsonism were excluded from the PD 
sample. 
 
4.4. Study area and population 
Tartu County is located in South Estonia and had a population of 152,188 
(71,395 men, 80,793 women) according to the census on 1st of January in 2014 
(Statistics Estonia website, 2018). The county is administratively divided into 3 
urban and 19 rural municipalities, and covers a total of 2,993 square kilometres. 
Tartu, the second largest city of Estonia, is the administrative centre of Tartu 
County. The male-female proportion in the entire country was the same as in 
Tartu in 2014, i.e 47% men and 53% women. 12.4% of individuals were over 
70 years old, there were twice as many women than men in that age (16% of 
women vs. 8% of men) in Tartu in 2014 (Statistics Estonia website, 2018). 
Tartu University Hospital is the regional hospital of South Estonia, with a 
well-developed digital patient record system that is connected to the national  
e-Health system, a platform that holds all the medical information of Estonian 
inhabitants. In addition to Tartu University Hospital, there is one local hospital 
that provides out- and in-patient services for neurological patients, and ten 
nursing homes and hospitals. In 2013, there were 61 family doctor’s offices in 
Tartu County. In Estonia, patients with a possible PD are referred to a neuro-
logist who confirms the diagnosis and starts the initial treatment that will be 
followed by a family doctor. The Tartu PD society was created in the end of 
1995 and has an average of 70 members. 
 
 
4.5. Case-ascertainment 
The following information from all available sources was regularly obtained 
during 2010–2016 for case-ascertainment of patients with PD (irrespective of 
age). In- and out-patient neurology visit data of the Department of Neurology 
and Neurosurgery of Tartu University Hospital were processed and neurologists 
were asked to provide the list of their PD patients. The member list of the PD 
Society was reviewed, and family doctors and neurologists were contacted by  
e-mail to identify eligible patients. All nursing institutions in the region were 
visited. Data from the Estonian Health Insurance Fund (EHIF) on all patients 
with the diagnosis of PD (coded as G20 by the International Statistical 
Classification of Diseases ICD-10) received during 2010–2015 were processed 
in 2016. 
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4.6. Subjects and data collection of the studies 
Although the case-finding methodology, diagnostic criteria and instruments 
used for the data collection were the same over the whole study period (2010–
2016), study samples of PD patients varied depending on the aims of the 
studies. 
 
 
4.6.1. Prevalence of PD  
The overall study population with possible diagnosis of PD from all sources in 
Tartu County over a study period (2010–2016) comprised 1011 subjects. From 
medical records 455 patients were found, and a PD diagnosis confirmed in 88% 
of cases. From the additional search of the EHIF, 556 cases were found, but 
only 32% had a confirmed diagnosis of PD and were enrolled in our study. The 
flow diagram of the subjects included to, and excluded from the study is shown 
in Figure 1. 
All patients with PD (n=431) living in the county of Tartu on the 1st of 
October 2013 were included into the final PD sample. This specific prevalence 
day was chosen at the midpoint of our study period and the proportion of 
clinically examined study participants was highest at that time. Subjects were 
classified as prevalent cases if their initial parkinsonian symptoms had occurred 
before the prevalence day. Eligible patients were contacted; the residence of 
patients was verified with data of the Estonian Population Register. Of the 431 
patients included in the prevalence analysis, 84.2% agreed to participate in the 
interview and clinical evaluation (more detailed information of clinical 
assessment is given below in the section of Clinical Examination, 4.7). Patients 
were examined in the Department of Neurology (n=265), at home (n=65), or in 
a nursing home or hospital (n=33). Those who refused to participate (7.4%), 
were unreachable (1%), or had died before their identification (7.4%), but were 
alive on the prevalence day, were enrolled as prevalent cases if they had a 
confirmed diagnosis of PD based on medical records. For these subjects, the full 
case record review of each case was conducted to find evidence for the presence 
of confirmed PD (i.e description of cardinal parkinsonian symptoms, 
prescription of antiparkinsonian treatment, no indications to other conditions 
besides PD). 
 
 
4.6.2. Incidence and mortality of PD 
All PD patients (n= 608) resident in Tartu county between 2010–2016 were 
included in the study. Retrospective PD onset data (i.e. the date of a subject’s 
first PD symptoms) was based either on recall (by the patient or caregiver), or 
on information obtained from medical records. All subjects were tracked 
annually by the online Electronic Health (e-Health) Record until either the end 
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of the study period, or their death. E-Health is a digital platform which holds the 
medical information of Estonian residents. During the seven-year period of 
survey, 19 subjects were excluded from the PD sample when a condition other 
than PD was suspected on the basis of data retrieved directly from the 
neurologists or from the e-Health Record. Out of the excluded patients from the 
initial cohort, alternative diagnosis suspected to have instead of PD were as 
follows: 5 with essential tremor; 5 with Lewy body dementia; 3 with vascular 
parkinsonism; 3 with other tremors; 1 with multisystem atrophy; 1 with 
progressive supranuclear palsy; and 1 with drug-induced parkinsonism.  
The final PD sample for the incidence analysis was based on those subjects 
(n=388) whose clinical onset of PD occurred between January, 2002 and 
December, 2012. The majority of incident subjects (76.3%) were seen once, in 
person, during the study period. A detailed information of clinical assessment is 
given below in the section of Clinical Examination, 4.7. Data for those patients 
who did not agree to participate in additional examination (7%), were unable to 
be contacted (0.5%), or who had died by the time of their identification 
(16.2%), was limited to the information obtainable from the electronic medical 
records.  
Mortality analysis calculations were based on all patients with PD identified 
between January, 2010 and December, 2016 (n=589). Based on the onset year 
of the disease, subjects included to the mortality analysis were stratified into 
two subcohorts; i.e. inception cohort (disease onset since the year 2008, n=293) 
and non-inception cohort (disease onset was before the year 2008, n=296). Data 
on subjects’ date of, and age at death was collected from the e-Health Record 
(and verified with data from the Estonian Population Registry). Data on causes 
of death was obtained from subjects’ death certificates, which were provided by 
the Estonian Causes of Death Registry (coded in accordance with the 
International Classification of Diseases 10th Revision (ICD-10)).  
 
 
4.6.3. Prevalence and factors associated  
with motor complications in PD  
This study was conducted by three medical centres in different regions of 
Estonia (Tartu, Pärnu, and Tallinn) between October 2010 and September 2013. 
From the initial cohort of 486 parkinsonian patients, 16 were excluded due to 
correction of diagnoses including other tremors, secondary or atypical 
parkinsonism, or Lewy body dementia, and 15 more were excluded due to 
refusal or incomplete testing. All the participants had to be seen in-personally 
once and data relevant for the measurement of motor complications (i.e. 
fulfilled scale of MDS-UPDRS and patient card) had to be provided. A total of 
455 patients were included in the final analysis. Majority of the study 
participants were derived from the PD cohort of epidemiological study in Tartu 
(n=353), other patients were enrolled and examined in Pärnu Hospital (n=96) 
and North Estonia Medical Centre (n=6). A majority of the study participants 
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were outpatients (n=390). A few were inpatients (n=14), in nursing homes 
(n=23) or visited at their own homes (n=28).  
 
 
4.6.4. HRQoL and non-motor symptoms in patients with PD  
These studies were conducted in the city and county of Tartu between October 
2010 and May 2013. Study participants (n=268) in those two studies were 
identical and were derived from a population-based PD cohort of the epidemio-
logical study including PD patients living in the city and county of Tartu. All 
the participants were seen in-personally once and data relevant for the measure-
ment of HRQoL and non-motor symptoms (i.e. fulfilled scale of PDQ-39 and 
MDS-UPDRS) had to be provided.  
 
 
4.7. Clinical examination  
Clinical assessment included a semi-structured interview based on a special 
Patient Case Report Forms, neurological examination and use of validated 
clinometric scales and questionnaires. Demographic and social data (age, 
gender, urban/rural living, marital status, living alone/with others, level of 
education) and data regarding PD (age at disease onset, disease duration, initial 
PD symptom, prevalent motor phenotype) and antiparkinsonian treatment-
related factors (levodopa daily dose, levodopa equivalent daily dose [LEDD], 
duration of levodopa treatment, time from symptom onset until the initiation of 
levodopa, presence of motor complications), and other factors (comorbidities, 
toxins) were recorded. Data on Case Report Forms regarding motor compli-
cations included binary questions assessing motor fluctuations, dyskinesias, and 
off-dystonia that had occurred at any time during the disease. LEDD was 
calculated using the standardized conversion formula (Tomlinson et al., 2010). 
During the neurological examination, a motor phenotype was determined based 
upon the most prevalent symptom: the dominance of tremor with other motor 
symptoms of only a mild level; non-tremor-dominant PD which includes 
syndromes with akinesia and rigidity; or PIGD.  
For assessing the frequency and severity of a wide range of symptoms 
related to PD, all the parts of MDS-UPDRS were performed. In 2008 the MDS 
adopted a new, validated version of the MDS-UPDRS, which included several 
significant updates in comparison with the previous version, including new non-
motor symptoms of PD (Goetz et al., 2008) 
The Estonian version of the MDS-UPDRS was translated, validated and 
officially approved in 2011 by the MDS Translation Program for non-English 
official versions. The MDS-UPDRS Part IA contains questions regarding a 
number of neuropsychiatric symptoms and is completed by the interviewer; Part 
IB consists of questions other non-motor symptoms and is answered by the 
patient or caregiver. Part II regards the motor experiences of daily living and is 
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assessed by the patient or caregiver; Part III assesses motor symptoms based on 
an objective neurological examination by the investigator. Part IV regards 
motor complications and is completed by the interviewer. All items in MDS-
UPDRS were scored by a scale of 0 to 4 (normal/slight/mild/moderate/severe), 
and the total score for each part was obtained from the sum of the corresponding 
item scores. The data on the prevalence of motor complications was obtained 
from two sources: Patient Case Report Forms and part IV of the MDS-UPDRS.  
The clinical stage of PD was assessed using the HY scale and their level of 
disability by the SE-ADL scale. The HY scale ranges from 1 (unilateral involve-
ment of the body) to 5 (wheelchair bound or bedridden). The SE-ADL scale 
ranges from 0% (completely dependent and bedridden) to 100% (completely 
independent). For assessment of depressive symptoms, the Beck Depression 
Inventory (BDI) was used (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961), 
whereby a score of ≥14 was indicative of depression (Leentjens, Verhey, 
Luijckx, & Troost, 2000). Cognitive impairment was measured using the 
MMSE, whereby a score of ≤24 was evidence of cognitive impairment. 
To evaluate HRQoL, PDQ-39 – a validated, disease-specific quality of life 
instrument – was used. The higher the PDQ-39 summary index (SI) score, the 
lower the perception by patients of their quality of life. An Estonian version of 
the PDQ-39 has been shown as a reliable instrument (Krikmann, Taba, Lai, & 
Asser, 2008)  
 
 
4.8. Statistical analysis 
4.8.1. Prevalence of PD  
 
Total crude and age-, gender-, and living area-specific crude prevalence rates 
were calculated based on the number of PD cases on prevalence day and the 
number of inhabitants of the county of Tartu according to the population census 
on January 1st, 2014. Crude rates were adjusted for age-structure of Estonian 
population on January 1st, 2014, using the direct method of standardization. To 
compare our prevalence figures to the previous epidemiological study in 
Estonia, an additional age-adjustment was made according to the age-structure 
of Estonia in 1989, which was the reference population used in the study by 
Taba and Asser (Taba & Asser, 2002). Furthermore, using the European 2011 
standard population as a reference (EuroStat website, 2018), a corresponding 
age-adjusted prevalence rate was also calculated. Descriptive statistics 
(percentages, means with standard deviation, medians with ranges) were used 
for the socio-demographic and clinical characteristics of the whole sample of 
the prevalent cases. 
95% confidence intervals (CIs) for the prevalence rates were calculated 
assuming the Poisson distribution of observed cases. The differences in crude 
prevalence rates between the groups were statistically evaluated using Poisson 
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regression analysis. The differences in age-adjusted prevalence rates between 
the groups and between two time-points were statistically evaluated using the  
Z-test. Familywise error rate was controlled with Bonferroni method. All 
statistical analysis was performed in R version 3.3.3. 
 
 
4.8.2. Incidence and mortality of PD  
To measure the frequency of occurrence of new PD cases, the number of 
incident cases was divided by the total number of person-years at risk. The age-
specific incidence rates for men and women, as well as for rural and urban 
patients, were estimated in 5-year age groups. Data on the age and gender of the 
study population were obtained from Statistics Estonia (Statistics Estonia 
website, 2018). Using the Europe 2011 Standard population as a reference, the 
age-adjusted incidence of PD was calculated by the use of direct method. Based 
on the age structure of Estonia in 1989, an additional age-adjustment was made, 
in order to compare the incidence rates of the two epidemiological studies (Taba 
& Asser, 2003). In order to assess the eligibility of the findings and conclusions 
based on the primary analysis of the incidence data, a sensitivity analysis was 
performed, for which incident PD cases were limited to the period of 2010–
2012, and the results were compared to the more retrospective period of disease 
onset (2002–2012). 
For the purpose of the mortality analysis, subjects were tracked pro-
spectively on the e-Health system between January, 2010 and December, 2016, 
or until their death. The standardized mortality ratios (SMR) for inception and 
non-inception cohorts, as well as for men and women separately, were 
calculated based on the ratio of observed to expected deaths. The latter was 
calculated using the person-years at risk in each group based on 5-year age 
category, gender and calendar year. These person-years were multiplied by the 
corresponding group-specific mortality rates in the general Estonian population 
(EuroStat website, 2018). Additional SMR analysis for the estimation of cause-
specific mortality in two disease categories (cancer and vascular diseases) was 
performed.  
The 95% confidence intervals (CI) for the incidence and mortality rates were 
calculated assuming Poisson distribution of observed cases. Differences in 
socio-demographic or clinical characteristics for men and women were statisti-
cally evaluated using the Chi-square or Fisher’s exact test (for categorical data) 
and the t-test or Wilcoxon test (for numerical data). Rate ratios (RRs) were 
calculated to compare incidence rates between urban and rural patients, and 
between males and females. Differences were considered statistically significant 
at a p-value of <0.05. All statistical analyses were conducted using R version 
3.4.3.  
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4.8.3. Prevalence and factors associated  
with motor complications in PD  
Primary analysis involved the evaluation of the frequency of motor compli-
cations in our sample of PD patients who received levodopa therapy. Out of the 
total cohort of 455 PD cases included to the study, 374 patients received 
levodopa therapy at the time of examination. Out of those 374 PD cases, 28 had 
started with levodopa the same day or a few days before the examination; 
therefore, they were excluded from the analysis. Another 18 levodopa users 
were excluded from the frequency analysis of motor complications due to 
missing the variable indicating the duration of their levodopa therapy. 
Secondary analysis comprised descriptive statistics for the total study sample 
(n=328), for the patients on levodopa who did not have motor complications 
(n=243), and for the patients on levodopa who had motor complications (n=85). 
Group comparisons were performed using the two-sample t-test, chi-squared 
test, Fischer’s exact test and Mann-Whitney U test. Multiple comparisons were 
corrected with the Bonferroni method. 
Tertiary analysis incorporated logistic regression models to examine the 
effects of multiple predefined variables on the binary outcome variable (whether 
motor complications were present). Based on the literature and clinical 
experience, the following variables were entered into the main model: age, 
gender, age at onset of PD, time from initial symptoms until starting levodopa, 
LEDD, MDS-UPDRS Parts II and III scores, BDI, PDQ-39 SI score, and 
akinetic-rigid dominant, tremor-dominant and PIGD-dominant motor phenotype 
of the disease. Odds ratios (OR) with 95% CIs were calculated for all above-
mentioned variables. The results were considered statistically significant at the 
p<0.05 level. Statistical analysis was performed in R version 3.3.1. 
 
 
4.8.4. Prevalence and factors associated  
with non-motor symptoms in PD  
Descriptive statistics (percentages, means with standard deviation, medians with 
interquartile ranges) were used for the variables of interest. The frequency of 
each non-motor symptom was expressed as the percentage of patients scoring 1 
or more points for each item of the MDS-UPDRS Part I. The mean total scores 
of MDS-UPDRS Part I among the patient subgroups were compared using the 
Mann-Whitney U or Kruskal-Wallis test. For the group comparisons, patients 
were divided into subgroups in terms of gender (male; female), age (≤64 years; 
≥65 years), disease onset age (≤50 years; ≥65 years), disease duration (≤5 years; 
6–10 years; ≥10 years), HY(≤2.5; ≥3), SE-ADL (≥80; ≤75), MMSE (≥25; ≤24), 
clinical subtype (tremor; akinesia-rigidity; PIGD), motor complications in 
general (present; absent), and motor fluctuations (present; absent), dyskinesias 
(present; absent) and off-period dystonia (present; absent). The severity of each 
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non-motor symptom was expressed as the mean score of each item, including 
all the possible scores (0–4). 
Statistical analysis of any differences in the frequency of individual non-motor 
symptoms among patient subgroups was performed using the chi-squared test or 
Fisher exact test (as appropriate), and multiple comparisons were corrected with 
the Bonferroni method. Spearman’s rank correlation coefficients (ρ) were  
used to test the significance of correlations (1) between total MDS-UPDRS  
Part I scores and different characteristics of interest; and (2) between total  
MDS-UPDRS Part I scores and individual non-motor symptoms. Correlation 
coefficients were interpreted as very weak (r = 0–0.19), weak (r = 0.20–0.39), 
moderate (r = 0.40–0.59), strong (r = 0.60–0.79) or very strong (r = 0.80–1.00). 
A p-value below 0.05 was considered significant. Statistical analysis was 
performed using SPSS version 20 software (IBM, Armonk, NY, USA). 
 
 
4.8.5. HRQoL of patients with PD  
PDQ-39 SI measures of HRQoL were calculated according to its scoring 
algorithm (Jenkinson, Fitzpatrick, Peto, & Greenhall, 1997; Peto et al., 1995). 
Prevalence of non-motor symptoms was based on scores ≥1, which denoted the 
presence of a symptom. Student’s t-test and z-test were applied for comparing 
socio-demographic and clinical outcomes between men and women. The non-
parametric Mann-Whitney U and Kruskal-Wallis tests were used to compare 
PDQ-39 SI scores between the groups. Spearman’s rank correlation coefficients 
(ρ) were calculated to assess associations between variables.  
A multiple linear regression analysis – based on a backward elimination 
approach – was conducted to determine the factors that contribute to HRQoL in 
persons with PD. PDQ-39 SI was used as a dependent variable. The R2 statistic 
was used to determine the proportion of variance explained by the predictors. 
The level of statistical significance was set at p<0.05. Statistical analysis was 
performed using STATA version 12.0 (StataCorp LP, College Station, TX, 
USA) and SPSS version 20.0 (IBM Corporation, Armonk, NY, USA). 
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5. RESULTS 
5.1. Prevalence of PD  
The flow diagram of the case-ascertainment procedure is shown in Figure 1. A 
total of 431 patients (160 men, 271 women) fulfilled the study criteria and were 
included into the prevalence analysis. Of them, 71% lived in urban areas and 
29% in rural areas. Without the use of the EHIF data, a total number of 321 
(120 men, 201 women) PD patients were identified. On prevalence day, the 
mean age of participants was 77.4 ± 9 years and the mean duration of the 
disease was 7.0 ± 5.9 years. The crude and age-adjusted PD prevalence rates are 
shown in Table 8. The total crude prevalence rate was higher for women than 
for men. There was no significant difference between age-adjusted prevalence 
rates of men and women (RR=0.83, p=0.07; Table 8). In terms of living area, no 
significant difference in adjusted prevalence rates of PD was shown between 
urban and rural populations (RR=1.02, p=0.83). We found a trend of increasing 
age-specific prevalence with age for both genders, peaking in the age-group 80–
84 years old per women and 85+ years old per men, followed by a significant 
decline among the most elderly women but not the men (Figure 2). After age-
adjustment to the European 2011 standard population, the overall prevalence 
rate was 324/100,000 people.  
 
Table 8. Crude and age-adjusted prevalence rates of PD according to gender and living 
area. 
 Cases Study 
popu-
lation 
Crude 
prevalence 
rates/100,000 
(95%CI)
Adjusted 
prevalence 
rates/100,000 
(95%CI)a
RR of 
adjusted 
preva-
lence 
p-value 
All patients 431 152,188 283 (257–310) 314 (285–344)   
Males 160 71,395 224 (189–259) 355 (299–412) 0.83 0.07 
Females 271 80,793 335 (296–375) 294 (259–330)   
Urban 
patients 
307 104,952 293 (260–325) 316 (281–352)   
Males 116 47,956 242 (198–286) 369 (302–437) 0.78 0.04 
Females 191 56,996 335 (288–383) 287 (246–329)   
Rural 
patients 
124 47,236 263 (216–309) 309 (255–364)   
Males 44 23,439 188 (132–243) 333 (229–437) 0.93 0.70 
Females 80 23,797 336 (262–410) 309 (240–377)   
a Adjusted to 2014 Estonian population for age; 
Adjusted prevalence rate ratios show the relative difference of the prevalence rates between men 
and women; 
p-value below 0.0125 (after Bonferroni correction) was considered significant; 
Abbrevations: PD, Parkinson’s disease; CI, confidence intervals; RR, rate ratio. 
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The age-specific, total crude and age-adjusted prevalence rates of current study 
and the study conducted in Estonia in 1996 are shown in Table 9. We found that 
the overall age-adjusted prevalence rate was significantly higher in the current 
study (RR=1.30, p=0.004), and among men (RR=1.44, p=0.0018; Table 9). 
Clinical and socio-demographic data of the 363 patients (139 men, 224 
women) involved in the full clinical examination are shown in Table 10. A total 
of 82.1% were using levodopa at the time of examination; 27% dopamine 
agonists; 17% MAO-B inhibitors; 16% amantadine; and 3% anticholinergics. 
Out of those on levodopa treatment, 63% were using controlled-release 
levodopa, 14% standard release levodopa; and 9% combination with a COMT-
inhibitor carbidopa/levodopa/entacapon. The mean daily levodopa dose was 
398 ± 219 mg (range: 100–1700). The proportion of patients with cognitive 
impairment was 23% (MMSE score ≤24), and with depressive symptoms 48% 
(BDI score ≥14).  
  
 
Figure 2. Age-specific prevalence rates of PD for all patients and according to gender 
on the prevalence day of 1st October, 2013. 
Abbrevations: PD, Parkinson’s disease. 
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Table 9. Age-specific, total crude for all, and age-adjusted prevalence rates for all and 
subgroups in two epidemiological studies of PD in Tartu, Estonia. 
 Study population, 1996 Study population, 2013 
Age 
groups Cases 
Popu-
lation 
Age-specific 
rate/100,000 Cases 
Popu- 
lation 
Age-specific 
rate/100,000 
0–39 0 87745 0 0 82322 0 
40–44 3 9597 31 2 10580 19 
45–49 1 8882 11 2 9302 22 
50–54 7 8517 82 9 8958 22 
55–59 15 8828 170 9 8472 106 
60–64 24 8070 297 23 7486 120 
65–69 53 7564 701 48 6195 371 
70–74 76 5951 1277 77 6460 743 
75–79 37 3218 1150 90 5298 1453 
80–84 43 2855 1506 104 3945 2636 
85+ 11 2013 546 67 3170 2114 
Total 270 153,240  431 152,188  
Total crude rates/ 
100,000 (95%CI) 
176 (155–197)   283 (257–310) 
Adjusted rates/ 
100,000 (95%CI)a 
Study population,  
1996 
Study  
population, 2013 RR p-value 
All  152 (128–176) 197 (178–216) 1.30 0.004b 
Males 154 (130–178) 221 (187–256) 1.44 0.0018c 
Females 153 (128–177) 183 (160–206) 1.20 0.08c 
Urban  160 (135–185) 198 (175–221) 1.24 0.029c 
Males 171 (146–197) 232 (189–275) 1.36 0.017c 
Females 157 (133–182) 178 (151–205) 1.13 0.26c 
Rural  139 (116–162) 193 (158–228) 1.39 0.011c 
Males 128 (106–150) 204 (143–265) 1.59 0.022c 
Females 145 (122–169) 194 (149–239) 1.34 0.058c 
a Adjusted to 1989 Estonian population for age; 
b For overall comparison between the two studies a p-value below 0.05 was considered 
statistically significant; 
c For the additional comparison among the subgroups the significance threshold after Bonferroni 
correction was set to 0.0062.  
Abbrevations: PD, Parkinson’s disease; CI, confidence interval; RR, rate ratio.  
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Table 10. Characteristics of prevalent patients with PD, clinical evaluation conducted in 
period 2010–2016. 
Variable Mean (SD) or 
n (%) 
Range 
Age at examination, years (n=363) 74.8 (8.9) 47–96 
Disease duration, years (n=360) 7.0 (5.5) 0.3–35 
Clinical phenotype (n=363)   
Tremor 157 (43.3%)  
PIGD 101 (27.8%)  
Akinesia-rigidity 105 (28.9%)  
MDS-UPDRS score (n=363)   
Part I 13.3 (7.8) 0–39 
Part II 17.2 (9.0) 1–52 
Part III 44.6 (18.5) 8–106 
Part IV 0.9 (2.9) 0–18 
HY (n=363)   
1–1.5 41 (11.3%)  
2–2.5 110 (30.3%)  
3 108 (29.8%)  
4 85 (23.4%)  
5 19 (5.2%)  
SE-ADL* (n=363) 75* 0–100 
MMSE* (n=348) 28* 0–30 
BDI (n=318) 15.1 (8.9) 0–47 
Duration of levodopa treatment, years (n=298) 4.5 (5.0) 0.1–22 
LEDD, mg (n=363) 396 (328) 0–2518 
Living status (n=363)   
With a spouse 167 (46%)  
With children 65 (17.9%)  
Alone 103 (28.4%)  
Nursing institution 28 (7.7%)  
Education (n=362)   
Primary 132 (36.5%)  
Secondary 141 (38.9%)  
Higher 89 (24.6%)  
Exposure to toxins (n=363)   
Pesticides  13 (3.6%)  
Heavy metals 16 (4.4%)  
Solvents and paints 51 (14%)  
Current smoking 16 (4.4%)  
Former smoking 68 (18.7%)  
* median 
Abbrevations: PD, Parkinson’s disease; SD, standard deviation; n, number of patients; PIGD, 
postural instability and gait disorder; MDS-UPDRS, Movement Disorders Society Unified 
Parkinson´s Disease Rating Scale; HY, Hoehn and Yahr stage; SE-ADL, Schwab and England 
Activities of Daily Living Scale; MMSE, Mini Mental State Examination; BDI, Beck Depression 
Inventory; LEDD, levodopa equivalent daily dose.  
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5.2. Incidence and mortality of PD  
5.2.1. Incidence of PD 
388 cases of PD incidence were found over the course of 1,699,709 person-
years. The clinical and socio-demographic data together with information on 
exposure to toxins are illustrated in Table 11. Age-specific incidence rates for 
both males and females rose exponentially until the 75–79 and 80–84 years age-
groups, after which they sharply declined. The age-distribution of subjects by 
onset age, as well as age-specific rates for the total cohort, are illustrated in 
Figure 3. Males had a slightly higher age-adjusted incidence rate than did 
females; this difference was statistically significant (RR=1.25; p=0.04). 
Incidence rates among people living in rural vs. urban were identical (RR=1.0; 
p=0.97). Comparison of the age-specific, total crude and age-adjusted incidence 
rates in two epidemiological PD studies are provided in Table 12. Statistically 
significant differences between the current and previous study were found only 
for males (Table 12).  
Sensitivity analysis confirmed that the age-adjusted incidence rates for all 
the subgroups (men, women, urban and rural patients) in the primary analysis 
(data extracted from the period of 2002–2012) were relatively comparable to the 
corresponding rates obtained for the period of 2010–2012. However, the total 
age-adjusted incidence rate (18.5/100,000) obtained from our primary incidence 
analysis was slightly below the confidence interval from the corresponding 
estimate retrieved from the analysis limited to the 2010–2012 period. Details of 
the sensitivity analysis are depicted in Table 13. 
Figure 3. The overall age-specific incidence rates per 100,00 person-years, and age-
distribution of PD cases stratified by gender in Tartu, Estonia, 2002–2012. 
Abbrevations: PD, Parkinson’s disease. 
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Table 11. Clinical and socio-demographic data of the incident patients with PD (disease 
onset between 2002–2012, clinical evaluation conducted in period 2010–2016), 
stratified by gender. 
Characteristic Mean (±SD) or n (%) p-value 
 Overall Men Women  
Age at onset of PD symptoms, 
years (n=388) 
71.4 (8.7) 69.7 (9.0) 72.6 (8.4) 0.001a 
Age at diagnosis, years (n=388) 73.1 (8.8) 71.3 (9.0) 74.4 (8.4) 0.0007 a 
Time from onset of PD symptoms 
to the diagnosis, years (n=388) 
1.8 (1.8) 1.7 (1.7) 1.9 (2.0) 0.5b 
First PD symptom (n=357)     
Tremor 232 (65.0) 85 (59.0) 147 (69.0)  
Bradykinesia-rigidity 65 (18.2) 33 (22.9) 32 (15.0)  
Handwriting problems 12 (3.4) 7 (4.9) 5 (2.4) 0.13c 
Gait problems  39 (10.9) 14 (9.7) 25 (11.7)  
Other 9 (2.5) 5 (3.5) 4 (1.9)  
Nationality (n=386)     
Estonian 333 (86.3) 138 (87.3) 195 (85.5)  
Russian 47 (12.2) 18 (11.4) 29 (12.7) 0.92c 
Other 6 (1.5) 2 (1.3) 4 (1.8)  
Living area (n=388)     
Urban 248 (63.9) 101 (63.5) 147 (64.2)  
Rural 140 (36.1) 58 (36.5) 82 (35.8) 0.98d 
Exposure to toxins (n=309)     
Pesticides  13 (4.2)    
Fertilizers 11 (3.6)    
Heavy metals 12 (3.9)    
Solvents and paints 40 (12.9) 15 (12) 25 (13.6) 0.81d 
Current smoking 18 (5.8) 9 (7.2) 9 (4.9) 0.55d 
Former smoking 56 (18.1) 20 (16.0) 36 (19.6) 0.52d 
PD family history (n=303)     
1st degree relative 23 (7.6) 11 (8.7) 12 (6.7)  
2nd degree relative 7 (2.3) 3 (2.3) 4 (2.3) 0.77c 
Statistical tests used for gender comparisons:  
a Student´s t-test; 
b Wilcoxon test; 
c Fischer exact test; 
d Chi-squared test. 
Exposure to certain toxins (i.e. pesticides, fertilizers, heavy metals) were very infrequent, 
therefore their prevalence is not displayed separately for men and women. 
Abbrevations: PD, Parkinson´s disease; SD, standard deviation; n, number.
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Table 12. Age-specific, total crude and age-adjusted incidence rates in two epidemio-
logical PD studies in Tartu, Estonia. 
Age group Study population, 1990–1998 Study population, 2002–2012 
Cases Person-
years at 
risk 
Age-specific 
crude 
rate/100,000 
person-years 
Cases Person-
years at 
risk 
Age-specific 
crude 
rate/100,000 
person-years 
All       
<39 1 814 674 0.1 1 961 481 0.1 
40–44 2 87 085 2.3 2 108 521 1.8 
45–49 5 79 848 6.3 4 102 467 3.9 
50–54 14 80 178 17.5 10 96 075 10.4 
55–59 11 79 783 3.8 22 86 167 25.5 
60–64 35 75 148 46.6 34 80 966 42.0 
65–69 69 66 479 103.8 67 77 067 86.9 
70–74 60 47 909 125.2 92 69 871 131.7 
75–79 36 33 976 106.0 88 55 965 157.2 
80–84 24 24 233 99.0 57 36 762 155.1 
85+ 7 18 443 38.0 11 24 371 45.1 
All ages 264 1 407 756 18.8 (10.3–27.2) 388 1 699 709 22.8 (20.6–25.1) 
Men       
<39 0 410 227 0 1 483 845 0.2 
40–44 2 41 606 4.8 1 53 546 1.9 
45–49 4 37 069 10.8 2 49 211 4.1 
50–54 5 36 212 13.8 7 44 811 15.6 
55–59 3 34 921 8.6 11 38 553 28.5 
60–64 13 31 163 41.7 16 34 492 46.4 
65–69 25 24 682 101.3 28 30 419 92.0 
70–74 15 15 490 96.8 40 25 389 157.5 
75–79 13 9931 130.9 33 17 694 186.5 
80–84 8 6538 122.4 19 9731 195.3 
85+ 2 4470 44.7 1 5261 19.0 
All ages 90 652 309 13.8 (6.5–21.1) 159 792 950 20.1 (16.9–23.2) 
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Age group Study population, 1990–1998 Study population, 2002–2012 
Cases Person-
years at 
risk 
Age-specific 
crude 
rate/100,000 
person-years 
Cases Person-
years at 
risk 
Age-specific 
crude 
rate/100,000 
person-years 
Women       
<39 1 404 445 2.1 0 477 636 0 
40–44 0 45 479 0 1 54 975 1.8 
45–49 1 42 779 2.3 2 53 256 3.8 
50–54 9 43 967 20.5 3 51 264 5.9 
55–59 8 44 862 17.8 11 47 615 23.1 
60–64 22 43 985 50.0 18 46 474 38.7 
65–69 44 41 798 105.3 39 46 649 83.6 
70–74 45 32 419 138.8 52 44 481 116.9 
75–79 23 24 045 95.7 55 38 271 143.7 
80–84 16 17 695 90.4 38 27 031 140.6 
85+ 5 13 973 35.8 10 19 111 52.3 
All ages 174 755 477 23.0 (13.6–32.4) 229 906 759 25.3(22.0–28.5) 
Age-adjusted incidence rates/ 100,000 person-yearsa RR p-values 
All 16.8 (14.7–19.0) 18.5 (16.6–20.4) 1.11 0.19 
Men 16.6 (13.5–19.8) 21.3 (18.0–24.7) 1.29 0.04 
Women 17.1 (14.2–20.1) 16.8 (14.5–19.0) 1.0 0.99 
a Adjusted to 1989 Estonian standard population for age; 
 For the comparison between the two studies a p-value below 0.05 was considered statistically 
significant; 
Abbrevations: PD, Parkinson’s disease; CI, confidence interval; RR, rate ratio. 
Table 13. Sensitivity analysis – crude and age-adjusted incidence rates obtained from 
two periods based on the onset year of the disease (2002–2012, n=137; and 2010–2012, 
n=388). 
 Disease onset in period  
2010–2012 
Disease onset in period  
2002–2012 
 Crude incidence 
rate (95% CI) 
Age-adjusted 
incidence rates/ 
100,000 person-
yearsa (95% CI) 
Crude incidence 
rate (95% CI) 
Age-adjusted 
incidence rates/ 
100,000 person-
yearsa (95% CI) 
All 29.5 (24.6–34.5) 23.0 (19.1–27.0) 22.8 (20.6–25.1) 18.5 (16.6–20.4) 
Men 25.9 (19.1–32.7) 27.6 (20.3–34.9) 20.1 (16.9–23.2) 21.3 (18.0–24.7) 
Women 32.7 (25.6–39.9) 19.7 (15.3–24.2) 25.3 (22.0–28.5) 16.8 (14.5–19.0) 
Urban 28.3 (22.4–34.3) 22.7 (17.9–27.6) 22.0 (19.3–24.8) 18.4 (16.1–20.8) 
Rural 32.0 (23.1–40.8) 23.3 (16.7–29.8) 24.4 (20.4–28.5) 18.5 (15.3–21.6) 
a Adjusted to 1989 Estonian standard population for age; 
 Abbrevations: PD, Parkinson’s disease; CI, confidence interval. 
Table 12. Continuation
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5.2.2. Mortality and causes of death 
The SMRs of the inception cohort were as follows: 1.12 for all (95% CI 0.88–
1.36; p=0.3), 1.06 for the women (95% CI 0.77–1.37; p=0.7, and 1.11 for the 
men (95% CI 0.76–1.45; p=0.5) in our study. The SMRs of the non-inception 
cohort were as follows: 1.42 for all (95% CI 1.19–1.65; p=0.00001), 1.44 for 
the women (95% CI 1.13–1.74; p=0.0007), and 1.32 for the men (95% CI 0.99–
1.65; p=0.03). The SMR of cancer was 0.86 (95% CI 0.56–1.15; p=0.4), and the 
SMR for vascular diseases was 1.3 (95% CI 1.1–1.51; p=0.001). Descriptive 
statistics on comorbidities and mortality are illustrated in Table 14.  
 
Table 14. Morbidity and mortality data of PD patients who died during 2010–2016, 
Tartu, Estonia. 
Characteristic Mean (±SD) or n (%) p-value 
 Overall Men Women  
Number of patients 235 (100) 103 (43.8) 132 (56.2) 0.06a 
Mean age at death, yrs 81.3 (6.7) 79.2 (6.8) 82.9 (6.2) <0.00001b 
PD duration until death, yrs 9.5 (6.4) 9.1 (6.3) 9.8 (6.4) 0.4c 
Comorbidities during lifetime*     
Cerebrovascular  46 (19.7) 24 (23.3) 22 (16.8) 0.28a 
Diabetes 31 (14.1) 15 (14.6) 18 (13.7) 1.0 a 
Cardiovascular  182 (77.8) 75 (72.8) 107 (81.7) 0.14a  
Tumors 44 (18.8) 22 (21.3) 22 (16.8) 0.47a 
Rheumatological  72 (30.8) 22 (21.4) 50 (38.2) 0.01a 
Peptic ulcer/gastritis 21 (9.0) 11(10.7) 10 (7.6) 0.56a 
Psychiatric  20 (8.5) 5 (4.9) 15 (11.5) 0.12a 
Immediate causes of death     
Cardiovascular 138 (58.7) 60 (58.3) 78 (59.1)  
Cerebrovascular 29 (12.3) 11 (10.7) 18 (13.6)  
Cancer 25 (10.6) 13 (12.6) 12 (9.1)  
PD 14 (6.0) 7 (6.8) 7 (5.3)  
Respiratory 14 (6.0) 6 (5.8) 8 (6.1)  
Sepsis 5 (2.1) 2 (1.9) 3 (2.3)  
Gastrointestinal 2 (0.9) 0 (0) 2 (1.5)  
Genitourinary 2 (0.9) 1 (1.0) 1 (0.8)  
Trauma 3 (1.3) 2 (1.9) 1 (0.8)  
Other 3 (1.3) 1 (1.0) 2 (1.5)  
* Data missing for one patient;  
Statistical tests used for gender comparisons: a chi-squared test; b Student´s t-test; c Wilcoxon test; 
Abbrevations: PD, Parkinson’s disease; SD, standard deviation; n, number. 
 
 
 
64 
Of the deceased subjects with clinically-diagnosed PD (n=235), 46.8% had PD 
noted on their death certificates. Immediate causes of death are illustrated in 
Table 14. The most frequent underlying causes of death were cardiovascular 
diseases (58.3%), cancer (14.0%), PD (13.6%) and cerebrovascular diseases 
(6.4%). PD was cited as a contributory cause of death on 32.8% of the death 
certificates. 
 
 
5.3. Prevalence and factors associated  
with motor complications in PD 
Out of 328 patients on levodopa (130 men and 198 women), some type of motor 
complication was present in 85 patients (25.9%). Dyskinesias were present in 
21% of patients and motor fluctuations in 20.1%, while 61% of all of those with 
motor complications experienced both fluctuations and dyskinesias. The sources 
for the case-identification of 69 patients with dyskinesias were distributed as 
follows: 61% were recorded on both patient cards and MDS-UPDRS Part IV, 
29% on patient cards, and 10% on MDS-UPDRS Part IV. Presence of motor 
fluctuations among 66 patients was indicated as follows: 68% from both patient 
cards and MDS-UPDRS Part IV, 20% from MDS-UPDRS Part IV, and 12% 
from patient cards. The functional impact of dyskinesias was reported to be at 
least moderate (MDS-UPDRS item 4.2≥3) by 17.4% of patients. Just over one 
third of those patients with motor fluctuations indicated that the functional 
impact of off-state was at least moderate (MDS-UPDRS item 4.4≥3). As Table 
15 shows, prevalence of motor complications was relatively low earlier in the 
course of PD but increased with the duration of levodopa treatment.  
 
Table 15. Motor complications in levodopa users according to the duration of levodopa 
treatment. 
Patients on levodopa 
therapy 
Motor 
fluctuations 
Dyskinesias Motor fluctuations 
and/or dyskinesias 
All patients (n=328) 66 (20.1%) 69 (21%) 85 (25.9%) 
≤2.5 years (n=147) 7 (4.8%) 5 (3.4%) 9 (6.1%) 
2.6–5 years (n=66) 14 (21.2%) 11 (16.7%) 19 (28.8%) 
5.1–10 years (n=62) 19 (30.6%) 24 (38.7%) 27 (43.5%) 
10.1–15 years (n=38) 15 (39.5%) 19 (50%) 19 (50%) 
≥15.1 years (n=15) 11 (73.3%) 10 (66.7%) 11 (73.3%) 
p-value* <0.0001 <0.0001 <0.0001 
* Fisher’s exact test was used to examine the significance of the association (contingency) 
between the two kinds of classification; 
Statistically significant p-values were set at 0.017. 
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The clinical profile of the entire study sample, as well as the group comparisons 
of those with and without motor complications, is depicted in Table 16. The 
ratio of females to males was similar in patients with and without motor 
complications (approximately 60% of females and 40% of males in both 
groups). Patients with motor complications were younger than patients without 
motor complications (71.7±8.9 vs. 75.2±8.2 years; t-test, p=0.002). The 
differences were most evident when regarding age at PD onset and duration of 
the disease. The outcomes of most of the clinometric scales differed more or 
less between patients with and without motor complications. No differences 
were seen in the severity of PD assessed by HY, with a median value of 3 in 
both groups. No statistically significant differences were found in the MMSE 
scores, with the median value of 27 among those without and 28 among those 
with motor complications (Mann-Whitney U test, p=0.08). Duration of 
levodopa treatment was higher among patients with motor complications 
compared to those without (8.8±5.3 vs. 3.7±4.1 years; Mann-Whitney U test, 
p<0.0001). Other antiparkinsonian treatment-related characteristics are shown 
in Table 17. 
The results of the logistic regression can be found in Table 18. An increase 
of LEDD by one unit (keeping all other variables fixed) increased the odds of 
having motor complications by 0.3% (p=0.0005). As a hypothetical example, if 
there were two patients who differed in that one of them had a LEDD of 1000 
mg and the other 1500 mg, and they were identical in all other variables entered 
into the model, then based on our model, the second patient would have 
1.002561^500=3.69 times higher odds than the first of having motor compli-
cations. 
Keeping all other variables fixed, each year of earlier initiation of levodopa 
from PD onset increased the odds of having motor complications by 34% 
(p=0.0006); each year younger of onset age increased the odds by 19.5% 
(p=0.000045); each year older of age at the time of examination increased the 
odds by 11% (p=0.018); and having akinesia-rigid phenotype of the disease (as 
opposed to the dominance of tremor) increased the odds by 156% (p=0.033). 
No statistically significant associations were found between motor compli-
cations and gender (p=0.3), PIGD-dominant phenotype of disease as opposed to 
tremor-dominant phenotype (p=0.9), BDI (p=0.8), MDS-UPDRS Part II and III 
scores (p=0.2, p=0.9, respectively), or PDQ-39 scores (p=0.5). 
To confirm that the effect of clinical phenotype and LEDD is not due to 
possible confounders (duration of PD and duration of levodopa treatment), we 
conducted an analysis using the second model, in which we adjusted for these 
two possible confounders. LEDD (OR=0.003; 95% CI 1.001–1.004, p=0.0004) 
and akinesia-rigid phenotype as opposed to tremor-dominant phenotype 
(OR=2.549; 95% CI 1.1–6.2, p=0.04) still emerged as significant independent 
variables associated with the occurrence of motor complications with almost the 
same OR coefficients as in the first model. As a post hoc analysis we examined 
the LEDD of patients stratified by age and found that younger patients tended to 
be on a higher LEDD than older patients. 
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Table 16. Disease-related characteristics of PD patients with and without motor 
complications. 
Variable All patients 
n=328 
Motor complications p-value 
without 
n=243 
with 
n=85 
 
Age at onset, years 
Mean (SD) 
Median (ranges) 
Missing 
 
66.4 (10.4) 
67 (35–91) 
9 
 
68.6 (9.7) 
70 (35–91) 
6 
 
60 (9.6) 
61 (35–83) 
3 
 
<0.0001a 
Disease duration, years 
Mean (SD) 
Median (ranges) 
Missing 
 
7.8 (6.2) 
6 (0–43) 
9 
 
6.5 (5.8) 
5 (0.3–43) 
9 
 
11.5 (5.7) 
10.6 (2.8–35) 
3 
 
<0.0001b 
Time from PD onset 
until diagnosis, years 
Mean (SD) 
Median (ranges) 
Missing 
 
 
1.8 (3.0) 
1 (0–10) 
12 
 
 
1.9 (3.4) 
1 (0–10) 
9 
 
 
1.4 (1.7) 
1 (0–10) 
3 
 
 
0.484b 
Clinical phenotype of 
PD, n (%) 
Tremor 
Akinetic-rigid 
PIGD 
 
 
122 (37.2) 
120 (36.6) 
86 (26.2) 
 
 
103 (42.4) 
77 (31.7) 
63 (25.9) 
 
 
19 (22.4) 
43 (50.6) 
23 (27.1) 
 
 
0.002c 
BDI 
Mean (SD) 
Median (ranges) 
Missing  
 
15.7 (9.0) 
14 (0–48) 
44 
 
15.1 (8.5) 
13 (0–45) 
32 
 
17.4 (10.2) 
15 (2–48) 
12 
 
0.126b 
PDQ-39 SI 
Mean (SD) 
Median (ranges) 
Missing 
 
31.9 (15.9) 
29.9 (1.6–71.1) 
43 
 
30.5 (16.1) 
27.4 (1.6–71.1)
31 
 
35.9 (14.8) 
35.1 (6.6–68.6) 
12 
 
0.011a 
MDS-UPDRS Part I 
Mean (SD) 
Median (ranges) 
 
12.8 (6.8) 
12 (0–38) 
 
12.0 (6.5) 
12 (0–35) 
 
14.8 (7.1) 
14 (1–38) 
 
0.002a 
MDS-UPDRS Part II 
Mean (SD) 
Median (ranges) 
 
17.8 (8.9) 
17 (0–45) 
 
16.4 (8.1) 
15 (1–45) 
 
21.8 (10.0) 
20 (3–42) 
 
<0.0001a 
MDS-UPDRS Part III 
Mean (SD) 
Median (ranges) 
 
44.1 (18.0) 
41.5 (9–106) 
 
42.3 (16.6) 
40 (9–83) 
 
49.1 (20.7) 
48 (11–106) 
 
0.007a 
Statistical tests used for group comparisons:  
a t-test; b Mann Whitney U test; c chi-squared test; 
Statistically significant p-values after Bonferroni’s correction were set at 0.0045; 
Abbrevations: PD, Parkinson’s disease; SD, standard deviation; n, number; PIGD, postural 
instability and gait disorder; BDI, the Beck Depression Inventory; PDQ-39 SI, the Parkinson’s 
Disease Questionnaire Summary Index; MDS-UPDRS, the Movement Disorders Society’s 
Unified Parkinson’s Disease Rating Scale. 
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Table 17. Antiparkinsonian treatment of PD patients with and without motor complications. 
Variable All patients 
n=328 
Motor complications p-value 
without 
n=243 
with 
n=85 
Current antiparkinsonian 
treatment, n (%) 
Levodopa summarily 
Regular levodopa 
CR levodopa 
Soluble levodopa 
Levodopa + COMT 
inhibitors 
Dopamine agonists 
MAO-B inhibitors 
 
 
328 (100%) 
62 (18.9%) 
220 (67.1%) 
6 (1.8%) 
63 (19.2%) 
 
103 (31.4%) 
64 (19.5%) 
67 (20.4%) 
9 (27%) 
 
 
243 (100%) 
50 (20.6%) 
181 (74.5%) 
2 (0.8%) 
19 (7.8%) 
 
55 (22.6%) 
46 (18.9%) 
32 (13.2%) 
8 (3.3%) 
 
 
85 (100%) 
12 (14.1%) 
39 (45.9%) 
4 (4.7%) 
44 (51.8%) 
 
48 (56.5%) 
18 (21.2%) 
35 (41.2%) 
1 (1.2%) 
 
 
 
0.251a 
<0.0001a 
0.041b 
<0.0001a 
 
<0.0001a 
0.771a 
<0.0001a 
0.456b 
Time from PD onset until 
levodopa treatment, years 
Mean (SD) 
Median (ranges) 
Missing 
 
 
2.6 (3.6) 
2 (0–10) 
9 
 
 
2.6 (3.9) 
2 (0–38) 
6 
 
 
2.5 (2.7) 
2 (0–13) 
3 
 
 
 
0.629c 
 
Levodopa daily dose, mg 
Mean (SD) 
Median (ranges) 
 
433.5 (221.9) 
400 (100–1300)
 
390.8 (184.0) 
400 (100–1000)
 
555.3 (271.8) 
500 (100–1300) 
 
<0.0001c 
LEDD, mg 
Mean (SD) 
Median (ranges) 
Missing 
 
537.1 (362.7) 
450 (75–2518) 
1 
 
421.7 (222.9) 
399 (75–1120) 
1 
 
865.8 (469.3) 
808.5 (100–2518) 
0 
 
<0.0001c 
Statistical tests used for group comparisons:  
a chi-squared test;  
b Fischer’s exact test;  
c Mann Whitney U test; 
Statistically significant p-values after Bonferroni’s correction were set at 0.0041; 
Abbrevations: PD, Parkinson’s disease; n, number; SD, standard deviation; CR, controlled release; 
LEDD, levodopa equivalent daily dose. 
 
 
  
Amantadine 
Anticholinergics 
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In order to assess a possible association between levodopa daily dose and the 
presence of motor complications, we conducted an analysis based on another 
logistic model in which we entered all the same variables as in the first model 
but included levodopa daily dose instead of LEDD. No evidence was found for 
associations between motor complications and levodopa daily dose (OR=1.002; 
95% CI–1.0 to 1.003, p=0.07).  
 
Table 18. Factors associated with motor complications in PD: the logistic regression 
model. 
Variable Odds ratio 95% CI 
Gender  1.616 0.721–3.727 
Age 1.106* 1.018–1.203 
Age at onset of PD 0.837*** 0.766–0.910 
Time from onset to initiation with levodopa 0.746*** 0.624–0.870 
Akinetic-rigid phenotype 2.559* 1.087–6.199 
PIGD phenotype 1.024 0.379–3.188 
LEDD 1.003*** 1.001–1.004 
MDS-UPDRS II 1.058 0.979–1.145 
MDS-UPDRS III 0.998 0.969–1.027 
BDI 1.008 0.956–1.063 
PDQ-39 SI 0.987 0.956–1.019 
***p<0.001, **p <0.01, *p<0.05; 
Abbrevations: PD, Parkinson’s disease; CI, confidence interval; PIGD, postural instability and 
gait disorder; LEDD, levodopa equivalent daily dose; MDS-UPDRS, the Movement Disorders 
Society’s Unified Parkinson’s Disease Rating Scale; BDI, the Beck Depression Inventory; PDQ-
39 SI, the Parkinson’s Disease Questionnaire Summary Index. 
 
 
5.4. Prevalence and factors associated  
with non-motor symptoms in PD  
The basic characteristics of the sample of 268 PD patients included: mean age 
equalled 74.2±8.8 years (range: 47–96 years), duration of the disease was 
7.6±5.9 years (range: 0.1–35 years), and age at onset amounted to 66.8±10.1 
years (range: 35–88 years). Of the total sample, 94.8% were on antiparkinsonian 
treatment. A total of 81.3% were using levodopa therapy (41% on monotherapy); 
31.3% dopamine agonists; 19% amantadine; 17.5% MAO-B inhibitors; 3% 
anticholinergics, and 35.8% were undergoing a combination of therapies. The 
mean duration of levodopa therapy at enrolment was 5.03±5.2 years (range: 0.1–
23) and the mean daily dose of levodopa 430±232 mg (range: 100–1200 mg).  
Among the patients screened, 99.6% complained of at least one non-motor 
symptom. There were a mean number of 6.7± 2.5 non-motor symptoms per 
patient of the 13 symptoms included in the MDS-UPDRS Part I. The most 
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frequent non-motor symptoms were cognitive impairment, night time sleep 
disorders, bladder disorders, fatigue, pain, daytime sleepiness and depression. 
Hallucinations and ICDs were the most infrequently reported non-motor 
symptoms. We did not find a statistically significant difference between mean 
BDI scores for persons with PD and with ICDs, and persons with PD and 
without ICDs (mean score 19.1 and 15.1, respectively, p= 0.254). Prevalence of 
non-motor symptoms is given in Table 19. 
 
Table 19. Prevalence of non-motor symptoms (n=268). 
Non-motor symptoms N %
Cognitive impairment 199 74.3% 
Nighttime sleep problems 192 71.6% 
Urinary problems 192 71.6% 
Fatigue 184 68.7% 
Pain 172 64.2% 
Daytime sleepiness 166 61.9% 
Depressed mood 163 60.8% 
Constipation problems  156 58.2% 
Anxious mood 151 56.3% 
Lightheadedness on standing 140 52.2% 
Apathy 122 45.7% 
Hallucinations and psychosis 37 13.8% 
ICDs 21 7.8% 
Abbrevations: ICDs, impulse control disorders. 
 
The frequency of non-motor symptoms was high, but the severity was assessed 
as low by the patients. The distribution of scores according to the severity range 
0–4 and the mean scores for each item are provided in Figure 4. Most 
frequently, in cases of the presence of a non-motor symptom, patients reported 
the problem to be slight or mild (scores 1–2), night-time sleep disorders had the 
highest and ICDs the lowest mean score. 
Statistically significant differences in the mean scores of MDS-UPDRS Part 
I among patient subgroups are shown in Figure 5: higher scores were seen in 
patients with a longer duration and advanced stages of the disease, the PIGD-
dominant motor phenotype and the presence of motor complications, 
depression, and impaired cognitive status. There were no statistically significant 
differences between the mean MDS-UPDRS Part I scores in terms of gender, 
age, and age at onset of the disease. As regards motor complications in their 
variations, significantly higher MDS-UPDRS Part I scores were reported in 
patients with motor fluctuations, compared to non-fluctuating patients 
(p<0.026), but no difference was seen comparing patients with or without 
dyskinesias (p<0.046), nor with or without off-period dystonia (p<0.065). 
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A significantly increased frequency of some non-motor symptoms in several 
specific subgroups of PD patients is shown in Table 20a and 20b. The different 
profile of specific non-motor symptoms was found in all group comparisons, 
including a higher rate of ICDs and fatigue in patients with onset age ≤50 years 
compared to patients with onset age ≥65 years. In patients of a more severe 
disease stage, most of the non-motor symptoms were more frequently com-
plained of when compared to patients of less severe disease stage or disability. 
Additionally, several specific non-motor symptoms including hallucinations and 
psychoses, depressed mood, sleep problems, and fatigue occurred more 
frequently in patients with motor complications compared to patients without 
those disabling problems (Table 20b). 
  
 
Figure 4. Bar diagram showing the two aspects of the severity of each non-motor 
symptom. Firstly, the proportional distribution of responses of MDS-UPDRS Part I for 
each item is shown in bars. Severity scores range from 0 (symptom is absent) to 4 
(symptom is severe). Secondly, the mean scores of each item of MDS-UPDRS Part I are 
shown by the continuous line, ICDs being with the lowest and nighttime sleep problems 
with the highest value. 
Abbrevations: MDS-UPDRS, the Movement Disorders Society’s Unified Parkinson’s Disease 
Rating Scale ICDs, impulse control disorders. 
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Figure 5. Bar diagram showing significant differences in mean scores of MDS-UPDRS 
Part I among subgroups of patients. 
Abbrevations: PIGD, postural instability and gait disorder; HY, Hoehn and Yahr stage; SE-ADL, 
Schwab and England Activities of Daily Living Scale; MMSE, Mini Mental State Examination; 
BDI, Beck Depression Inventory. 
 
 
Table 21 illustrates the correlation analysis between the MDS-UPDRS Part I 
scores and different variables. The strongest correlations were found between 
BDI and MDS-UPDRS Part I (ρ=0.621, p<0.001) and between PDQ-39 and 
MDS-UPDRS Part I (ρ=0.617, p<0.001), indicating that the presence of higher 
load of non-motor symptoms was associated with more severe depression or 
reduced quality of life. When assessing correlations between individual non-
motor symptoms, we found a statistically significant association between a 
depressed mood and anxiety (ρ=0.492, p<0.001) and between a depressed mood 
and apathy (ρ=0.451, p<0.001), indicating that more depressed patients have 
more frequently also other psychiatric symptoms. For the correlations between 
individual non-motor symptoms and total MDS-UPDRS Part I scores, we found 
that cognitive impairment (ρ=0.623, p<0.001) and fatigue (ρ=0.66, p<0.001) 
were strongly related to the higher overall burden of non-motor symptoms.  
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Table 20b. Frequency of each non-motor symptom among patients with and without 
motor complications (n=237). 
 Dyskinesias Motor 
fluctuations
Off-state dystonias 
 No Yes No Yes No Yes 
 (n=236) (n=31) (n=237) (n=30) (n=251) (n=16) 
1.1 Cognitive 
impairment 
73.4% 80.6% 73.8% 80.0% 74.1% 81.2% 
1.2 Hallucinations and 
psychoses 
12.2% 25.8%* 12.2% 26.7%* 13.1% 25.0% 
1.3 Depressed mood 57.4% 87.1%* 57.4% 90.0%* 58.6% 100.0%*** 
1.4 Apathy 55.3% 64.5% 55.3% 63.3% 55.8% 62.5% 
1.5 Anxious mood 46.6% 38.7% 45.8% 43.3% 45.2% 50.0% 
1.6 ICDs 6.8% 16.1% 6.3% 16.7% 6.8% 18.8% 
1.7 Nighttime sleep 
problems 
70.0% 83.9% 68.8% 93.3%* 70.1% 93.8%* 
1.8 Daytime sleepiness 59.5% 80.6%* 58.6% 86.7%* 60.6% 81.2% 
1.9 Pain 64.4% 66.7% 65.7% 58.6% 64.7% 68.8% 
1.10 Urinary problems 70.9% 77.4% 70.9% 76.7% 72.1% 62.5% 
1.11 Constipation 
problems 
58.2% 58.1% 57.4% 63.3% 58.2% 56.2% 
1.12 Lightheadedness 
on standing 
52.7% 48.4% 52.7% 50.0% 53.8% 31.2% 
1.13 Fatigue 66.9% 83.9% 66.9% 83.3% 67.2% 93.8%* 
*p<.05; **p<.01;***p<0.001; 
Chi-squared test for all the differences in the frequency of individual non-motor symptoms. 
Abbrevations: ICDs, impulse control disorders. 
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Table 21. Spearman’s correlation analysis between the total score of non-motor 
symptoms assessed by the MDS-UPDRS Part I, and variables. 
Variable Correlation coefficient ρa p-value 
Age 0.192 0.002 
Disease onset age 0.005 0.940 
Duration of disease 0.278 <0.001 
HY 0.457 <0.001 
SE-ADL –0.524 <0.001 
BDI 0.621 <0.001 
MMSE –0.243 <0.001 
PDQ-39 SI 0.617 <0.001 
MDS-UPDRS II 0.579 <0.001 
MDS-UPDRS III 0.364 <0.001 
MDS-UPDRS IV 0.160 0.009 
Duration of levodopa therapy 0.285 <0.001 
Daily dose of levodopa 0.300 <0.001 
a Spearman rank coefficient; 
Abbrevations: MDS-UPDRS, Movement Disorders Society Unified Parkinson’s Disease Rating 
Scale; HY, Hoehn and Yahr stage; SE-ADL, Schwab and England Activities of Daily Living 
Scale; BDI, Beck Depression Inventory; MMSE, Mini Mental State Examination; PDQ-39 SI, 
Parkinson´s Disease Questionnaire Summary Index. 
 
 
5.5. HRQoL of patients with PD 
Demographic and clinical characteristics of the study population are given in 
Table 22. Men were slightly younger than women (72.1 and 75.6 years 
respectively, p=0.0014), which reflects the shorter life expectancy of men in 
Estonia. No significant differences in terms of PD onset age, disease duration, 
HY stage, SE-ADL stage or MMSE performance were found between men and 
women. The mean BDI depression score was significantly higher in women 
compared to men (17.1 and 12.3 respectively, p=0.0001). A significantly higher 
rate of men compared to women were: a family status as married (71.4% and 
32.5 % respectively, p<0.0001), and living together with their spouse and or 
children (89.5% and 60.1% respectively, p<0.0001). There were more widows 
among female than male patients (48.5% and 17.1% respectively, p=0.02). 
Women had a higher mean number of comorbidities compared to men (2.2 and 
1.9, respectively, p=0.0124), including a significantly higher rate of cardio-
vascular diseases (99.4% and 89.6% respectively, p<0.0001). Mean scores of 
PDQ-39 domains are presented in Figure 6. In persons with PD, mobility was 
the most negative HRQoL domain and social support the least negative domain. 
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Figure 6. Mean values of PDQ-39 domains. HRQoL was assessed by using the PDQ-
39. PDQ-39 is composed of 39 items grouped in 8 subscales: (1) mobility, (2) activities 
of daily living, (3) emotional well-being, (4) stigma, (5) social support, (6) cognition, 
(7) communication, and (8) bodily discomfort. The PDQ-39 SI is an overall score 
calculated from these domains, with 0 indicating the best HRQoL and 100 the worst.  
Abbrevations: HRQoL, health-related quality of life; PDQ-39, Parkinson’s Disease Quality of 
Life Questionnaire; SI, Summary Index score. 
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Table 22. Characteristics of the PD patients included to the study on HRQoL (n=268). 
Variable Value Range 
Age, years a 74.2±8.8 47–96 
Disease onset age, years a 66.8±10.1 35–88 
Duration of disease a 7.6±5.9 1–35 
HY ≥3, n (%) 164 (62.6%)  
SE-ADL ≤75%, n (%) 139 (53.3%)  
MMSE ≥25, n (%) 197 (76.7%)  
BDI ≥14, n (%) 134 (52.1%)  
MDS-UPDRS 
MDS-UPDRS Part I 
MDS-UPDRS Part II 
MDS-UPDRS Part III 
MDS-UPDRS Part IV 
 
12.52 (6.79) 
18.2 (8.4) 
46.3 (18.3) 
1.3 (3.4) 
 
0–38 
1–48 
10–106 
0–18 
Clinical subtype 
Tremor dominant 
Akinetic-rigid dominant  
PIGD  
 
118 (44%) 
77 (28.7%) 
73 (27.3%) 
 
LEDD, mga 427.5±231.6 100–1200 
Duration of levodopa treatment, years a 3.9±5.03 0.1–23 
Marital status, n (%) 
Single 
Married 
Divorced 
Widowed 
 
20 (7.4%) 
128 (47.8%) 
23 (8.6%) 
97 (36.2%) 
 
Living status, n (%)  
With a spouse  
With children 
Alone 
Nursery home 
 
137 (51.1%) 
55 (20.5%) 
66 (24.6%) 
10 (3.8%) 
 
Education, n (%) 
Primary 
Secondary 
Higher  
 
104 (38.8%) 
95 (35.5%) 
69 (25.7%) 
 
a Mean±standard deviation; 
Abbreviations: HRQoL, health related quality of life; HY, Hoehn and Yahr stage; mg, 
milligrams; SE-ADL, Schwab and England Activities of Daily Living Scale; MMSE, 
Mini Mental State Examination; BDI, Beck Depression Inventory; MDS-UPDRS, 
Movement Disorders Society Unified Parkinson’s Disease Rating Scale; PIGD, postural 
instability and gait disorder; LEDD, levodopa equivalent daily dose. 
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The results of univariate analysis of socio-demographic and clinical parameters 
and mean scores of PDQ-39 SI in persons with PD are shown in Table 23. 
Emotional well-being and bodily discomfort affected women significantly more 
than men (mean scores for the corresponding subdomains: 20.2 for men, 30.4 
for women, p=0.0001; and 34.4 for men and 42.7 for women, p= 0.0048, 
respectively). Being over 65 years old was associated with lower mobility 
(mean scores 35.7 for ≤64 years old and 55.7 for ≥65 years old, p=0.0007); 
being younger was associated with higher stigmatisation (mean scores 31.3 for 
≤64 years old and 17.9 for ≥65 years old, p=0.0012). Marital status was not 
significantly associated with PDQ-39 scores. Emotional well-being was 
significantly related to living status, i.e. patients living alone had lower 
emotional well-being compared to patients living with their spouse (mean 
scores 31.3 and 23.5, respectively, p=0.012). Education did not significantly 
influence overall HRQoL. People who had undergone no more than the primary 
level of education were significantly more affected in the domain of mobility 
(mean scores of 61.8 for patients with primary education, 49.9 for patients with 
secondary education, 44.3 for patients with higher education, p= 0.001). 
Overall HRQoL was significantly lower in patients with depression, which 
had an impact on all the PDQ-39 domains. Longer disease duration, a HY stage 
≥3 and SE-ADL ≤75% were associated significantly with lower overall HRQoL 
and affected most of the PDQ-39 domains. Patients with cognitive impairment 
had lower overall HRQoL and were significantly more adversely affected in the 
domains of mobility, activities of daily living and communication. By clinical 
PD subtype, the group with PIGD had the lowest overall HRQoL (compared to 
the tremor and akinetic-rigid clinical subtypes).  
PDQ-39 SI correlated significantly with higher MDS-UPDRS Part II, BDI 
and MDS-UPDRS Part IB scores. All non-motor symptoms – except ICDs – 
correlated significantly with PDQ-39 SI. All correlations between PDQ-39 and 
the other characteristics of PD are shown in Table 24.  
 
 
 
78 
Table 23. PDQ-39 associations with demographic and clinical features. 
Variable PDQ-39 SIa p value 
Gender  
Male  
Female 
 
29.8 (15.5) 
32.7 (15.1) 
0.066 
 
Living area 
Urban 
Rural 
 
32.5 (15.3) 
29.6 (15.1) 
0.192 
Marital status 
Single 
Married 
Divorced 
Widowed 
 
32.7 (17.4) 
30.8 (15.3) 
34.2 (13.1) 
31.7 (15.4) 
0.770 
Living status 
With a spouse 
With children 
Alone 
Nursery home 
 
30.6 (15.4) 
31.5 (17.1) 
33.5 (13.5) 
32.7 (15.3) 
0.638 
Education 
Primary 
Secondary 
Higher 
 
33.6 (13.6) 
30.4 (15.1) 
30.1 (17.6) 
0.339 
Clinical subtypes 
Tremor 
Akinetic-rigid 
Postural instability and gait disturbance 
 
28.6 (14.9) 
30.5 (14.4) 
37.3 (15.3) 
0.0017; 1vs. 3 
Disease duration 
≤5 yr 
6–10 yr 
>10 yr 
 
26.5 (13.0) 
32.1 (16.1) 
38.8 (14.8) 
0.00010; 1 vs. 3 
HY 
≤2.5 
≥3 
 
24.2 (13.9) 
35.7 (14.6) 
<0.0001 
SE-ADL 
≥80 
≤75 
 
25.0 (14.4) 
37.0 (14.0) 
<0.0001 
MMSE 
≥25 
≤24 
 
29.9 (14.9) 
35.9 (14.6) 
0.0037 
BDI 
<14 
≥14 
 
23.0 (11.9) 
39.2 (14.1) 
<0.0001 
a Mean (standard deviation);  
The Mann–Whitney U and Kruskal-Wallis tests were used to compare PDQ-39 SI scores between 
the groups; 
Abbrevations: HY, Hoehn and Yahr stage; SE-ADL, Schwab and England Activities of Daily 
Living Scale; MMSE, Mini Mental State Examination; BDI, Beck Depression Inventory.  
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Table 24. Spearman’s correlation analysis of clinical variables and PDQ-39 SI scores. 
Variable Coefficient p value 
Disease duration  0.30 <0.0001 
HY  0.51 <0.0001 
SE-ADL  –0.51 <0.0001 
MMSE  –0.25 0.0001 
BDI 0.63 <0.0001 
Daily dose of levodopa 0.32 <0.0001 
Duration of levodopa treatment 0.23 0.0001 
Number of comorbidities 0.07 0.5041 
MDS-UPDRS Part I – Non-motor experiences of daily living 0.62 <0.0001 
MDS-UPDRS Part IA 0.51 <0.0001 
MDS-UPDRS Part IB 
Cognitive impairment 
Hallucinacions and psychosis 
Depressed mood 
Anxious mood 
Apathy 
ICDs 
Nighttime sleep problems 
Daytime sleepiness 
Pain and other sensations 
Urinary problems 
Constipation problems 
Lightheadedness on standing 
Fatigue 
0.61 
0.38 
0.24 
0.35 
0.29 
0.33 
0.07 
0.29 
0.35 
0.38 
0.30 
0.13 
0.34 
0.44 
<0.0001 
<0.0001 
0.0001 
<0.0001 
<0.0001 
<0.0001 
0.2490 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
0.0281 
<0.0001 
<0.0001 
MDS-UPDRS Part II – Motor experiences of daily living 0.65 <0.0001 
MDS-UPDRS Part III – Motor examination 0.46 <0.0001 
MDS-UPDRS Part IV – Motor complications 0.22 0.0003 
Abbrevations: PDQ-39, the Parkinson’s Disease Questionnaire; SI, summary index score; PIGD, 
postural instability and gait disturbance; HY, Hoehn and Yahr stage; SE-ADL, Schwab and 
England Activities of Daily Living Scale; MMSE, Mini Mental State Examination; BDI, Beck 
Depression Inventory; MDS-UPDRS, Movement Disorders Society Unified Parkinson´s Disease 
Rating Scale; ICDs, impulse control disorders. 
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Potential predictors were determined based on the previous correlation analysis. 
Duration of disease, HY, SE-ADL, MMSE, BDI, MDS-UPDRS Parts IA, IB, 
II–IV, duration of levodopa treatment, daily dose of levodopa, were identified 
as independent variables using univariate regression analysis. Multiple linear 
regression analysis was then performed on all the independent variables found 
during the previous univariate regression analysis and common epidemiological 
variables, i.e. age and gender. The final model (Table 25) explained 59.9% 
(adjusted R2, p<0.0001) of the variance of PDQ-39 SI, with BDI, MDS-UPDRS 
II, MDS-UPDRS Part IB significant predictors and depression the most 
significant predictor of HRQoL. 
 
Tabel 25. Predictors of HRQoL in stepwise multiple regression analysis. 
Model Unstandardized coefficients p value 
B                      SE 
BDI  0.734 0.089 0.0001 
MDS-UPDRS Part IB 0.603 0.201 0.003 
MDS-UPDRS Part II 0.546 0.127 0.0001 
MDS-UPDRS Part III 0.067 0.050 0.182 
Age –0.124 0.077 0.108 
Duration of the disease 0.251 0.184 0.175 
Duration of levodopa treatment –0.339 0.211 0.109 
 Multiple R2=0.611 
Adjusted R2=0.599 
Abbrevations: HRQoL, health-related quality of life; SE, standard error; BDI, Beck depression 
Inventory; MDS-UPDRS, Movement Disorder Society Unified Parkinson´s Disease Rating Scale. 
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6. DISCUSSION 
6.1. Prevalence of PD  
The first goal of this study was to determine the current frequency of PD in 
Estonia. Age-adjusted prevalence rates of PD in several other community-based 
studies as well as in our previous study that used the same diagnostic criteria, 
have reported remarkably lower rates than the current study (197/100,000), 
ranging from 109–183/100,000 (Kuopio et al., 1999a; Osaki et al., 2011; Schrag 
et al., 2000b; Taba & Asser, 2002; Walker et al., 2010). However, the use of 
different case-ascertainment methods and standard populations sets limits to the 
comparability of prevalence estimates reported by various studies. 
In line with the literature, PD prevalence increased continuously with age 
among both men and women (Blin et al., 2015; Kuopio et al., 1999a; Liu et al., 
2016; Newman et al., 2009; Riedel et al., 2016). Though the crude prevalence 
rate was significantly higher for women, no difference of the age-adjusted 
prevalence rates was evidenced between men and women, the latter finding 
being in line with a few earlier studies (de Rijk et al., 1997; Taba & Asser, 
2002; Walker et al., 2010). The discrepancy of the crude and adjusted pre-
valence rates in our study might result from the predominance of women in the 
oldest age groups in Estonia, i.e, in 2014, there were 3.8 times more women 
than men aged 85 years and more. The highest age-specific crude rate for 
women in the subgroup of 80–84 year old people had big influence on the crude 
measure, while the standardization removed the difference coming from the 
population structure.  
Our study did not demonstrate a statistically significant difference between 
the prevalence rates of PD among urban and rural populations, a finding that 
contrasts with the results of some Scandinavian studies where higher PD 
prevalence rates were found in rural compared to urban areas (Kuopio et al., 
1999a; Tandberg et al., 1995), but is supported by several other previous 
surveys (Benito-León et al., 2003; de Rijk et al., 1997; Walker et al., 2010). 
There is substantial evidence that exposure to pesticides is associated with an 
increased risk of PD although specific compounds remain unclear (Ascherio & 
Schwarzschild, 2016). A nested case-control study by Tanner et al. (2011) 
found that rotetone impairs mitochondrial function and paraquat increases 
oxidative stress. The use of pesticides has not been extensive in Estonia, 
supported by only a minority (3.6%) of patients in our study indicating that they 
had been exposed to these chemicals over their life-time, a rate that is lower 
than reported in one other study (Kuopio et al., 1999b). Exposure to chemical 
solvents or paints was reported by a higher number of patients (14%), but these 
environmental factors are less linked with living area than occupation. 
With respect to the research question regarding PD prevalence over time, we 
found that the overall disease prevalence in Estonia has risen from 152/100,000 
in 1996 to 197/100,000 in 2013. Age-specific rates in the older age-groups have 
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grown considerably. Considering the demographical situation in the entire 
country in 1996 and 2014, the changes have been substantial. An increase in the 
population proportion of older age groups and a decrease in younger groups are 
notable. A total of 4.8% of people in Estonia were aged 75 years or more in 
1996, the same proportion was as high as 8.9% in 2014. We believe that longer 
life expectancy nowadays compared to 20 years ago has an important 
contribution to the higher frequency of PD. Life expectancy of men was 64 
years in 1996 and 72 years in 2014; and for women 75 years in 1996 and 81 
years in 2014 (Statistics Estonia website, 2018). The most striking aspect to 
emerge from the results is that the prevalence of PD has increased mainly among 
men. Men’s life expectancy is longer now due to better health behaviours and 
improved medical care. 
Another reason for the higher prevalence of PD could be related to awareness. 
First, knowledge of the management of PD has improved remarkably among 
family doctors and neurologists due to continuous research on the disease, and 
new insights into the clinical heterogeneity and therapeutic approaches to PD 
have been adopted into clinical practice. Second, resulting from the improved 
general awareness of the disease in society, patients themselves are more 
attentive to the physical signs and seek specialist consultation. The internet 
might have a major role in spreading information on PD among the society; this 
source was almost unavailable 20 years ago (Lubi, Vihalemm, & Taba, 2013). 
Men’s health receives more attention than decades ago, resulting in improved 
medical care. It could be possible that 20 years ago, an undetermined number of 
actual cases of PD were missed, because people were less likely to seek help 
from the medical system. 
In the current study, we used the same diagnostic criteria and a similar case-
ascertainment methodology as the previous epidemiological study by Taba and 
Asser (2002) except that the EHIF database was used as an additional source in 
the current study, with a high number of persons with suspected PD (coded as 
G20 in ICD-10). However, quite a large proportion of them were removed from 
the study, as their initial family doctor’s diagnosis was not confirmed by a 
specialist (Figure 1). 
Another objective of this research was to describe the natural history of PD. 
The proportion of patients moderately or severely affected by the disease 
compared to mild disease was higher in the current study than in the previous 
study in Estonia (Taba & Asser, 2002) as well as in prevalence surveys with in-
person examination conducted elsewhere (Benito-León et al., 2003; Wermuth et 
al., 2008). First, this could be associated with the relatively high proportion of 
patients who were visited at their homes or in nursing institutions, indicating 
that they were bed-ridden or had otherwise serious problems with walking or 
general health. Second, patients in our cohort were older and had a longer 
disease duration compared to the earlier study in Estonia (Taba & Asser, 2002). 
As prevalence is associated with the duration of the disease, an increased 
frequency of PD could at least partially be attributed to this trend. Approxi-
mately half of our patients presented depressive symptoms and a quarter were 
 
 
83 
cognitively impaired, which makes the management of this chronic disorder 
even more challenging. 
The main strength of our study was the nearly complete identification of PD 
cases, based on all available sources over a long time frame, including the 
database of the EHIF that includes all recorded cases in the country. Second, the 
evaluation of the participants was thorough, including the collection of socio-
demographic and disease-related data from quite a large sample of study 
subjects. Furthermore, wide-ranging clinical aspects were assessed based on 
validated clinometric scales and questionnaires. We think that the profile of our 
study participants is generalizable to the Estonian PD population as a whole. 
Last, given that there are only a few repeat epidemiological PD studies 
conducted on the same population at different time periods, our study provides 
valuable information about temporal trends of PD prevalence. 
Some limitations of this study need to be taken into account when inter-
preting the findings. The first limitation concerns the small but existing pro-
portion of patients whose diagnosis was only obtained through a review of 
medical records, i.e. they were not personally examined during the study. 
Another limitation is the extra source list used in our repeat study, as data from 
the EHIF was not used in the previous PD prevalence study, thus affecting the 
comparability of the two studies. 
 
 
6.2. Incidence and mortality of PD 
The main result of interest in this study was that the overall incidence of PD has 
remained comparatively unchanged since the previous epidemiological study in 
Estonia (incidence rate of 18.5/100,000 in the current study compared to 
16.8/100,000 approximately twenty years ago) (Taba & Asser, 2003). The age-
adjusted incidence in males has increased slightly (a 1.3-fold increase compared 
to the first Estonian study). These findings, of comparable overall incidence, 
and an increase in incidence for males, align with those of a study in Turku, 
Finland, in which PD incidence was reinvestigated after an interval of approxi-
mately thirty years (Kuopio et al., 1999a). However, retrospective studies in 
Taiwan (Liu et al., 2016) and the UK (Horsfall et al., 2013), and a prospective 
study in the Netherlands (Darweesh et al., 2016) each showed a decline in 
incidence over time. Three record-based studies in Japan, Yonago (1980, 1992, 
2004), found no change in adjusted incidence rates (Harada et al., 1983; Kusumi 
et al., 1996; Yamawaki et al., 2009). Prospective comparative incidence studies 
in Cambridgeshire, UK, conducted in years 2000–2002 and 2008–2010, also did 
not find a change in incidence rates over time (Evans et al., 2016; Foltynie et 
al., 2004). However, a record-based retrospective study in Minnesota, USA, 
showed an increased incidence of PD over a thirty-year period, particularly for 
males over 70 years of age (Savica et al., 2016). The slight increase in PD 
prevalence in Estonia reported in our previous study (Kadastik‐Eerme, Taba, 
Asser, & Taba, 2018) may be attributable to the aging population, the higher 
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absolute number of elderly people at risk, and the longer duration of disease, 
rather than to increased incidence.  
This study’s observation of the slightly higher occurrence of PD for males 
adds to the already extensive body of epidemiological evidence for this finding. 
However, in the current study, the risk of PD for males was not as high as that 
reported in most other studies. For example, the male to female incidence ratio 
was 1.25:1, whereas a nearly two-fold increase in risk for males was reported in 
several other studies (Alves et al., 2009; Caslake et al., 2013; Hristova et al., 
2010; Jones et al., 2012; Moisan et al., 2016; Myall et al., 2017). On the other 
hand, other studies have reported no gender difference in the adjusted incidence 
rates (Das et al., 2010; Linder et al., 2010; Winter et al., 2010a). Furthermore, a 
recent meta-analysis reported the pooled total crude incidence rate for males as 
44.2/100,000 and for females as 37.2/100,000 (Hirsch et al., 2016). In the 
current study, crude estimates were much lower (i.e. 20/100,000 for males, and 
25/100,000 for females).  
A recent meta-analysis by Macleod et al. (2018) reported the pooled estimate 
of mean age at symptom onset to be 68.1 years (95% CI 65.8–70.4). The current 
study’s mean onset age of 71.4 years was slightly higher, but was more similar 
to the pooled estimate of 71.6 (95% CI 70.6–72.6) years reported by the same 
meta-analysis including specifically those studies that showed the mean age at 
diagnosis. No significant differences in age-specific incidence rates for males 
and females were observed. However, the small sample size of subjects in each 
of the different age groups may have limited the power of the subgroup analysis 
to reveal gender differences. In contrast, Moisan et al. (2016) reported that, in 
France, male-female incidence ratios increased with age. In line with the results 
of other studies, males in this current study were observed to develop PD 
approximately two years earlier than females (Alves et al., 2009; Heinzel et al., 
2018; Winter et al., 2010a). Possible factors which may contribute to the male 
preponderance include a neuroprotective effect of female sex hormones, a sex-
associated genetic mechanism, or differences in levels of exposure to environ-
mental risk factors (Gillies et al., 2014).  
This study’s observation of a comparative increase in PD incidence for 
males since the previous Estonian study may be partly attributable to the fact 
that life expectancy, particularly for males, has risen substantially over the 
intervening time period. As onset of the disease is typically in the late sixties, 
less number of males might historically have developed the disease because of 
their shorter life expectancy. In other words, the increased incidence rate of PD 
for males over time may be attributable to demographical changes, and to the 
higher representation of males in the healthcare system. However, there may 
also be other explanations for the observed change in incidence rates for males. 
For example, some studies have suggested that smoking has a protective effect 
on the development of PD (Martino et al., 2017). Smoking rates in Estonia have 
significantly decreased since 1990, particularly for males. In 1996, 45.4% of 
males were everyday smokers, whereas this figure was 31.4% in 2014 (for 
women, the rates were 20.8% and 15.8%, respectively) (National Institute for 
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Health Development website. 2018). The observed increase in PD incidence 
rates in Estonia may be partially attributable to this change. In addition, a 
previous meta-analysis identified exposure to pesticides, previous head injury, 
rural living, beta-blocker use, farming/agricultural occupation and well-water 
drinking as significant risk factors for PD (Noyce et al., 2012). However, in the 
current study, exposure to different environmental factors was not seen to differ 
between males and females (Table 11). In addition, the current results did not 
show PD to be associated with either rural (Kab et al., 2017; Kuopio et al., 
1999a) or urban living (Horsfall et al., 2013; Hristova et al., 2010), as had been 
found in previous studies.  
For both men and women, the age-specific incidence rates peaked in the 75–
84 years age-group, after which a sharp decline in incidence rates was observed. 
This decline in older age-groups aligns with the results of multiple other 
studies; indicating that PD may be an age-dependent rather than an aging-
dependent disease (Alves et al., 2009; Linder et al., 2010; Myall et al., 2017; 
Winter et al., 2010a). Other studies have found the incidence of PD to increase 
up until the ninth decade (Blin et al., 2015; Caslake et al., 2013; Jones et al., 
2012). Methodological issues related particularly to studies on elderly people 
(such as smaller sample size and under-reporting) may contribute to the 
observed heterogeneity of these results (Hirsch et al., 2016). 
The majority of longitudinal cohort studies have found PD patients to have 
an approximately two-fold higher mortality risk than persons without PD. This 
risk correlates with the duration of disease (de Lau et al., 2014; Heinzel et al., 
2018; Hobson & Meara, 2018; Pinter et al., 2015). Several reports have 
observed no higher mortality rates than in the general population in the first ten 
years of the disease (Williams-Gray et al., 2013; Zhang et al., 2018). In the 
current study, mortality risk for the inception cohort was similar to the general 
Estonian population. The phenomenon of the lower standardized mortality ratio 
in the inception cohorts and higher estimate in the non-inception cohorts is 
supportive to Macleod et al. (2014) who suggested that non-inception cohorts 
tend to capture those with longer disease duration and biasing towards shorter 
survival. The ratio of observed to expected deaths was insignificant in our 
inception cohort, whereas a 1.5-folded increased risk of mortality among PD 
patients was reported in the abovementioned meta-analysis. We believe that this 
difference could at least partially be attributed to the relatively short follow up 
duration in the current study (i.e. median of 5 years) compared to the follow-up 
time of 9 years in the meta-analysis by Macleod et al. (2014). 
A comparison of the results for causes of death with those of other studies 
confirms that PD is underrepresented on death certificates. A PD diagnosis was 
noted on 46.8% of death certificates in this study. This result was slightly lower 
than that of some previous studies (Hobson & Meara, 2018; Williams-Gray et 
al., 2013), but higher than that of others (Benito-León et al., 2014; Moscovich et 
al., 2017). The inconsistent reporting of PD on death certificates indicates the 
suboptimal quality of these documents (Hobson & Meara, 2018). Other studies 
have shown that, compared with the general population, PD patients have an 
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increased risk of dying of pneumonia (Hobson & Meara, 2018; Moscovich et 
al., 2017; Pinter et al., 2015; Zhang et al., 2018). However, the current study did 
not find respiratory diseases to be amongst the most common causes of death. 
Underdiagnosis of pneumonia in our study cannot be excluded. For example, an 
accuracy of the death causes of those who died at homes or nursing homes 
might not be as high as in those cases who died in the hospital. Different docu-
mentation practices across distinct geographical areas could also at least 
partially be related to the much lower prevalence of pneumonia as an immediate 
or underlying death cause in the current study.  
PD patients and the general population had a comparable risk of dying from 
cancer, the finding also shown in the study by Pinter et al. (2015). Several other 
studies have found that cancer as a death cause is less common in PD popu-
lation compared to controls (Hobson & Meara 2018; Hely et al. 2005). Our 
finding of an increased risk of dying from vascular diseases among PD patients 
is supportive to one study showing that PD patients had a higher risk of having 
cardiovascular and cerebrovascular diseases recorded as death causes (Pinter et 
al., 2015), but another longitudinal study did not show such a difference 
compared to the general population (Hely et al. 2005). 
The most important limitation of the current study was that the incidence 
data was based largely on retrospective information. Case-ascertainment in the 
current study was more thorough than in the previous Estonian incidence study, 
since the current study sourced data from the Estonian Health Insurance Fund (a 
source which was not previously available). The higher number of identified 
cases in the current study may therefore partially be attributable to this change 
in methodology. According to the sensitivity analysis limited to the incidence 
data for the period 2010–2012, a slight underestimation of the real burden of the 
disease cannot be excluded, and therefore this should be taken into account 
when interpreting the findings. The short-term duration of the follow-up of 
patients for the estimation of SMRs allows us only to draw conclusions in 
regards of the death risk in the early years of the disease duration. 
One of the strengths of the current study was that subjects were identified 
from multiple sources and over a long period of time. An almost complete 
sample of PD patients from the geographical area of interest was therefore 
obtained. Another strength of the current study was that a clinical examination 
was conducted and a detailed history (including information about possible risk 
factors) was collected from the majority of subjects. The current study was 
conducted across the same geographical area and used the same diagnostic 
criteria and substantially overlapping case-ascertainment methods (Taba & 
Asser, 2003). 
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6.3. Prevalence and factors associated  
with motor complications in PD  
This study aimed to address two main questions. Our first goal was to assess the 
prevalence of motor complications among a representative sample of PD 
patients in Estonia. Our second goal was to examine the association between 
multiple factors and the development of the disabling side effects of levodopa. 
With respect to the first research question of this study, we found a slightly 
lower frequency of motor complications in our patients than several other 
studies (approximately 20% of our study participants with either of the motor 
complications vs. more than 22% of motor fluctuations and more than 26% of 
dyskinesias in other cross-sectional studies) (Hashim et al., 2014; Larsen et al., 
2000; Nicoletti et al., 2016; Schrag & Quinn, 2000a; Yoritaka et al., 2013). It is 
possible that the somewhat lower frequency of motor complications was partly 
due to the profile of the study participants. Regarding the usage of levodopa, the 
mean daily levodopa dose of 434 mg in our study was lower than that reported 
in other studies (500 mg in the study by Hashim et al. (2014); and 548 mg in the 
study by Yoritaka et al. (2013). As this study was part of an epidemiologic 
survey of PD, all patients in the region were enrolled, included early cases. 
Among patients with early stages of PD who have been on levodopa therapy for 
a short time, motor complications are rather unexpected, a phenomenon 
demonstrated in Table 15. This finding contrasts with the results of Stocchi et 
al. (2014), in which more than half of patients under levodopa therapy for one to 
two years were diagnosed as having wearing-off symptoms, whereas only a 
minority of patients under levodopa ≤2.5 years had motor fluctuations in our 
study. Discrepancies in results could be caused by the variability in cohorts or by 
differing methodology of assessment. MDS-UPDRS Part IV was used in our 
study, whereas Stocchi et al. (2014) used a patient-assessed 19-item Wearing-off 
Questionnaire with the aim to detect wearing-off symptoms in early stages of PD.  
With respect to the second research question, our findings confirm the 
results by others showing that motor complications are perhaps the greatest 
concern for PD patients who receive high cumulative doses of dopaminergic 
medications (Larsen et al., 2000; Nicoletti et al., 2016; Olanow et al., 2013; 
Schrag & Quinn, 2000a; Scott et al., 2016). Instead of levodopa daily dose, we 
chose LEDD as a total daily dose of medication expressing dose intensity of 
different antiparkinsonian drug regimens. Levodopa equivalent dose of a drug is 
defined as that which produces the same level of symptomatic control as 100 
mg of immediate release levodopa (Tomlinson et al., 2010). Advanced PD 
patients are often treated with a combination of antiparkinsonian medications to 
handle their PD symptoms and levodopa-induced side effects. Therefore, 
especially in Estonia, where levodopa doses seem to be somewhat lower than in 
other countries, levodopa daily dose may underestimate the total dopaminergic 
load. Furthermore, approximately half of patients (57%) with motor compli-
cations were on dopamine agonists, which were used more than twice as than 
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they were by patients without motor complications (Mann-Whitney U, 
p<0.0001). Our findings on LEDD emerged from the multivariate regression 
analysis as a significant predictor of motor complications that was not found for 
the levodopa daily dose. It may support our observation that the levodopa dose 
alone may underestimate the cumulative dopaminergic burden. Although motor 
complications are traditionally considered to result from long-term use of 
levodopa (Aquino & Fox, 2015), the total burden of antiparkinsonian treatment 
may play a significant role in the emergence of motor complications.  
One of the key findings of this study is that a shorter duration of disease until 
the initiation of levodopa appears to increase the odds of motor complications. 
This finding is supportive of a few studies indicating that earlier initiation of 
levodopa might be associated with earlier emergence of motor complications 
(Denny & Behari, 1999; Schrag & Quinn, 2000a) but contrary to some other 
surveys suggesting that delaying the start of levodopa therapy is not associated 
with a smaller risk of motor complications in the long term (Cilia et al., 2014; 
Scott et al., 2016). Our results support the opinion that younger age at onset of 
PD seems to be a risk factor for motor complications per se (Bjornestad et al., 
2016; García-Ruiz et al., 2012; Hashim et al., 2014; Olanow et al., 2013). Post 
hoc analysis revealed that younger patients tended to be on a higher LEDD than 
older patients. They might be more prone to the higher usage of dopaminergic 
treatment in order to reduce their parkinsonian symptoms than older patients as 
a result of having more commitments concerning their employment status and 
families than older patients. Levodopa may be postponed in patients who are 
not troubled by their PD-related motor symptoms and in patients with young-
onset PD who are at the highest risk for developing levodopa-related compli-
cations (Jankovic & Poewe, 2012). At the same time, the possibility of the 
different effects of dyskinesias and motor fluctuations on quality of life should 
be taken into account. Some studies have found that PD patients with fluc-
tuations have lower quality of life than patients without fluctuations (Skorvanek 
et al., 2015; Stocchi et al., 2014), but no such association was found between 
quality of life and dyskinesias in another study (Hechtner et al., 2014). In our 
survey, a majority of patients with dyskinesias reported that drug-induced 
complications impair their functional ability only mildly, and severe dyskinesias 
were rarely described. This finding may provide some support for the 
possibility that patients themselves might not be particularly troubled by their 
dyskinesias, at least when those features are mild. In summary, we conclude 
that the traditional clinical approach of balancing efficacy and risk of motor 
complications is needed for each patient, using the lowest dose of levodopa that 
will provide satisfactory clinical control (Olanow et al., 2013). Still, improved 
quality of life should be the ultimate goal of our treatments. 
In controversion with the data of recent studies, we did not find female 
gender to be associated with higher occurrence of motor complications 
(Bjornestad et al., 2016; García-Ruiz et al., 2012; Olanow et al., 2013; Scott et 
al., 2016; Stocchi et al., 2014; Yoritaka et al., 2013). It has also been suggested 
that the severity of motor PD symptoms predicts a higher risk of developing 
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motor complications (Bjornestad et al., 2016). However, this does not appear to 
be the case in our study, supporting the results of another study based on a 
cohort of incident PD patients (Scott et al., 2016). Although we found more 
severe MDS-UPDRS Part II scores for those experiencing motor complications, 
according to logistic regression analysis, everyday activities were not 
significantly associated with the presence of levodopa-induced side effects, 
which does not support the observation by one other study based on a cohort of 
early PD patients (Olanow et al., 2013). 
One rather important finding was that the akinetic-rigid phenotype of PD 
emerged as a significant independent associated factor in the higher occurrence 
of motor complications. This association remained significant even after 
including possible confounders, such as duration of PD and levodopa therapy, 
to the second model. Patients with non-tremor dominant types of PD are 
characterized as being more often depressed and having a more severe clinical 
picture, higher LEDD, and longer disease duration than patients with tremor-
dominant subtype (Burn et al., 2012). In a recent case-control study in Italy 
investigating the relationship between clinical phenotype and the risk of 
developing dyskinesias, a significant negative association between tremor-
dominant phenotype as an initial PD manifestation and levodopa-induced 
dyskinesia was established (Nicoletti et al., 2016). Another case-control study 
conducted in Finland investigated differences in the binding of striatal 
dopamine transporter and the extent of caudate dopamine terminal loss, and the 
consequent dopamine function was relatively more preserved in PD patients 
with tremor compared to akinetic-rigid patients (Kaasinen, Kinos, Joutsa, 
Seppänen, & Noponen, 2014). Our study allows us to confirm information 
about the clinical heterogeneity of distinct PD phenotypes. Due to the higher 
risk for motor complications, achieving effective treatment results in patients 
whose dominant symptoms are akinesia and rigidity might be more challenging 
than in patients with the tremor-dominant disease. 
Our study has several strengths. First, the case identification in our study 
was based on all available sources in the area, and we accordingly enrolled a 
relatively large sample of patients with PD, including early cases as well as both 
moderately and severely ill patients. Thus, the results may be extrapolated to the 
Estonian PD population as a whole. Secondly, the evaluation of the participants 
was thorough, and wide-ranging aspects (motor, non-motor, functional, 
cognitive, and emotional) were assessed based on validated clinometric scales 
and questionnaires. Therefore, we believe that the measurements are accurate 
and reflect the profile of study participants correctly. 
Some limitations of this study need to be taken account when interpreting 
the findings. The main weakness of the study is a relatively small sample size of 
patients with motor complications, which can be a source of low power for the 
logistic regression analysis. The second limitation might be a potential 
underestimation of motor complications with subtle presentations, especially 
among patients with impaired cognitive ability. Finally, due to the cross-
sectional design of our study, each patient was assessed once, so no pattern of 
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progression of the disease could be estimated, and causes and effects could not 
be determined. 
 
 
6.4. Non-motor symptoms in PD  
We assessed non-motor symptoms in Estonian PD patients and found that the 
frequency of the total load of non-motor symptoms and specific items showed 
considerable differences with respect to their association with some demo-
graphic and clinical variables. The data analysis revealed that age, PD progres-
sion, presence of depressive symptoms, cognitive impairment, lower quality of 
life, and higher dose or longer duration of levodopa treatment correlated 
significantly with the total burden of non-motor symptoms.  
An association between the increasing burden of non-motor symptoms with 
disease duration has been shown in several previous studies (Barone et al., 
2009; Guo et al., 2013a; Krishnan, Sarma, Sarma, & Kishore, 2011; Špica, 
Pekmezović, Svetel, & Kostić, 2013), but a relationship with increasing age and 
non-motor symptoms was not found (Krishnan et al., 2011) or was weak (Guo 
et al. 2013a; Špica et al. 2013) as in the present study. However, some particular 
non-motor symptoms appear to become more frequent in older PD patients, 
such as urinary and gastrointestinal disturbances including constipation, or 
cognitive impairment (Kim et al., 2013; Krishnan et al., 2011; Müller et al., 
2011), that were complained more frequently by patients older than 65 years 
also in our study, additionally to daytime sleepiness. While several of these 
non-motor symptoms occur quite commonly in normal elderly populations, 
their presence is significantly higher in PD patients (Duncan et al., 2014b; Kim 
et al., 2013; Krishnan et al., 2011; Müller et al., 2011). Krishnan et al. (2011) 
found that 68% of controls reported non-motor features associated with aging, 
but presented less severe levels than in PD patients, and that cardiovascular 
disorders, mood and cognition impairment, and perceptual problems and 
hallucinations were more related to PD than normal aging. A South Korean 
group found that the domains of perceptual problems and hallucinations, and 
sexual function, were more related to PD than the age per se (Kim et al., 2013). 
Cognitive impairment was the most frequently reported non-motor symptom 
among our study participants (74.3%), which was higher than in several 
previously published studies (44.7–54%) (Barone et al., 2009; Gallagher et al., 
2010; Martinez-Martin et al., 2011a; Špica et al., 2013). However, 63% of our 
patients admitted having cognitive problems only at slight or mild level. 
Though the use of different scales may play a role, a study by Martinez-Martin 
et al. demonstrated a convergent validity for the MDS-UPDRS and NMSS 
(Martinez‐Martin et al., 2013). Although both studies included patients at any 
age and disease stage, in comparison with our study, the mean age and disease 
severity of the participants differed significantly in the study by Martinez-
Martin et al. (2013). The higher rate of cognitive impairment among our patients 
might at least partly be explained by the older mean age and more advanced 
 
 
91 
disease severity, i.e. the mean age of 74.2 years vs. 66.7 years and the per-
centage of patients with HY stage ≥3 62.7% in our study participants and only 
26.7% in the study of Martinez-Martin et al. (2013). 
In this study, ICDs were the most uncommon non-motor symptoms comp-
lained by our patients, with the higher rate in patients with longer duration of PD 
and younger age at disease onset, the latter has been also demonstrated in the 
study by Voon et al. (Voon et al., 2007). Among other factors, dopamine agonist 
treatment, younger age, a pre-PD history of ICDs, a personal or family history of 
substance abuse, bipolar disorder, and gambling problems have been found to be 
possible risk factors for ICDs (Weintraub, David, Evans, Grant, & Stacy, 2015). 
As the initial treatment with a dopamine agonist is recommended in younger 
patients according to the PD treatment recommendations (Ferreira et al., 2013), 
ICDs may cumulate with risks related to use of agonists: therefore, challenging 
issues in treatment in young patients may arise (Weintraub et al., 2015).  
Some studies have demonstrated that sexual dysfunction (Guo et al. 2013a), 
restless legs (Špica et al., 2013), excessive sweating (Špica et al., 2013), and 
loss of taste or smell (Kägi et al., 2010) are more common in patients with 
younger onset age of the disease. However other studies have demonstrated 
opposite results with higher prevalence of loss of taste or smell (Guo et al. 
2013a; Špica et al. 2013) and restless legs (Kägi et al., 2010) in patients with 
older onset age of disease. In addition to ICDs, our study found that fatigue was 
more prevalent in patients with younger onset age of PD, and constipation was 
more frequent in patients with older onset age of the disease. Defining tresholds 
for the classification of early versus late onset subtypes vary in different studies, 
ranging from 45–55 years (Guo et al. 2013a; Špica et al. 2013; Kägi et al. 
2010). Distinct profile of specific non-motor symptoms among younger vs. 
older onset age groups may partly be explained by different questionnaires (e.g. 
NMSQuest by Kägi et al. and Spica et al., and NMSS by Guo et al.), and 
different border-lines for defining the age groups. Younger onset age has been 
also shown to be associated with lower prevalence and severity of the total load 
of non-motor symptoms (Guo et al. 2013a; Špica et al. 2013), but this difference 
was not revealed in our study nor in one previous study (Kägi et al., 2010). In 
addition, the same study by Kägi et al., found that patients with genetic forms of 
PD reported significantly less non-motor symptoms compared to patients 
without proven genetic aetiology of PD. 
The present study did not demonstrate gender differences regarding the total 
load of non-motor symptoms, supporting the same observation in some other 
studies (Guo et al. 2013a; Picillo et al. 2013), however other studies have shown 
more non-motor symptoms among female patients (Krishnan et al., 2011; Solla 
et al., 2012). We found a different profile of specific non-motor symptoms, with 
a depressed mood, anxiety, pain, and light-headedness more frequently in 
women, and daytime sleepiness and fatigue more often reported by men (Table 
20a). Similar gender differences were found in a study by Solla et al. (Solla et 
al., 2012), except that fatigue was more common in women, as it was in a study 
by Barone et al. (Barone et al., 2009).  
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Our analysis revealed an association between the presence of cognitive 
impairment and a higher burden of all other non-motor symptoms that is 
consistent with the study by Barone et al. (Barone et al., 2009). Also fatigue – 
one of the most common complaints in our study – was strongly related to the 
higher overall burden of non-motor symptoms in our and a previous study 
(Solla et al., 2014). In addition to gender differences, we found that fatigue 
appears to be more frequent in patients with younger age at PD onset, longer 
disease duration, advanced disease severity, and the PIGD clinical phenotype. 
Generally, participants with the PIGD as the leading symptom experienced a 
higher burden of non-motor features compared to patients with tremor or 
akinetic-rigid predominant symptoms, which is in concordance with some other 
studies (Duncan et al., 2014b; Müller et al., 2011). 
There was an overall trend towards the more frequent occurrence of non-
motor symptoms in patients with the PIGD phenotype that may be associated 
with a more complex pathophysiology, involving other neurotransmitters in 
addition to the dopaminergic system. This is supported by observations that the 
symptoms of axial impairment are typically less responsive to dopaminergic 
therapy for PIGD than other subtypes of PD, indicating differences in the 
mechanisms between distinct clinical subtypes of PD (Lees et al., 2009). 
However, by individual symptoms some differences have been described in 
other studies suggesting that patients of PIGD phenotype are more likely to 
experience a higher frequency of depression, anxiety, cognitive impairment, 
constipation and hypersalivation (Anang et al., 2014; Burn et al., 2012; Duncan 
et al., 2014b; Müller et al., 2011), but in our study, daytime sleepiness and 
fatigue were significantly more frequently experienced. 
Longer disease duration, advanced disease, longer levodopa use and higher 
daily dose of levodopa in early PD are the known risk factors for motor 
complications (Aquino & Fox, 2015) but majority of the abovementioned 
factors are also associated with the higher occurrence of non-motor symptoms 
of PD (Barone et al. 2009; Krishnan et al. 2011; Špica et al. 2013; Guo et al. 
2013a). In our study, a higher burden of non-motor symptoms was demon-
strated only in patients with motor fluctuations but not in patients with 
dyskinesias or off-period dystonia that could be associated with a phenomen 
that the concomitant non-motor symptoms also fluctuate: pathogenesis of non-
motor fluctuations has also been explained with pulsatile dopaminergic stimu-
lation, similarly to motor fluctuations (Chaudhuri, Odin, Antonini, & Martinez-
Martin, 2011). Seki et al. (2013) reported that 53% of patients with motor 
fluctuations, also suffer from non-motor fluctuations, and patients with both 
motor and non-motor complications exhibited more severe motor symptoms, 
more non-motor symptoms, and higher levodopa daily doses.  
The strengths of this study included a relatively large sample of PD patients, 
including the most elderly, severely ill, disabled and institutionalised patients, 
which represented a whole PD population. Patients were evaluated with a wide 
range of rating scales that covered motor, non-motor, functional, cognitive, and 
emotional aspects. 
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This study had some methodological limitations. First, we did not cover all 
the non-motor symptoms of PD, e.g. sexual function, olfaction, or restless legs 
as these are not included into the MDS-UPDRS. Another limitation was the 
collection of clinical data at a single point in time that did not reflect the 
progression of the disease. Also, there were no controls to assess differences in 
the prevalence of non-motor symptoms in an ageing general population 
compared to those with PD. 
 
 
6.5. HRQoL of patients with PD 
The purpose of this study was to investigate factors that may contribute to low 
HRQoL in persons with PD. We found that the main clinical determinants of 
low HRQoL in persons with PD were depressive symptoms and the high 
burdens of motor and non-motor aspects of daily living. None of the investi-
gated socio-demographic variables were significantly associated with HRQoL. 
Clinically significant depression has an average prevalence of about 35% 
among persons with PD (Reijnders et al., 2008) and is a recognized predictor of 
low HRQoL. As previous studies (Carod-Artal et al., 2007; Gallagher et al., 
2010), we found depression to be one of the most significant determinant of 
HRQoL. A study by Leentjens et al. (2002) demonstrated that the risk factors in 
the general population for depression – such as older age, female gender, somatic 
comorbidities, and personal and family history of depression – also predict 
depression in persons with PD. In our sample the prevalence of depression in 
female patients was significantly higher than in male patients (58% and 43% 
respectively, p=0.0189). In addition to BDI, depressed mood was more often 
reported by women according to the item 1.3 of the MDS-UPDRS Part IA. 
Studies examining gender differences regarding prevalence of depression have 
yielded inconsistent results. While van der Hoek et al. (2011) found no 
difference in the prevalence of depression in male and female persons with PD, 
Solla et al. (2012) found prevalence of depression significantly higher in female 
persons with PD. The reason why women are more disposed to depression 
might partly be explained by the greater exposure of competing risk factors, as 
suggested by Sonnenberg et al. (2000) who demonstrated this association in a 
study on gender differences for depression in the elderly of a general 
population: controlling for age, comorbid somatic disease, and a number of 
other risk factors reduced the relative risk of depression in women by more than 
a half. The female patients in our study were slightly older than the male 
patients, were more often widowed and had a higher mean number of 
comorbidities. Men in our cohort were significantly more often married and 
lived together with their wife and or children. Based on the studies by 
Sonnenberg et al., it could be assumed that controlling for several factors 
associated with social and health status might reduce the relative risk of 
depression in female persons with PD. 
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In recent years there has been increasing evidence suggesting that the impact 
of non-motor symptoms on HRQoL is more important than the impact of motor 
features (Gallagher et al., 2010; Martinez-Martin et al., 2011a). Similar to 
previous studies, our study revealed that HRQoL was significantly lower with 
higher loads of non-motor symptoms. All non-motor symptoms correlated 
significantly with PDQ-39 SI, except the features of ICDs: a heterogeneous 
group of pathological behaviours associated with dopamine replacement 
treatment that include pathological gambling, compulsive sexual behaviour, 
compulsive shopping, and binge eating, together with pounding and the 
addiction-like compulsive use of dopamine replacement therapy (Djamshidian, 
Averbeck, Lees, & Sullivan, 2011). A case-control study by Voon et al. (2011) 
indicated that patients with ICDs have more depressive symptoms than patients 
without ICDs. We did not find a statistically significant difference between 
mean BDI scores for persons with PD and with ICDs (based on positive item 
1.6 in MDS-UPDRS Part IA), and persons with PD and without ICDs. 
Reducing the dosage or discontinuing the administration of dopaminergic 
agonists or substituting another drug from this group is a frequently effective 
therapeutic measure (Djamshidian et al., 2011). Only a few studies on the 
impact of ICDs on HRQoL have been published and some found controversial 
results, i.e. ICDs as a predictor of lower HRQoL (Leroi et al., 2011; Phu et al., 
2013), but in other studies ICDs did not affect HRQoL (D’Iorio et al., 2017). 
The current study did not reveal a negative impact of ICDs on quality of life. 
Our finding is supported by a study by Ondo and Lai (2008), where only 18% 
of patients with increased impulsivity felt that the change was deleterious. Our 
daily clinical practice suggests that ICDs cause considerable distress to patients’ 
families or caregivers, but the patients themselves are not that annoyed by these 
behaviours. Out of the 268 patients screened in our study, 7.8% (n=21) 
complained of ICDs. It could be assumed that at least one reason why ICDs did 
not correlate significantly with HRQoL is that the pathological behaviours were 
relatively mild. About half (52%) of these patients reported only slight problems 
with behavioural disturbances and it could be that the problems did not yet 
affect their social and occupational functioning.  
Dependency in activities of daily living as assessed using the SE-ADL scale 
and disability in the performance of daily living experiences as measured by the 
previous version of the UPDRS Part II, have been found to be significant 
contributors to HRQoL (Carod-Artal et al., 2007). A study by Rodriguez-
Blazquez et al. (2013) showed that there was a significant negative association 
between the more advanced disability (assessed by the MDS-UPDRS Part II) 
and HRQoL. The current study demonstrated that disability evaluated by SE-
ADL and MDS-UPDRS Part II significantly contributed to lower HRQoL. 
However, motor symptoms (MDS-UPDRS Part III) were not an independent 
predictor of HRQoL. Even though for antiparkinsonian treatment Part III with 
motor assessments is of high importance, it can be seen that for HRQoL, the 
self-assessment of non-motor symptoms and ability to perform daily activities 
have more impact. 
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An axial impairment has been shown to be associated with reduced HRQoL 
in persons with PD (Muslimović et al., 2008). We found that patients with 
PIGD had significantly lower overall HRQoL compared to patients with tremor 
dominance or akinetic-rigid dominance of motor phenotype. Persons with PD in 
general, but particularly patients with the PIGD, are likely to become less able 
to move around inside their homes and out in the community. They also become 
more prone to falls as the disease progresses. Regular physical exercise is 
associated with higher HRQoL, mobility, physical function, slowing the 
progression of the disease, lower caregiver burden, and less cognitive decline 
(Oguh, Eisenstein, Kwasny, & Simuni, 2014). In view of this, patients with the 
PIGD may benefit most from education on using rehabilitation activities (e.g. 
physical exercise, physiotherapy) and assistive devices (e.g. reaching aids). 
Therefore, in addition to pharmacological treatment, the management of PD 
should include rehabilitative care, which helps to maintain patients’ ability to 
participate in daily living activities and avoid the decline of HRQoL. 
In our study, socio-demographic characteristics including age, gender, urban/ 
rural living, level of education, marital status and living alone/with others, did 
not significantly affect overall HRQoL. However, we found several associations 
between these factors and domains of PDQ-39. Women received lower scores 
for emotional well-being and bodily discomfort, which is in accordance with the 
study by Carod-Artal et al. (2007). As regards to patients’ living status, those 
who lived alone received lower scores for emotional well-being compared with 
patients who lived with others. Another study by Winter et al. (2010b) showed 
that patients living alone had worse HRQoL than patients living with somebody. 
Our results did not reveal any statistically significant difference in HRQoL 
among patients with different educational backgrounds, whereas greater number 
of years in education was found to be associated with higher HRQoL in some 
other studies (Carod-Artal et al., 2007). Klepac et al. (2007) found that rural 
patients had lower overall HRQoL, with most of the domains of PDQ-39 affected. 
In contrast, the results of our study suggest that living area is not associated with 
overall HRQoL. Moreover, our results showed that patients living in rural areas 
had significantly less stigmatization and better social support than patients 
living in urban areas. 
The strength of the study was the relatively large sample of persons with PD, 
which included institutionalised and severely ill patients, and thus was 
representative of the PD population as a whole. The study participants were also 
evaluated with a wide range of clinimetric properties that covered motor, non-
motor, functional, cognitive and emotional aspects. 
The study has some methodological limitations that ought to be recognized 
and taken into account when interpreting the findings. The analysis was based 
on clinical data collected at a single point in time; therefore, any pattern of 
progression of the disease could not be estimated. Also, we cannot exclude the 
possibility that some of the variables, such as gender (female patients 
outnumbered male patients) or stage of disease (62.6 % of patients had HY ≥3) 
could have influenced the results found.   
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7. CONCLUSIONS 
1. As there are only a few studies of repeat prevalence and incidence of PD in 
the same geographical area, the main contribution of our epidemiologic 
surveys in the County of Tartu has been to evaluate the dynamic changes in 
the frequency and occurrence of this neurodegenerative disease. Over the 
last twenty years, the overall incidence of PD in Estonia has remained 
comparatively stable. Increased incidence among males may be related to 
demographic changes and improved diagnosis; however environmental 
causes cannot be ruled out. In the contrary, the overall prevalence of PD has 
risen significantly. A stable incidence accompanied with an increased 
prevalence may be explained by a lengthened disease duration and aging of 
the general population. To manage an increasing disease burden, health 
planning should take into account, for example, the growing requests for 
nursing institutions and rehabilitation services. 
2. Mortality rates of PD in Estonia have never before been studied. No 
significant differences in the mortality risk among PD patients in the first 5 
years of the disease and general population were found. PD patients and the 
non-recruited controls had a comparable risk of dying from cancer, but PD 
patients were at higher risk of dying from vascular diseases. The latter 
finding attenuates the need to control more efficiently the cardiovascular 
risk factors of the patients with PD. Data obtained from the death certi-
ficates revealed that approximately only half of all the deceased subjects 
with clinically-diagnosed PD had the disease noted on their death certi-
ficates. This finding reflects that death certificates may not provide enough 
validity for their use in the surveillance of this neurodegenerative disease. 
3. A total of approximately 25% of patients on levodopa therapy had some 
type of motor complication, indicating to the relatively low frequency of 
those antiparkinsonian medication-related side-effects in our PD population 
compared to other studies. Patients receiving a higher LEDD and having 
akinetic-rigid dominant phenotype as opposed to tremor-dominant pheno-
type of the disease are at greater risk of having motor complications. The 
results of the research do not support the idea that levodopa should be 
initiated as early as possible; instead, postponing the start of levodopa, 
together with prescribing optimal daily doses, might reduce the odds of 
motor complications. 
4. Though the severity of individual non-motor symptoms assessed with the 
MDS-UPDRS Part I was generally rated by PD patients as “mild” or less, 
these symptoms were highly prevalent in patients. A higher frequency of 
the total burden of non-motor symptoms in patients with the PIGD as the 
leading motor symptom and in patients with more advanced stage and 
longer duration of the disease, also in those with depression, cognitive 
disorder or motor complications. This highlights the need to pay a special 
attention to the screening for non-motor symptoms in these groups. 
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5. Approximately 60% of the variation in the PDQ-39 SI score reflecting the 
HRQoL of PD patients was explained by the predictive variables identified 
in this study, i.e. depression, non-motor and motor aspects of daily living. 
Our results are consistent with other studies that have suggested depression 
to be the strongest predictor of HRQoL in persons with PD, and therefore 
should be recognized early and treated appropriately. 
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SUMMARY IN ESTONIAN 
Parkinsoni tõbi Eestis: epidemioloogia, elukvaliteet,  
kliinilised karakteristikud ja farmakoteraapia 
Parkinsoni tõve vanusele kohandatud levimus-ja haigestumuskordajad variee-
ruvad uuringutes ulatuslikult, jäädas vastavalt vahemikesse 53–511/100 000 
inimese kohta ning 6–36/100 000 inimaasta kohta (Blin et al., 2015; Das et al., 
2010; Heinzel et al., 2018; Myall et al., 2017). Epidemioloogiliste uuringute 
võrreldavust kahandavad erinevused uuringu disainis, uuritavate värbamis-
meetodites, diagnoosikriteeriumites ja populatsiooni iseärasustes. Väga vähe on 
tehtud korduvaid Parkinsoni tõve epidemioloogilisi uuringuid samas geograafi-
lises regioonis haigestumus- ja levimusnäitajate dünaamika hindamiseks. 
Tartumaal on Parkinsoni tõve epidemioloogilisi näitajaid uuritud ligikaudu 20 
aastat tagasi, mil leiti, et vanusele kohandatud levimus- ja haigestumuskordajad 
olid vastavalt 152/100 000 kohta ja 16,8/100 000 inimaasta kohta (Taba & 
Asser, 2002, 2003). Hiljutise metaanalüüsi järgi on Parkinsoni tõvega patsien-
tidel ligi 1,5 korda suurem suremisrisk võrreldes üldpopulatsiooniga (Macleod 
et al., 2014). Suremust pole Eesti Parkinsoni tõvega haigete seas varem uuritud. 
Levinuimad mittemotoorsed sümptomid Parkinsoni tõvega haigetel on 
urineerimishäired, mäluprobleemid, alanenud meeleolu, kõhukinnisus, valu ja 
unehäired (Chaudhuri et al., 2010). Mõned uuringud on näidanud, et mitte-
motoorsetel sümptomitel võib Parkinsoni tõvega patsiendi elukvaliteedile olla 
suurem kumulatiivne negatiivne mõju kui motoorsetel sümptomitel (Erro et al., 
2016; Gallagher et al., 2010; Ophey et al., 2018). 
Parkinsoni tõve ravi on sümptomaatiline. Kliinilises praktikas kasutata-
vaimaks ja efektiivseimaks ravimiks on suukaudselt manustatav levodopa, mille 
kõrvaltoimena võivad kasutajal tekkida motoorsed komplikatsioonid (on-off 
fluktuatsioonid ja düskineesiad) (Chaudhuri et al., 2018). Motoorsete komp-
likatsioonide peamisteks riskiteguriteks peetakse levodopa suuremaid annused 
ja pikaaegset ravimi tarvitamist (Olanow et al., 2013; Scott et al., 2016). 
 
 
Uurimistöö eesmärgid 
1. Kirjeldada Parkinsoni tõve levimus-ja haigestumusnäitajaid Tartu linnas ja 
maakonnas ning hinnata esinemisnätajate dünaamilisi muutusi võrreldes 
eelmise epidemioloogilise uuringuga samas regioonis (Uuring I, II). 
2. Kirjeldada Parkinsoni tõve kohordi suremusnäitajaid, surmatunnistusele 
märgitud Parkinsoni tõve diagnoosi esinemissagedust ja teisi surma-
põhjuseid (Uuring II). 
3. Hinnata motoorsete komplikatsioonide esinemissagedust levodopa ravi 
saavatel Parkinsoni tõvega patsientidel, ja analüüsida valitud demograafi-
liste ja kliiniliste tegurite seost nimetatud ravimist tingitud kõrvaltoimete 
tekkega (Uuring III). 
 
 
 
117 
4. Hinnata Parkinsoni tõve korral esinevate mittemotoorsete sümptomite levi-
must ja raskusastet, ning analüüsida nende sümptomite esinemissageduse 
varieeruvust Parkinsoni tõvega patsientide alagruppide vahel (Uuring IV).  
5. Iseloomustada Parkinsoni tõvega patsientide tervisega seotud elukvaliteeti 
ning analüüsida viimast mõjutavaid sotsiodemograafilisi ja kliinilisi tegu-
reid (Uuring V). 
 
Uuritavad ja meetodid 
Tegemist oli Parkinsoni tõve epidemioloogilise ja kliinilise uuringuga, mille jaoks 
andmete kogumine vältas perioodil 2010–2016. Uuringu lõplik valim koosnes 
589 Parkinsoni tõve diagnoosiga uuritavast (neist mehi, 236; naisi, 353), kellest 
65% elas Tartu linnas ja 35% Tartu maakonnas. Lisaks Tartu Ülikooli Kliini-
kumi Närvikliinikule, osalesid uuringus ka Pärnu Haigla ja Põhja-Eesti Regio-
naalhaigla, nende keskuste poolt värvatud patsiendid (n=102) olid kaasatud 
ainult motoorsete komplikatsioonide uuringusse. Parkinsoni tõve diagnoos lähtus 
Suurbritannia PT Ühingu Ajupanga tunnustatud diagnoosikriteeriumitest – 
Parkinsoni tõbe kinnitab, kui kliiniliselt esineb bradükineesia ja lisaks üks 
järgnevatest sümptomitest: rahutreemor, rigiidsus või posturaalsete reflekside 
häire (Gibb & Lees, 1988; Lees et al., 2009).  
Uuritavate värbamiseks olid kasutusel järgmised allikad – Tartu Ülikooli 
Närvikliinik, erakliinikute neuroloogid, Tartu Parkinsoni Haiguse Selts, linna ja 
maakonna perearstid, hooldusasutused ja Eesti Haigekassalt saadud nimekiri 
kõikide isikute kohta regioonis, kellele perioodil 2010–2015 olid elektroonsesse 
meditsiinisüsteemi märgitud G20 diagnoosikood. Need isikud, kes keeldusid 
kliinilisest testimisest, polnud kättesaadavad või olid identifitseerimise hetkeks 
surnud, kaasati siiski epidemioloogilisse uuringusse, kui meditsiinilises doku-
mentatsioonis olid fikseeritud kindlad viited Parkinsoni tõvele. Iga uuritavat 
jälgiti prospektiivselt üleriigilise elektroonilise terviselugude süsteemi kaudu 
kuni uuringuperioodi lõpuni või uuritava surmani. 
Uuritavate põhjalik hindamine hõlmas ühekordsel kokkusaamisel sotsio-
demograafiliste ja kliiniliste andmete kogumist, mille aluseks oli poolavatud 
intervjuu spetsiifiliselt selle uurimistöö jaoks välja töötatud patsiendi kaardi 
baasil ja neuroloogiline läbivaatus. Lisaks hindasime patsiendi haiguse raskus-
astet, mõju funktsionaalsele võimekusele, meeleolu, kognitiivset seisundit ja elu-
kvaliteeti, kasutades erinevaid valideeritud kliinilisi skaalasid ja küsimustikke.  
Haiguse levimuse väljendamiseks kasutati levimuskordajaid 100 000 elaniku 
kohta, milleks leiti Parkinsoni tõve haigusjuhtude esinemise osakaal Tartu linna 
ja maakonna populatsioonis levimuspäeval 01.10.2013. Haiguse avaldumise 
väljenduseks kasutati haigestumuskordajaid 100 000 inimaasta kohta, milleks 
leiti valdavalt retrospektiivselt Parkinsoni tõve esmased haigusjuhud aja-
perioodil 2002–2012 summaarse riskiaja kohta Tartu linna ja maakonna popu-
latsioonis. Parkinsoni tõve suremusuuringusse kaasati kõik haigusjuhud regioonist 
perioodil 2010–2016. Suremust väljendati standardiseeritud suremuskordajatega, 
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referentspopulatsiooniks kasutati Eesti soo- ja vanusspetsiifilisi suremuskordajaid 
vastaval kalendriaastal. Surma põhjuste registrist saadud andmete alusel leiti 
vaadeldud perioodil surnud uuritavate (n=235) surmapõhjused. 
Doktoritöö teised osad baseerusid läbilõikelistel kliinilistel uuringutel, mida 
kajastavad Uuringud III–V (motoorsete komplikatsioonide esinemissagedus ja 
prognostilised faktorid; mittemotoorsete sümptomitega seonduvad tegurid; 
elukvaliteedi determinandid). Neis uuringutes kasutati vastavaid statistilisi 
meetodeid nagu logistilist regressioonanalüüsi, korrelatsioonanalüüsi, mitmest 
regressioonanalüüsi, ja gruppide võrdlusteste. Statistilise olulisuse nivooks oli 
üldjuhul võetud p<0,05. 
 
Tulemused ja arutelu 
Levimus, haigestumus ja suremus (Uuring I, II) 
Levimuspäeval 01.10.2013 tuvastati Tartu linnas ja maakonnas 431 Parkinsoni 
tõvega patsienti. Vanusele kohandatud levimuskordaja oli 314/100 000. Võrreldes 
Parkinsoni tõve varasema epidemioloogilise uuringuga, oli vanusele kohandatud 
levimuskordaja oluliselt tõusnud (152/100 000 vs 197/100 000 kohta; RR=1,3; 
p=0,004).  
Perioodil 2002–2012 tuvastati 1 699 709 inimaasta jooksul 388 uut Parkin-
soni tõve juhtu. Vanusespetsiifilised haigestumuskordajad kasvasid nii meestel 
kui ka naistel eksponentsiaalselt kuni 75–84 aastasete vanusgrupini, millele 
järgnes haigestumuse langus. Vanusele kohandatud haigestumuskordaja kogu-
kohordile oli 28/100 000 inimaasta kohta, mis on võrreldav teiste viimaste 
aastate uuringute vastavate näitajatega. Vanusele kohandatud haigestumus-
kordaja meestel oli veidi kõrgem kui naistel (32,0 vs 25,6/100 000 inimaasta 
kohta; RR=1,25; p=0,04). Mitmed teised uuringud on näidanud pigem veelgi 
ülekaalukamat meeste riski haigestuda võrreldes naistega. Võrreldes Parkinsoni 
tõve varasema haigestumusuuringuga, püsis vanusele kohandatud haigestumus-
kordaja oluliselt muutumatuna (16,8 ja 18,5/100 000 inimaasta kohta; RR=1,1; 
p=0,19), mida on näidanud ka teised samalaadsed korduvad epidemioloogilised 
uuringud. Stabiilne haigestumus kasvava levimuse foonil toetab arvamust, et 
haiguse esinemissageduse tõus on seotud eeskätt vananeva ühiskonnaga. Meeste 
seas oli täheldatav mõningane haigusavaldumuse tõus (16,6 ja 21,3/100,000 
inimaasta kohta; RR=1,3; p=0,04). Nimetatud nähtust saab vähemalt osaliselt 
seletada meeste pikenenud elueaga, kuid välistada ei saa ka seost teatud kesk-
konnateguritega. Parkinsoni tõvega patsiendid praeguses uuringus olid pikema 
haiguse kestusega ning suurem osakaal oli nendel isikutel, kelle haigusstaadium 
oli kaugelearenenud. 
589 Parkinsoni tõvega patsienti Tartu linnas ja maakonnas, keda jälgiti 3145 
inimaasta jooksul, lisati suremusanalüüsi. Standardiseeritud suremuskordajad 
Parkinsoni tõvega patientide kohordile, kelle esmashaigestumine oli 2008. 
aastal või hiljem, olid järgmised: 1,1 kõikidele (95% CI 0,–1,3), 1,0 naistele 
(95% CI 0,7–1,3), ja 1,1 meestele (95% CI 0,8–1,4). Parkinsoni tõve diagnoos 
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oli veidi alla pooltel surnud uuritavate surmatunnistustel, mis on kooskõlas 
teiste uuringutega, ning viitab viletsale surmapõhjuste dokumenteerimisele. 
Kõige sagedasemad surma algpõhjused olid järgmised: kardiovaskulaarsed 
haigused (58%), vähk (14%), Parkinsoni tõbi (14%) ja tserebrovaskulaarsed 
haigused (6%). Kaasuva haigusena oli Parkinsoni tõbi märgitud 33% surma-
tunnistustest.  
 
 
Motoorsed komplikatsioonid (Uuring III) 
Läbilõikelisse uuringusse kaasati 328 Parkinsoni tõvega patsienti, kes kõik 
kasutasid levodopat (levodopa päevase annuse mediaan oli 450 mg). Düski-
neesiaid esinesid 21% ja motoorseid fluktuatsioone (on-off perioode) 20% 
patsientidest. Kuivõrd muu maailmaga võrreldes on Eestis motoorsete kompli-
katsioonide esinemissagedus pigem madalamapoolne, siis nimetatud nähtus 
võibki olla seotud arstide poolt määratud antiparkinsonistlike ravimite opti-
maalsete annustega. Motoorsete komplikatsioonide sagedus kasvas koos 
levodopa kasutusajaga, kõrgeim esinemissagedus (73,3%) oli neil, kelle levodopa 
kasutusaeg oli vähemalt 15 aastat. Logistilisel regressioonanalüüsil selgus, et 
motoorsete komplikatsioonide esinemise šanssi suurendavad LEDD (OR=1,003; 
95% CI 1,001–1,004), akineetilis-rigiidne motoorne fenotüüp (OR=2,559; 
95% CI 1,087–6,199), lühem aeg haigestumisest levodopa kasutuselevõtuni 
(OR=0,746; 95% CI 0,624–0,870), noorem iga haigestumisel (OR=0,837; 
95% CI 0,766–0,910) ja kõrgem vanus uurimise ajal (OR=1,106; 95% CI 
1,018–1,203).  
 
 
Mittemotoorsed sümptomid ja elukvaliteet (Uuring IV, V) 
268-st läbilõikelisse uuringusse kaasatud isikust (keskmine vanus 74,2±8,8 
aastat, keskmine haiguse kestus 7,6±5,9 aastat) esines 99,6% vähemalt üks ning 
keskmiselt 6,7±2,5 mittemotoorset sümptomi ühe patsiendi kohta. Kuigi mitte-
motoorsed sümptomid olid sagedased, siis üldiselt oli nende kaebuste raskusaste 
kerge. Kõige sagedasemad mittemotoorsed sümptomid olid kognitsioonihäire 
(74,3%), öised unehäired (71,6%), põiehäired (71,6%), väsimus (68,7%), valu 
(64,2%), päevane liigne unisus (61,9%) ja alanenud meeleolu (60,8%). Hallut-
sinatsioonid (13,8%) ja impulsi kontrolli häired (7,8%) olid kõige harvemini 
esitatud mittemotoorsed sümptomid. Mitmesel regressioonanalüüsil, kus küsi-
mustiku PDQ-39 summaarne indeks oli sõltuvaks tunnuseks, ilmnes, et elukvali-
teedile avaldavad tugevaimat mõju depressioon, mittemotoorsed ja motoorsed 
igapäevaeluga seotud aspektid. Need sõltumatud tunnused seletasid ära 59,9 
(R2=0,599) elukvaliteedi küsimustiku summarse indeksi hajuvusest. Ükski 
sotsiodemograafiline tegur ei mõjutanud elukvaliteeti. 
Töö tulemused lubavad väita, et suur mõju patsientide elukvaliteedile on 
depressioonil ning sellel, kuidas nad tulevad toime enda igapäevaelu toimin-
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gutega (riietumine, hügieen jne.). Neuroloogi poolt objektiivselt hinnatud 
parkinsonistlike sümptomite raskusaste ei pruugi peegeldada seda, kuidas haige 
tegelikult enda elukvaliteeti tunnetab. 
 
 
Kokkuvõte 
Käesolev korduv epidemioloogiline uurimistöö samas baaspopulatsioonis, kasu-
tades samu diagnoosikriteeriume ja suuresti kattuvaid värbamismeetodeid, näitas 
Parkinsoni tõve diagnoosiga patsiente arvu olulist kasvu Eestis 20 aasta jooksul. 
Samas Parkinsoni tõve haigestumus pole võrreldes 1990-ndate aastatega 
oluliselt muutunud, mistõttu saab järeldada, et haiguse levimuse kasvu võib 
eelkõige seostada vananeva rahvastiku, pikenenud haiguskestuse, paranenud 
haigusteadlikkusega ühiskonnas ning diagnostika arengutega. Pikema haiguse 
kestuse ning enamväljendunud raskusastmega Parkinsoni tõvega patsiente oli 
nüüdses uuringus rohkem kui varasemas uuringus. Nimetatud tulemused võivad 
osutada sellele, et ühiskonnas tekib kasvav vajadus Parkinsoni tõvega patsienti-
dele rehabilitatsiooniteenuste ja hooldusasutuste kättesaadavuse tagamiseks.  
Motoorsete komplikatsioonide edasilükkamiseks võib kasu olla sellest, kui ei 
kiirustata levodopa alustamisega (seda eeskätt just nooremate patsientide puhul) 
ning hoitakse päevase dopaminergilise ravimite koguannused optimaalsel 
tasemel. Oluline on siinjuures see, et motoorsete komplikatsioonide edasilükka-
mine ei tuleks langenud elukvaliteedi arvelt – antiparkinsonistlike ravimite doosid 
peaksid olema siiski piisavalt suured, et vähendada patsientide motoorseid 
vaevuseid ja kasvaks haige subjektiivne rahulolu enda eluga. Mittemotoorsed 
sümptomid kuuluvad selle kliiniliselt heterogeense haiguse sümptomatoloogia 
hulka ning nende skriinimine kuulub iga Parkinsoni tõvega haige käsitluse 
hulka. Depressioonil on Parkinsoni tõvega patsientide elukvaliteedi mõjutajana 
kandev roll, mistõttu tuleb meeleoluhäireid nendel haigetel rohkem uurida ja 
vajadusel ravivõimalusi pakkuda. 
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